<SEC-DOCUMENT>0001493152-23-005990.txt : 20230224
<SEC-HEADER>0001493152-23-005990.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224161528
ACCESSION NUMBER:		0001493152-23-005990
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanara MedTech Inc.
		CENTRAL INDEX KEY:			0000714256
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				592220004
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251652
		FILM NUMBER:		23667465

	BUSINESS ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
		BUSINESS PHONE:		817-529-2300

	MAIL ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WOUND MANAGEMENT TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20080611

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MB SOFTWARE CORP
		DATE OF NAME CHANGE:	19960805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INAV TRAVEL CORPORATION
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-251652</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS
SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
Prospectus Dated January 4, 2021)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Up
to $75,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_001.jpg" ALT="" STYLE="height: 87px; width: 220px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Sanara
MedTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald &amp; Co. (&ldquo;Cantor Fitzgerald&rdquo;) relating to shares of our common stock, $0.001 par value per share, offered by this prospectus.
In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price
of up to $75,000,000 from time to time through Cantor Fitzgerald, acting as sales agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo; On February 23, 2023, the last
reported sale price of our common stock on The Nasdaq Capital Market was $41.39 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock, if any, under this prospectus may be made in sales deemed to be an &ldquo;at the market offering&rdquo; as defined
in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Cantor Fitzgerald is not
required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts
consistent with its normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement
for funds to be received in any escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation to Cantor Fitzgerald for sales of common stock sold pursuant to the Sales Agreement will be at a fixed commission rate of
3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock
on our behalf, Cantor Fitzgerald will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the
compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification
and contribution to Cantor Fitzgerald with respect to certain civil liabilities, including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. See the section titled &ldquo;Risk Factors&rdquo; beginning on page S-14 of
this prospectus supplement and page 4 of the accompanying prospectus and the risk factors in the documents incorporated by reference
in this prospectus supplement and the accompanying prospectus to read about factors you should consider before buying our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_002.jpg" ALT="LOGO" STYLE="height: 49px; width: 257px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is February 24, 2023.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Ha_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#Ha_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-25</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 48px; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Cautionary Statement Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Prospectus Summary</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Risk Factors</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Use of Proceeds</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Description of Warrants</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Description of Units</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Plan of Distribution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#Hz_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Incorporation of Documents by Reference</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
THIS PROSPECTUS SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the U.S. Securities and
Exchange Commission (the &ldquo;SEC&rdquo;) utilizing a &ldquo;shelf&rdquo; registration process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also
adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second
part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to
both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement
and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date
of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one
of these documents is inconsistent with a statement in another document having a later date&mdash;for example, a document incorporated
by reference in the accompanying prospectus&mdash;the statement in the document having the later date modifies or supersedes the earlier
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or
covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus supplement, the accompanying prospectus, any free writing prospectus
or document incorporated by reference herein or therein. Neither we nor Cantor Fitzgerald have authorized anyone to provide you with
different or additional information. The information contained in this prospectus supplement, the accompanying prospectus, any free writing
prospectus or document incorporated by reference herein or therein is accurate only as of the respective dates thereof, regardless of
the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. Our business,
financial condition, results of operations and prospects may have changed since those dates. It is important for you to read and consider
all information contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference
herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we
have referred you in the sections titled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Documents by Reference&rdquo;
in this prospectus supplement and in the accompanying prospectus, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering to sell, and seeking offers to buy, our common stock only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and the accompanying prospectus and the offering of our common stock in certain jurisdictions may be restricted
by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must
inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus
supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not
constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by
this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person
to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context otherwise requires, financial data included, or incorporated by reference, in this prospectus supplement
and the accompanying prospectus reflects the business and operations of Sanara MedTech Inc. and its consolidated subsidiaries and all
references herein to &ldquo;Sanara MedTech Inc.,&rdquo; &ldquo;Sanara MedTech,&rdquo; &ldquo;Sanara,&rdquo; the &ldquo;Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo; refer to Sanara MedTech Inc. and its consolidated subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
and Market Data</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus
concerning our industry, our market share and the markets that we serve is based on information from independent industry and research
organizations, other third-party sources (including industry publications, surveys and forecasts) and management estimates. Management
estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well
as data from our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry
and markets that we believe to be reasonable. Although we believe the data from these third-party sources is reliable, we have not independently
verified any such information. In addition, projections, assumptions and estimates of the future performance of the industry in which
we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described
in &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo; These and other factors could
cause results to differ materially from those expressed in the estimates made by third parties and by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademarks,
Trade Names and Service Marks</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara,
Sanara MedTech, our logo and other trademarks or service marks appearing in this prospectus supplement, the accompanying prospectus and
the documents incorporated by reference herein and therein are the property of Sanara MedTech Inc. Trade names, trademarks and service
marks of other companies appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference
herein and therein are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names
included in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein are
without the &reg;, &trade; or other applicable symbols, but such references are not intended to indicate, in any way, that we will not
assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service
marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<BR STYLE="clear: both"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS
SUPPLEMENT SUMMARY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain significant aspects of our business and this offering and is a summary of information contained elsewhere
in this prospectus supplement, in the accompanying prospectus and the documents incorporated by reference herein and therein. This summary
does not contain all of the information that you should consider before deciding to invest in our securities. You should read the entire
prospectus supplement, the accompanying prospectus, any free writing prospectus prepared by us or on our behalf and the information incorporated
by reference herein and therein carefully, including the section titled &ldquo;Risk Factors&rdquo; and our financial statements and related
notes thereto, before making an investment decision.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and
reduce healthcare expenditures in the surgical, chronic wound and skin care markets. Each of our products, services, and technologies
contributes to our overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive
care. We strive to be one of the most innovative and comprehensive providers of effective surgical, wound and skin care solutions and
are continually seeking to expand our offerings for patients requiring treatments across the entire continuum of care in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently market several products across surgical and chronic wound care applications and have multiple products in our pipeline. We
currently license certain of our products from Applied Nutritionals, LLC (&ldquo;AN&rdquo;) (through a sublicense with CGI Cellerate
RX, LLC (&ldquo;CGI Cellerate RX&rdquo;), an affiliate of The Catalyst Group, Inc. (&ldquo;Catalyst&rdquo;)) and Rochal Industries, LLC
(&ldquo;Rochal&rdquo;) and have the right to exclusively distribute certain products manufactured by Cook Biotech Inc. (&ldquo;Cook Biotech&rdquo;).
In addition, through Scendia Biologics, LLC (&ldquo;Scendia&rdquo;), we license our products from multiple manufacturers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, we acquired certain assets from Rochal, including, among others, intellectual property, four U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) 510(k) clearances, rights to license certain products and technologies currently under development, equipment and
supplies. As a result of the asset purchase, our pipeline now contains product candidates for mitigation of opportunistic pathogens and
biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. Since our acquisition of
assets from Rochal, we have been developing additional products in our own product pipeline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we entered into a merger agreement through which Precision Healing Inc. (&ldquo;Precision Healing&rdquo;) became a wholly
owned subsidiary of the Company. Precision Healing is developing a diagnostic imager and lateral flow assay (&ldquo;LFA&rdquo;) for assessing
a patient&rsquo;s wound and skin conditions. This comprehensive wound and skin assessment technology is designed to quantify biochemical
markers to determine the trajectory of a wound&rsquo;s condition to enable better diagnosis and treatment protocol. We plan to submit
a 510(k) premarket notification for the Precision Healing diagnostic imager in 2023. We also plan to submit a 510(k) premarket notification
for the Precision Healing LFA in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we entered into a membership interest purchase agreement with Scendia and Ryan Phillips (the &ldquo;Seller&rdquo;) pursuant
to which we acquired 100% of the issued and outstanding membership interests in Scendia from the Seller. Since our acquisition of Scendia,
we have been selling a full line of regenerative and orthobiologic technologies including (i) TEXAGEN Amniotic Membrane Allograft (&ldquo;TEXAGEN&rdquo;),
(ii) BiFORM Bioactive Moldable Matrix (&ldquo;BiFORM&rdquo;), (iii) AMPLIFY Verified Inductive Bone Matrix (&ldquo;AMPLIFY&rdquo;) and
(iv) ALLOCYTE Advanced Cellular Bone Matrix (&ldquo;ALLOCYTE&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we established a partnership with InfuSystem Holdings, Inc. (&ldquo;InfuSystem&rdquo;) focused on delivering a complete
wound care solution targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction.
The partnership is expected to enable InfuSystem to offer innovative products, including Cork Medical, LLC&rsquo;s negative pressure
wound therapy devices and supplies, and our advanced wound care product line and associated services to new customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comprehensive
Value-Based Care Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we formed a subsidiary, United Wound and Skin Solutions, LLC (&ldquo;UWSS&rdquo; or &ldquo;WounDerm&rdquo;), to hold certain
investments and operations in wound and skin care virtual consult services. Through WounDerm, we plan to offer a comprehensive wound
and skin care solution and partner with value-based care providers with the dual goal of lowering the cost to treat wounds while improving
clinical outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
comprehensive solution consists of four key components: diagnostics, virtual consult services for wound care and dermatology, proprietary
efficacious products, and a wound care and dermatology specific electronic medical record (&ldquo;EMR&rdquo;) and mobile application.
We expect these components will work synergistically to allow clinicians to analyze and treat wound and dermatology conditions more efficiently
than the current standard of care:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diagnostics </I>&ndash;
    Our proprietary imager and LFA currently under development, which we recently acquired from Precision Healing, are designed to quantify
    key biomarkers that dictate the trajectory of wound healing and identify deficiencies to aid in treatment. Ultimately, we believe
    that our diagnostics will lead to treatment algorithms based on the data collected by the Precision Healing technology.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Virtual Consult Services
    </I>&ndash; Through our exclusive affiliation with Direct Dermatology Inc., we can offer virtual consult services for wound care
    and dermatology provided by experienced, specialized physicians and clinicians.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proprietary Products
    </I>&ndash; We currently offer products for improving patient outcomes by addressing conditions that impact wound healing. We are
    currently conducting multiple studies to prove the efficacy of our products while developing and exploring new products and opportunities
    in our six focus areas of (1) debridement, (2) biofilm removal, (3) hydrolyzed collagen, (4) advanced biologics, (5) negative pressure
    wound therapy products and (6) the oxygen delivery system segment of the wound and skin care market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>EMR and Mobile Application
    </I>&ndash; Our EMR and mobile application were developed specifically for wound care and dermatology. We are currently developing
    the capability for the EMR and mobile application to offer wound tracking analytics, recommended treatments and decision support,
    and automated referrals.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that by offering a proprietary comprehensive solution for wound care and dermatology, we will be a value-added partner for providers
in value-based care programs, such as Medicare Advantage and other risk-based contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
Scale</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
study by a physician at the Department of Surgery for the Indiana University Health Comprehensive Wound Center found that approximately
8.2 million patients suffer from surgical and chronic wounds each year in the United States. Furthermore, according to an article published
by the <I>American College of Surgeons and Surgical Infection Society</I>, in the United States, the annual treatment cost projections
for all wounds is approximately $28 billion with the estimated annual cost of surgical site infections ranging from $3.5 billion to $10
billion. Looking at the target markets for our specific products, according to SmartTRAK Advanced Wound Care, the U.S. advanced dressings
market is estimated to be $1.3 billion and the U.S. wound biologics market is estimated to be $2 billion. The U.S. teledermatology market
alone is estimated to grow from $5 billion in 2019 to $45 billion by 2027 according to a research report by <I>Fortune Business Insights</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Summary
of Our Product, Service and Technology Offerings and Development Programs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to developing and commercializing innovative products that address the challenges physicians face in diagnosing and treating
wound and skin care ailments. The following table sets forth our product and services portfolio:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_1.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
surgical products, CellerateRX Surgical Activated Collagen (Powder and Gel) (collectively, &ldquo;CellerateRX Surgical&rdquo;), TEXAGEN,
BiFORM, AMPLIFY and ALLOCYTE, FORTIFY TRG Tissue Repair Graft, and FORTIFY FLOWABLE Extracellular Matrix are used in a wide range of
surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products,
FORTIFY TRG Tissues Repair Graft, and FORTIFY FLOWABLE Extracellular Matrix are used in specialties including cardiothoracic, colorectal,
general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, orthopedic (hip and
knee, sports, spine, joint, foot and ankle, ortho trauma and ortho oncology), plastic/reconstructive, podiatric, urology, and vascular.
BiFORM, AMPLIFY, and ALLOCYTE are used in orthopedic specialties including hip and knee, sports, spine, joint, foot and ankle, ortho
trauma and ortho oncology. Currently, substantially all of our revenue is derived from the sale of surgical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
2021 we launched FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix, which we license from Cook Biotech. FORTIFY
TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix, are currently 510(k) cleared for use in the surgical segment. We believe
that both products are a complementary offering to CellerateRX Surgical, and we are working to increase both the number of contract opportunities
and facility approvals to drive further sales growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
July 2022, through the acquisition of Scendia, we expanded our surgical product offerings to include regenerative and orthobiologic technologies.
We chose to focus our sales and marketing on four products: TEXAGEN, BiFORM, AMPLIFY, and ALLOCYTE. As part of the integration of Scendia
into Sanara, we are continuing to work to add facility approvals for these products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
chronic wound care products, HYCOL Hydrolyzed Collagen (Powder and Gel) (collectively, &ldquo;HYCOL&rdquo;), BIAKO&#772;S Antimicrobial
Skin and Wound Cleanser (&ldquo;BIAKO&#772;S AWC&rdquo;) and BIAKO&#772;S Antimicrobial Wound Gel (&ldquo;BIAKO&#772;S AWG&rdquo;), are
targeted for use across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled
nursing facilities (&ldquo;SNFs&rdquo;), and wound care clinics. Our chronic wound care products can be used on stage I-IV pressure ulcers,
diabetic foot ulcers (&ldquo;DFUs&rdquo;), venous stasis, arterial, post-surgical wounds, first- and second-degree burns and donor sites.
BIAKO&#772;S AWC is also available in an irrigation bottle (BIAKO&#772;S Antimicrobial Skin and Wound Irrigation Solution) that can be
used in conjunction with negative pressure wound therapy instillation and dwell and other wound irrigation needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we have a robust pipeline of products under development for the surgical and chronic wound care markets. Over the next few years, we
expect to introduce the following wound care and surgical products:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_2.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our pipeline efforts will deepen our comprehensive portfolio of offerings as well as allow us to address additional clinical
applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
WounDerm technology-based services include an EMR software platform for both wound and skin conditions, wound and skin virtual consult
services (through Direct Dermatology Inc.) and diagnostic products and services for chronic wounds through Precision Healing. Following
the anticipated launch of WounDerm, we expect to be able to provide wound treatment solutions for patients across the entire acute and
post-acute continuum of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_005.jpg" ALT="" STYLE="height: 351px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Drive additional market
    penetration as well as geographic expansion for our products.</I> While our primary markets for sales of our surgical products have
    historically been regional in nature, we are actively working to expand our geographic footprint across the entire United States.
    We also intend to leverage our comprehensive product, services and technology-based offerings portfolio and relationships with key
    constituents to deepen our presence in the chronic wound and skin care markets. We believe the breadth and flexibility of the products
    we offer allow us to address a wide variety of surgical site needs, wound types and sizes and offer significant new opportunities
    for sales growth. In addition, we believe that as we continue to offer new products, services and technology-based offerings, our
    salesforce&rsquo;s ability to reach additional customers in new and existing geographic regions while penetrating further in existing
    customer accounts will be enhanced.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Launch new innovative
    products.</I> We are actively developing additional proprietary products for the surgical and chronic wound and skin care markets.
    We expect these products and services to deepen our portfolio of technologies to improve surgical site outcomes and treat chronic
    wounds. We are focused on offering additional products and services that are more efficacious than competing products and services
    and provide a stronger value proposition (lower total cost to heal and less time to heal, leading to reduced costs to the healthcare
    system).</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Capture patients throughout
    the entire continuum of care.</I> We intend to continue expanding our platform to aid in treating wound and skin care patients as
    they progress through the healing process in all care settings. We formed WounDerm to hold certain investments in technologies and
    operations in wound and skin care virtual consult services. We believe our service offerings will allow us to collect and analyze
    large amounts of data on patient conditions and outcomes that will improve treatment protocols and ultimately lead to more evidence-based
    healing formularies to improve outcomes in the future. We anticipate that this data will also enable us to participate in the creation
    of new standards of care that promote patient compliance and enable direct dialogue between patients, clinicians and payors, resulting
    in greater satisfaction for patients, their caregivers, clinicians and payors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Seek and establish partnerships
    and product, services and/or technology acquisitions.</I> We plan to continue to seek and establish partnerships in the United States
    and internationally to provide innovative products, services, and technologies. We believe that partnerships will be a key driver
    of our growth in the future. We also intend to selectively pursue acquisitions of businesses and technologies that complement our
    existing strategy and footprint.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Seek and establish partnerships
    with Medicare Advantage, at-risk payors, and other types of healthcare at-risk models.</I> We believe we have assembled the products,
    services and technologies to offer a comprehensive strategy to help improve outcomes and lower wound care costs across the continuum
    of care. Looking ahead, we plan to leverage these capabilities to partner with value-based care models to aid in the treatment of
    their wound care patients who currently are a significant cost for the healthcare system and challenging population to heal. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competitive
Strengths</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attractive markets for
    surgical and chronic wound care.</I> We believe the surgical and chronic wound care markets will continue to see accelerated growth
    given favorable global tailwinds that include an aging population, increasing costs of health care, recognition of difficult-to-treat
    infection threats such as biofilms, and the increasing prevalence of diabetes and obesity. We believe there will be growing adoption
    of our products due to their clinical efficacy and cost effectiveness for all key constituents compared to traditional wound care
    products.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Comprehensive solution
    for improved wound care outcomes.</I> We are dedicated to offering a comprehensive portfolio of products, services and technologies
    to improve wound care treatment outcomes. We believe we are the only company that will be able to provide a comprehensive solution
    for wound care which includes a wound and skin specific EMR, virtual consult services with expert wound care providers and dermatologists,
    propriety diagnostics, and highly efficacious proprietary products allowing us to effectively treat wound care patients in any care
    setting.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Wound care products
    for all care settings.</I> Our wound care product portfolio allows clinicians to personalize solutions to meet the needs of individual
    wound care patients in all care settings including acute (hospitals and long-term acute care hospitals) and post-acute (wound care
    clinics, physician offices, SNFs, home health, hospice, podiatrists and retail).</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Innovative pipeline
    and proven clinical performance.</I> We have a robust pipeline of surgical and chronic wound and skin care products that we expect
    to market in the near term. We believe the efficacy of our offerings, will be proven via statistically significant collected and
    analyzed clinical and health economic outcomes data, resulting in expanded adoption of our products at a lower overall cost to payors.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proven executive leadership
    team with a long-term track record of value creation.</I> We are led by a dedicated and seasoned management team with significant
    industry experience who have successfully executed our strategic implementation to date by launching new products and technologies
    through investment in new areas of growth. We believe our management has the vision and experience to implement our future growth
    strategy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
Opportunities for Our Products, Services and Technology-Based Offerings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a study published by the <I>Value in Health</I> journal, roughly 15% of the Medicare beneficiary population has chronic nonhealing
wounds. Chronic wounds do not advance through the phases of healing in a normal progression and do not show significant progress toward
healing in 30 days. Factors contributing to the chronicity of the wound may include pressure/friction, trauma, insufficient blood
flow and oxygenation in locations such as the lower extremities, increased bacterial load, excessive proteases,
degraded growth factors, matrix metalloproteinases, senescent/aberrant cells or inappropriate treatment. Examples of chronic
wounds include DFUs, venous leg ulcers (&ldquo;VLUs&rdquo;), arterial ulcers, pressure ulcers and hard-to-heal surgical/traumatic wounds.
In each of the various wound types, the presence of biofilms is a frequent cause for chronification of wounds and the removal of biofilms
is a crucial step to commence healing. Biofilms need to be eradicated to prevent further deterioration of the wound that may result in
additional negative patient outcomes. If not effectively treated, these wounds can lead to potentially severe complications, including
further infection, osteomyelitis, fasciitis, amputation and increased mortality. Chronic wounds are primarily seen in the elderly population.
For example, a 2019 study published in <I>Advances in Wound Care </I>reported that in the United States, 3% of the population over the
age of 65 had open wounds. According to the same study, in 2020, the U.S. government estimated that the elderly population totaled 55
million people, suggesting that chronic wounds will continue to be an increasingly persistent problem in this population. Four common
chronic and other hard-to-heal wounds are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Surgical/traumatic wounds.
    </I>Surgical wounds form as a result of various types of surgical procedures such as investigative or corrective, minor or major,
    open (traditional) or minimal access surgery, elective or emergency, and incisions (simple cuts) or excision (removal of tissue),
    among others. Traumatic wounds form as a result of cuts, lacerations or puncture wounds, which have caused damage to the skin and
    underlying tissue. Severe traumatic wounds may require surgical intervention to close the wound and stabilize the patient. Surgical/traumatic
    hard-to-heal wounds develop for various reasons, such as local surgical complications, suboptimal closure techniques, presence of
    foreign materials, exposed bones or tendons and infection. In the United States, millions of people receive post-surgical wound care
    annually, and the typical operative patient has comorbidities that create challenges with post-operative wound healing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diabetic Foot Ulcers.
    </I>Diabetes can lead to a reduction in blood flow, which can cause patients to lose sensation in their feet and may prevent them
    from noticing injuries, sometimes leading to the development of DFUs, which are open sores or ulcers on the feet that may take several
    weeks to heal, if ever. According to the 2020 National Diabetes Statistics Report by the Center for Disease Control and Prevention,
    in the United States alone, over 34 million people, or approximately 10% of the population, suffer from diabetes, a chronic, life-threatening
    disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Venous Leg Ulcers. </I>VLUs
    develop as a result of vascular insufficiency, or the inability for the vasculature of the leg to return blood back toward the heart
    properly and, according to a 2013 report published by the <I>International Journal of Tissue Repair and Regeneration</I>, VLUs affect
    approximately 600,000 people per year in the United States alone. These ulcers usually form on the sides of the lower leg, above
    the ankle and below the calf, and are slow to heal and often recur if preventative steps are not taken. The risk of venous ulcers
    can be increased as a result of a blood clot forming in the deep veins of the legs, obesity, smoking, lack of physical activity or
    work that requires many hours of standing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pressure Ulcers. </I>Pressure
    ulcers, also known as decubitus ulcers or bed sores, are injuries to skin and underlying tissue resulting from prolonged pressure,
    or pressure in combination with shear or friction. Constant pressure on an area of skin reduces blood supply to the area and over
    time can cause the skin to break down and form an open ulcer. These often occur in patients who are hospitalized or confined to a
    chair or bed and most often form on the skin over bony areas, where there is little cushion between the bone and the skin, such as
    heels, ankles, hips and the tailbone. Annually, 2.5 million pressure ulcers are treated in the United States in acute care facilities
    alone, according to a 2006 study published in the <I>Journal of the American Medical Association</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Published Studies on CellerateRX</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CellerateRX
Surgical is a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness
wounds as well as first- and second-degree burns. CellerateRX Surgical is sterilized, packaged and designed, specifically for use in
the operating room (or sterile field), including additional sterility validation. It can be applied in the operating room to surgical
wounds that may result from a wide variety of surgical procedures to support the wound healing environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
research findings involving CellerateRX Surgical powder have been noted in scientific literature. For example, in November 2021, Dr.
William Hotchkiss published a retrospective study of 154 patients in <I>JSM Neurosurgery and Spine</I>, in which patients underwent spinal
surgery and CellerateRX Surgical was utilized in the surgical wound. The study found a lower wound dehiscence rate in a high-risk patient
population, when compared to previously published wound complication rates in the literature. Another retrospective case study
regarding the use of CellerateRX was recently published by Dr. Alex Gitelman in November 2022. This study of 54 patients undergoing spinal
surgery demonstrated no incidence of surgical wound complication. Lastly, an oral presentation given at the Surgical Infection Society&rsquo;s
41st Annual Meeting in April 2022 noted that, based on data from a study of 5,335 patients in a surgical registry, the use of CellerateRX
Surgical in patients undergoing elective surgery resulted in a 59% overall reduction in surgical wound complications. We believe that
studies like these further support the use of CellerateRX Surgical as an effective wound management agent in spinal surgery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the Rochal and Precision Healing acquisitions, our research and development activities have included internally developing additional
proprietary products, services and technologies for the surgical and chronic wound and skin care markets and actively working with third-party
research and development partners from which we license products. For our internally developed products, we seek patent protection for
our inventions in order to protect and differentiate our products and technologies and establish a defense against third-party infringement
claims. With the aim of optimizing commercial and regulatory success, our proprietary technology and innovative applications thereof
are protected by product, system, process, and method-of-use patent claims. We believe that our granted patents and pending applications
collectively protect our internally developed intellectual property, both in terms of our existing products, as well as our anticipated
pipeline of new offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, we acquired certain assets from Rochal, including intellectual property. With respect to the assets we acquired from Rochal
and products developed following the Rochal acquisition, our patent portfolio includes, among others, eight issued U.S. patents, including
U.S. Patent No. 8,829,053 entitled &ldquo;<I>Biocidal Compositions and Methods of Using the Same</I>&rdquo; (expiring December 7, 2031)
relating to BIAKO&#772;S AWC, BIAKO&#772;S AWG and BIASURGE Antimicrobial Surgical Wash, as well as over 100 issued patents in foreign
jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our acquisition by merger of Precision Healing in April 2022, described in further detail below, our patent portfolio now also includes,
among others, five pending U.S. patent applications as well as one pending international patent application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above patents, our pending patent applications and new filings are representative of our ongoing efforts to broaden our
portfolio as we continue developing new products for the surgical and chronic wound and skin care markets. We intend to further grow
our patent portfolio by continuing to patent new products as they are developed, to defend intellectual property as we believe necessary
by actively pursuing any infringements, to pursue the commercial opportunities our patents provide for our innovations, and to continue
to develop our brands and trademarks.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Acquisitions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, we acquired certain assets from Rochal, including, among others, intellectual property, four FDA 510(k) clearances, rights
to license certain products and technologies currently under development, equipment and supplies. As a result of the asset purchase,
our pipeline now contains product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure,
necrotic tissue debridement and cell compatible substrates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we closed a merger transaction with Precision Healing, pursuant to which Precision Healing became a wholly owned subsidiary
of the Company. Precision Healing is developing a diagnostic imager and LFA for assessing a patient&rsquo;s wound and skin conditions.
This comprehensive wound and skin assessment technology is designed to quantify biochemical markers to determine the
trajectory of a wound&rsquo;s condition to enable better diagnosis and treatment protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we entered into a membership interest purchase agreement with Scendia and the Seller pursuant to which we acquired 100% of
the issued and outstanding membership interests in Scendia from the Seller. Scendia provides clinicians and surgeons with a full line
of regenerative and orthobiologic technologies including (i) TEXAGEN, (ii) BiFORM, (iii) AMPLIFY and (iv) ALLOCYTE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
Developments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Precision
Healing Merger</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, in April 2022, we closed a merger transaction with Precision Healing pursuant to which Precision Healing became our
wholly owned subsidiary. Pursuant to the merger agreement, among other things, we agreed to (i) pay the holders of Precision Healing
common stock and preferred stock closing consideration consisting of 165,738 shares of our common stock, which was issued to accredited
investors, and $125,966 in cash, which was paid to stockholders who were not accredited investors (ii) pay approximately $0.6 million
of transaction expenses on behalf of the equity holders of Precision Healing, (iii) assume all outstanding options and warrants of Precision
Healing and (iv) pay, subject to the achievement of certain performance thresholds, earnout consideration of up to $10.0 million which
is payable in cash or, at our election, is payable to accredited investors in shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Scendia
Acquisition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, in July 2022, we entered into a membership interest purchase agreement by and among the Company, Scendia and Seller
pursuant to which we acquired 100% of the issued and outstanding membership interests in Scendia from the Seller. Scendia provides clinicians
and surgeons with a full line of regenerative and orthobiologic technologies. Beginning in early 2022, the Company began co-promoting
certain products with Scendia, including: (i) TEXAGEN, (ii) BiFORM, (iii) AMPLIFY and (iv) ALLOCYTE. Prior to the acquisition, Scendia
owned 50% of the issued and outstanding membership interests in Sanara Biologics, LLC (&ldquo;Sanara Biologics&rdquo;), and the Company
owned the remaining 50% of the membership interests. As a result of the acquisition, the Company indirectly acquired all the interests
in Sanara Biologics, such that the Company now holds 100% of the issued and outstanding equity interests in Sanara Biologics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the purchase agreement, the aggregate consideration at closing for the acquisition was $7.3 million, which consisted of (i) a $1.3
million cash payment, subject to certain adjustments, and (ii) 291,686 shares of our common stock, with an agreed upon value of $6.0
million. Pursuant to the purchase agreement, at closing, we withheld 94,798 shares of common stock with an agreed upon value of $1.95
million (the &ldquo;Indemnity Holdback Shares&rdquo;), which such Indemnity Holdback Shares shall be withheld, issued, and released to
the Seller after closing as and to the extent provided in the purchase agreement to satisfy the Seller&rsquo;s indemnification obligations,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the cash and stock consideration, the purchase agreement provides that the Seller is entitled to receive two potential earnout
payments, payable on an annual basis, not to exceed $10.0 million in the aggregate. The earnout consideration is payable to the Seller
in cash or, at our election, in up to 486,145 shares of our common stock upon the achievement of certain performance thresholds relating
to net revenue attributable to sales of Scendia products during the two-year period following the closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sanara
Pulsar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, we organized Sanara Pulsar, LLC, a Texas limited liability company (&ldquo;Sanara Pulsar&rdquo;), which was owned 60% by our
wholly owned subsidiary Cellerate, LLC (&ldquo;Cellerate&rdquo;), and 40% by Wound Care Solutions, Limited (&ldquo;WCS&rdquo;), an unaffiliated
company registered in the United Kingdom. At the time of the formation of Sanara Pulsar, Sanara Pulsar and WCS entered into a supply
agreement whereby Sanara Pulsar became the exclusive distributor in the United States of certain wound care products, including the Sanara
Pulsar II AWI Wound Debridement System, that utilized intellectual property developed and owned by WCS (collectively, the &ldquo;Pulsar
Products&rdquo;). When we formed Sanara Pulsar, we believed the Pulsar Products would provide clinicians with a novel debridement solution.
We also believed the Pulsar Products would receive an expanded reimbursement code for use by all clinician types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
we did not receive an additional reimbursement code, which limited the adoption of the Pulsar Products. Sanara Pulsar, which had minimal
sales since its inception, was dissolved effective December 2022. As a result, the Company recorded a noncash loss on disposal of investment
in the fourth quarter of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preliminary
Summary Results for Fourth Quarter and Fiscal Year 2022</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2023, we announced certain unaudited preliminary results for the fourth quarter and year ended December 31, 2022,
as described below. Our estimated unaudited financial condition and results of operations as of and for the fourth quarter and year ended
December 31, 2022 presented below are preliminary and are subject to change based upon the completion of our year-end closing procedures
and further financial review. Our independent registered public accounting firm has not completed its procedures with respect to the
preliminary financial information or its audit of our financial statements for the year ended December 31, 2022. Our actual results
may differ from these estimates as a result of the completion of our year-end closing procedures, review adjustments and other developments
that may arise between now and the time our financial results for the year are finalized. Our financial statements for the fourth quarter
and year ended December 31, 2022 will not be available when this offering commences, and consequently may not be available to you prior
to investing in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fourth quarter and year ended December 31, 2022, our unaudited preliminary results are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
                                            revenue of approximately $15.3 million for the three months ended December 31, 2022,
                                            compared to net revenue of $7.0 million for the three months ended December 31, 2021, which
                                            would represent a 119% increase from the prior year period.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
                                            revenue of approximately $45.8 million for the year ended December 31, 2022, compared
                                            to net revenue of $24.1 million for the year ended December 31, 2021, representing a 90%
                                            increase from the prior year. The higher net revenues in 2022 were primarily due to increased
                                            sales of surgical products as a result of our increased market penetration and expanded product
                                            offering, our continuing strategy implementation of expanding our sales force and
                                            independent distribution network in both new and existing U.S. markets, as well as
                                            additional revenues from the Scendia acquisition.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
                                            loss is expected to be between $2.0 million and $3.5 million for the three months
                                            ended December 31, 2022, compared to an operating loss of $3.4 million for the three months
                                            ended December 31, 2021.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
                                            loss is expected to be between $11.0 million and $12.5 million for the year ended
                                            December 31, 2022, compared to operating loss of $7.4 million for the year ended December
                                            31, 2021. The higher operating loss in 2022 was primarily due to higher expenses related
                                            to research and development, higher non-cash amortization expense related to intangible
                                            assets acquired as part of the Precision Healing and Scendia acquisitions and higher costs
                                            related to sales force expansion and operational support.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
                                            and cash equivalents were approximately $9.0 million as of December 31, 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a result of the dissolution of Sanara Pulsar discussed above, we recorded a non-cash loss on disposal of investment
in the fourth quarter of 2022 totaling approximately $1.0 million. The loss on disposal of investment will be included in &ldquo;Other
expense&rdquo; in our Statement of Operations for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Texas on December 14, 2001. Our principal executive offices are located at 1200 Summit Ave, Suite 414, Fort Worth,
Texas 76102, telephone number (817) 529-2300. Our website address is <I>www.sanaramedtech.com</I>. Information accessed through our website
is not incorporated into this prospectus supplement and is not a part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of our
    common stock having an aggregate offering price of up to $75.0 million.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock to be outstanding immediately after
    this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 10,115,760 shares, assuming sales at a price of $41.39 per share, which was the closing price of our common stock on The
    Nasdaq Capital Market on February 23, 2023. The actual number of shares issued will vary depending on the sales price under this
    offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan of Distribution</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At
    the market offering&rdquo; that may be made from time to time through our sales agent, Cantor Fitzgerald. See &ldquo;Plan of Distribution&rdquo;
    on page S-23.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently intend to use the net proceeds we receive from this offering to fund potential acquisitions, further develop our products,
    services and technologies pipeline and clinical studies, expand our sales force and for general corporate purposes. See the section
    titled &ldquo;Use of Proceeds&rdquo; beginning on page S-21 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend policy</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future
    earnings for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. See
    &ldquo;Dividend Policy&rdquo; beginning on page S-21 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. See the section titled &ldquo;Risk Factors&rdquo; beginning on page S-14
    of this prospectus supplement and page 4 of the accompanying prospectus and the other information included elsewhere, or incorporated
    by reference, in this prospectus supplement and the accompanying prospectus for a discussion of factors you should carefully consider
    before deciding to invest in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Nasdaq Capital Market Symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SMTI&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding immediately after this offering is based on 8,303,729 outstanding shares of common
stock as of September 30, 2022 and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155,691 shares of common
    stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $10.36 per share as of September
    30, 2022;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,725 shares of common
    stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $10.80 per share as of September
    30, 2022; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,518,805 shares of common stock reserved for future
    issuance under the Sanara MedTech Inc. Restated 2014 Omnibus Long Term Incentive Plan (the &ldquo;2014 Plan&rdquo;) as of September
    30, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
FACTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information
in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, before deciding
whether to invest in our common stock. You should also consider the risks, uncertainties and assumptions discussed under the heading
&ldquo;Risk Factors&rdquo; included in our most recent annual report on Form 10-K and the subsequent quarterly reports on Form 10-Q and
other reports that we file with the SEC and that are incorporated herein by reference, and which may be amended, supplemented or superseded
from time to time by other reports we file with the SEC in the future. If any of the following risks actually occur, our business, results
of operations and financial condition could be materially adversely affected. In this case, the trading price of our common stock would
likely decline, and you might lose part or all your investment in our common stock. The risks and uncertainties described below are not
the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also
harm our business. Please also read carefully the section below titled &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
Risks Related to Our Products and Our Product Pipeline</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
revenue generated from the sale of Scendia products is heavily dependent on license agreements with certain manufacturers, and the termination
of any of these license agreements could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we entered into a membership interest purchase agreement with Scendia and the Seller, pursuant to which we acquired 100% of
the issued and outstanding membership interests in Scendia from the Seller. Scendia provides clinicians and surgeons with a full line
of regenerative and orthobiologic technologies including (i) TEXAGEN, (ii) BiFORM, (iii) AMPLIFY and (iv) ALLOCYTE. We rely on license
agreements with certain manufacturers in order to sell Scendia products. These license agreements are nonexclusive and generally have
a term between one and five years. The license agreements are subject to renewal; however, the manufacturers may determine not to renew
the agreements or to terminate the contracts pursuant to their terms. We cannot be certain that these license agreements will continue
to be available to us or will be available to us on reasonable terms. If any of these agreements are terminated, we may be unable to
reacquire the necessary license on satisfactory terms or at all. The loss of, or inability to maintain, any of these license agreements
could negatively impact our ability to sell Scendia products, which could have a material adverse effect on our business, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interruptions
in the supply of our products or inventory loss may adversely affect our business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are manufactured using technically complex processes requiring specialized facilities, highly specific raw materials and other
production constraints. The complexity of these processes, as well as strict company and government standards for the manufacture and
storage of our products, subjects us to production risks. In addition to ongoing production risks, process deviations or unanticipated
effects of approved process changes may result in noncompliance with regulatory requirements including stability requirements or specifications.
Most of our products must be stored and transported within a specified temperature range. For example, if environmental conditions deviate
from that range, our products&rsquo; remaining shelf-lives could be impaired or their safety and efficacy could be adversely affected,
making them unsuitable for use. These deviations may go undetected. Severe weather conditions and natural disasters may make compliance
with these processes and maintenance of these standards more difficult, and climate change threatens more extreme weather events, which
could increase our production risks. The occurrence of actual or suspected production and distribution problems can lead to lost inventories,
and in some cases recalls, with consequential reputational damage and the risk of product liability. The investigation and remediation
of any identified problems can cause production delays and result in substantial additional expenses. Any unforeseen failure in the storage
of our products or loss in supply could result in a loss of our market share and negatively affect our revenues and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Scendia operates a state-licensed and FDA registered tissue bank for the storage and distribution of allograft tissue-based
products to hospitals, surgery centers and clinicians across the United States. We are currently experiencing, and may continue to experience,
disruptions in the supply of tissues. Such disruptions in the supply of tissues are having, and may continue to have, a negative impact
on our inventory of ALLOCYTE. Prolonged disruptions to the supply of our products or inventory could materially affect our business,
financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to this Offering and Ownership of Our Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
may experience immediate and substantial dilution.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the price per share of common stock being offered may be substantially higher than the net tangible book value per share of our common
stock, you may experience substantial dilution to the extent of the difference between the offering price per share of common stock you
pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible
book value as of September 30, 2022, was $9.2 million, or $1.10 per share of common stock. Net tangible book value per share is equal
to our total tangible assets minus total liabilities, all divided by the number of shares of common stock outstanding. Based on the assumed
public offering price of $41.39 per share of common stock in this offering, which was the last reported sale price of our common
stock on The Nasdaq Capital Market on February 23, 2023, and our historical net tangible book value per share as of September
30, 2022 described above, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution
of $33.31 per share. See &ldquo;Dilution&rdquo; for a more detailed description of the dilution to new investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
issuance of shares upon the exercise of derivative securities or as earnout payments may cause immediate and substantial dilution to
our existing shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we had approximately 172,416 shares of common stock that were issuable upon the exercise of vested outstanding
stock options and warrants. The issuance of shares upon the exercise of these stock options and warrants may result in dilution to the
equity interest and voting power of holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also issue additional shares of common stock or other securities convertible into or exchangeable for shares of common
stock. For instance, certain of the product license agreements we have entered into with third parties require us to make payments to
such third parties upon the occurrence of certain events. Pursuant to these product license agreements, we may choose to make such payments
in shares of our common stock. In addition, the Precision Healing merger agreement and the Scendia membership interest purchase agreement
require us to pay up to an aggregate of $20.0 million upon the achievement of certain performance thresholds. In each case and subject
to certain limitations, the earnout consideration is payable in cash or, at our election, in shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional shares of our common stock may substantially dilute the ownership interests of our existing shareholders. Furthermore,
sales of a substantial amount of our common stock in the public market, or the perception that these sales may occur, could reduce the
market price of our common stock. This could also impair our ability to raise additional capital through the sale of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management
will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways
that do not improve our results of operations or enhance the value of our common stock. Accordingly, you will be relying on the judgment
of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision,
to assess whether the proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse
effect on our business, delay the development of our products and cause the price of our common stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is possible that we will require additional capital to meet our financial obligations and support business growth, and this capital might
not be available on acceptable terms or at all; new investors face possible future dilution.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to make significant investments to support our business growth and expect to require additional funds to respond to
business challenges. Accordingly, we may need to engage in equity or debt financings to secure additional funds. If we raise additional
funds through future issuances of equity or convertible debt securities, our existing shareholders could suffer significant dilution,
and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock.
Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other
financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities,
including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable
to obtain adequate financing or financing on terms satisfactory to us when and if we require it, our ability to continue to support our
business growth and to respond to business challenges could be significantly impaired, and our business may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
trading price of the shares of our common stock is highly volatile, and purchasers of our common stock could incur substantial losses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock has been and is likely to continue to be highly volatile and could fluctuate widely in response to various
factors, many of which are beyond our control, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological innovations
    or new products and services by us or by our competitors, including announcements by us or our competitors of significant contracts,
    acquisitions, strategic partnerships or capital commitments;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures
    of key personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in expectations
    as to our future financial performance;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to execute
    our business plan;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of any strategic relationship;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">industry developments;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates
    by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate
    or maintain coverage of our common stock;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market conditions,
    including market volatility and inflation;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in stock market
    prices and trading volumes of similar companies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic, political and
    other external factors;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period fluctuations
    in our financial results;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable regulatory developments
    in the United States and foreign countries, both generally or specific to us and our products; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual property,
    product liability or other litigation against us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
publicly traded securities are subject to price and volume fluctuations, it is likely that our common stock will experience these fluctuations
to a greater degree than the securities of more established and better capitalized organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock does not have a vigorous trading market, and you may not be able to sell your securities at or near ask prices, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there is a public market for our common stock, trading volume has been historically low, which could impact our stock price and your
ability to sell shares of our common stock at or near ask prices, or at all. We can give no assurance that a more active and liquid public
market for the shares of our common stock will develop in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
potential sale of large amounts of common stock may have a negative effect upon the market value of our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a significant number of shares of our common stock in the public market or the perception that these sales might occur could harm
the market price of our common stock and make it more difficult for us to raise funds through future offerings of common stock. As additional
shares of our common stock become available for resale in the public market, the supply of our common stock will increase, which could
decrease the price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not paid, and we are unlikely to pay, cash dividends on our securities in the near future. Because we have no current plans to pay
cash dividends on our common stock for the foreseeable future, you may not receive any return on investment unless you sell your common
stock for a price greater than that which you paid for it.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid and do not currently intend to pay dividends on our common stock, which may limit the current return available on an investment
in our stock. Future dividends on our stock, if any, will depend on our future earnings, capital requirements, financial condition and
such other factors as our management may consider relevant. Currently, we intend to retain earnings, if any, to increase our net worth
and reserves. Consequently, shareholders will only realize an economic gain on their investment in our common stock if the price appreciates.
Shareholders should not purchase our common stock expecting to receive cash dividends. Because we currently do not pay dividends, and
there may be limited trading in our common stock, shareholders may not have any manner to liquidate or receive any payment on their common
stock. Therefore, our failure to pay dividends may cause shareholders to not see any return on their common stock even if we are successful
in our business operations. In addition, because we do not pay dividends, we may have trouble raising additional funds, which could affect
our ability to expand our business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
few of our existing shareholders own a large percentage of our voting stock and have control over matters requiring shareholder approval
and may delay or prevent a change in control or otherwise lead to actual or potential conflicts of interest.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, our directors beneficially owned, including through their affiliates, 55.0% of our outstanding common stock. As
a result, our directors and their affiliates could have the ability to exert substantial influence over all matters requiring approval
by our shareholders, including (i) the election and removal of directors, (ii) any proposed merger, consolidation or sale of all or substantially
all of our assets as well as other corporate transactions and (iii) any amendment to our Certificate of Formation, as amended (the &ldquo;Certificate
of Formation&rdquo;). This concentration of control could be disadvantageous to other shareholders having different interests. This significant
concentration of share ownership may adversely affect the trading price for our common stock because investors sometimes perceive disadvantages
in owning stock in companies with controlling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Certificate of Formation contains a provision which under the Texas Business Organizations Code (the &ldquo;TBOC&rdquo;)
could allow the shareholders who own a majority of our common stock to approve certain major transactions without the approval of other
shareholders that otherwise would be required under Texas corporation law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Certificate of Formation includes provisions limiting the personal liability of our directors for breaches of fiduciary duties under
Texas law.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Formation contains a provision eliminating a director&rsquo;s personal liability to the fullest extent permitted under
Texas law. Pursuant to the TBOC, a corporation has the power to indemnify its directors and officers against judgments and certain expenses
other than judgments that are actually and reasonably incurred in connection with a proceeding, provided that there is a determination
that the individual acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the corporation
and, with respect to any criminal proceeding, had no reasonable cause to believe the individual&rsquo;s conduct was unlawful. However,
no indemnification may be made in respect of any proceeding in which such individual is liable to the corporation or improperly received
a personal benefit and is found liable for willful misconduct, breach of the duty of loyalty owed to the corporation, or an act or omission
deemed not to be committed in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal effect of the limitation on liability provision is that a shareholder will be unable to prosecute an action for monetary damages
against a director unless the shareholder can demonstrate a basis for liability for which indemnification is not available under the
TBOC. This provision, however, should not limit or eliminate our rights or any shareholder&rsquo;s rights to seek nonmonetary relief,
such as an injunction or rescission, in the event of a breach of a director&rsquo;s fiduciary duty. This provision will not alter a director&rsquo;s
liability under federal securities laws. The inclusion of this provision in our Certificate of Formation may discourage or deter shareholders
or management from bringing a lawsuit against directors for a breach of their fiduciary duties, even though such an action, if successful,
might otherwise have benefited us and our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Texas
law and our Certificate of Formation and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that
shareholders may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Certificate of Formation, our board of directors can authorize the issuance of preferred stock, which could diminish the rights of
holders of our common stock and make a change of control of the Company more difficult even if it might benefit our shareholders. The
board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences and
other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our common
stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely affect the voting or
other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences and designations of
the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control might
benefit our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, provisions of our Certificate of Formation and bylaws may delay or discourage transactions involving an actual or potential
change in our control or change in our management, including transactions in which shareholders might otherwise receive a premium for
their shares, or transactions that our shareholders might otherwise deem to be in their best interests. For example, our Certificate
of Formation and bylaws (i) do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of
common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose),
(ii) require that special meetings of the shareholders be called by the Chairman of the board of directors, the President or the board
of directors, or by the holders of not less than ten percent (10%) of all the shares issued, outstanding and entitled to vote, (iii)
permit our board of directors to alter, amend or repeal our bylaws or to adopt new bylaws, and (iv) enable our board of directors to
increase the number of persons serving as directors and to fill vacancies created as a result of the increase by a majority vote of the
directors present at a meeting of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are subject to the provisions of Title 2, Chapter 21, Subchapter M of the TBOC, which provides that a Texas corporation that qualifies
as an &ldquo;issuing public corporation&rdquo; (as defined in the TBOC) may not engage in specified types of business combinations, including
mergers, consolidations and asset sales, with a person, or an affiliate or associate of that person, who is an &ldquo;affiliated shareholder,&rdquo;
the restrictions in Title 2, Chapter 21, Subchapter M of the TBOC do not apply to us because we have elected, in the manner provided
under the TBOC, not to be subject to such provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are currently listed for trading on The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo; If we fail
to satisfy the continued listing requirements of The Nasdaq Stock Market, LLC (&ldquo;Nasdaq&rdquo;), such as the corporate governance
requirements, the shareholder&rsquo;s equity requirement or the minimum closing bid price requirement, Nasdaq may take steps to delist
our common stock. Such a delisting or even notification of failure to comply with such requirements would likely have a negative effect
on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event
of a delisting, we expect that we would take actions to restore our compliance with Nasdaq&rsquo;s listing requirements, but we can provide
no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve
the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future
noncompliance with Nasdaq&rsquo;s listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus and the documents incorporated herein and therein contain forward-looking statements
within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or our future financial
or operating performance. In some cases, you can identify forward-looking statements because they contain words such as &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;contemplates,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;guidance,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;possible,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;preliminary,&rdquo; &ldquo;projects,&rdquo; &ldquo;seeks,&rdquo; &ldquo;should,&rdquo;
&ldquo;target,&rdquo; &ldquo;will&rdquo; or &ldquo;would&rdquo; or the negative of these words, variations of these words or other similar
terms or expressions that concern our expectations, strategy, plans, or intentions. Such forward-looking statements are subject to certain
risks, uncertainties and assumptions relating to factors that could cause actual results to differ materially from those anticipated
in such statements, including, without limitation, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shortfalls in forecasted
    revenue growth;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to implement
    our comprehensive wound and skin care strategy through acquisitions and investments and our ability to realize the anticipated benefits
    of such acquisitions and investments;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet our
    future capital requirements;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain and
    recruit key personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the intense competition
    in the markets in which we operate and our ability to compete within our markets;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of our products
    to obtain market acceptance;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of security
    breaches and other disruptions;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    effective internal controls over financial reporting;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to develop
    and commercialize new products and products under development, including the manufacturing, distribution, marketing and sale of such
    products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    and further grow clinical acceptance and adoption of our products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competitors
    inventing products that are superior to ours;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions of, or changes
    in, our distribution model, consumer base or the supply of our products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manage product
    inventory in an effective and efficient manner;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of third-party
    assessments to demonstrate desired outcomes in proposed endpoints;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    expand into wound and skin care virtual consult and other services;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability and the ability
    of our research and development partners to protect the proprietary rights to technologies used in certain of our products and the
    impact of any claim that we have infringed on intellectual property rights of others;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on technologies
    and products that we license from third parties;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the COVID-19
    pandemic on our business, financial condition, and results of operations;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of current
    and future laws, rules, regulations and reimbursement policies relating to the labeling, marketing and sale of our products and our
    planned expansion into wound and skin care virtual consult and other services and our ability to comply with the various laws, rules
    and regulations applicable to our business; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of defects,
    failures or quality issues associated with our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
caution that the foregoing list may not contain all of the risk factors that may impact the forward-looking statements made in this prospectus
supplement and the accompanying prospectus and the documents incorporated herein and therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained
in this prospectus supplement and the accompanying prospectus and the documents incorporated by reference herein and therein primarily
on our current expectations and projections about future events and trends that we believe may affect our business, financial condition,
results of operations, and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties
and other factors described in the section titled &ldquo;Risk Factors&rdquo; in this prospectus supplement and the accompanying prospectus
and in the documents incorporated by reference herein and therein. Moreover, we operate in a very competitive and rapidly changing environment.
New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could
have an impact on the forward-looking statements contained in this prospectus supplement and the accompanying prospectus and the documents
incorporated by reference herein and therein. We cannot assure you that the results, events, and circumstances reflected in the forward-looking
statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the
forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements made, or incorporated by reference, in this prospectus supplement and the accompanying prospectus relate only
to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made,
or incorporated by reference, in this prospectus supplement and the accompanying prospectus to reflect events or circumstances after
the date of this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein or therein or to
reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans,
intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint
ventures, or investments we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that include &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this prospectus supplement and the accompanying prospectus,
and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available
relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE
OF PROCEEDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue and sell shares of our common stock having aggregate sales proceeds of up to $75.0 million from time to time. Because there
is no minimum offering amount required to be sold in connection with this offering, the actual total public offering amount, commissions
and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under, or fully
utilize, the Sales Agreement with Cantor Fitzgerald as a source of financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. We currently intend to
use the net proceeds we receive from this offering to fund potential acquisitions, further develop our products, services and technologies
pipeline and clinical studies, expand our sales force and for general corporate purposes. While we do not have definitive agreements
or binding commitments for any specific acquisitions at this time, we are constantly seeking long-term strategic partnerships with a
focus on products that improve outcomes at a lower overall cost. In particular, we are actively seeking to expand within our six focus
areas of wound and skincare for the acute, post-acute, and surgical markets, including debridement, biofilm removal, hydrolyzed collagen,
advanced biologics, negative pressure wound therapy adjunct products and the oxygen delivery system segment of the healthcare industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected use of the net proceeds from this offering and our existing cash and our cash equivalents and short-term investments represents
our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions
evolve. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular uses for the proceeds to
be received in connection with this offering or the actual amounts that we will spend on the uses set forth above. Pending our use of
the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including
short-term, investment-grade, interest-bearing instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET
INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock currently trades on The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo; On February 23, 2023, the last
reported sale price of our common stock on The Nasdaq Capital Market was $41.39 per share. As of February 23, 2023, we
had 273 holders of record of our common stock. This does not reflect the number of persons or entities who held stock in nominee
or street name through various brokerage firms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND
POLICY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any decision to declare
and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our
results of operations, cash requirements, financial condition, contractual restrictions, and other factors that our board of directors
may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the offering price
per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering.
As of September 30, 2022, our historical net tangible book value was $9.2 million, or $1.10 per share of our common stock. Our historical
net tangible book value is the amount of our total tangible assets less our liabilities. Historical net tangible book value per share
is our historical net tangible book value divided by the number of shares of common stock outstanding as of September 30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
as adjusted net tangible book value as of September 30, 2022, which is our net tangible book value at that date, after giving effect
to the sale of $75.0 million of our common stock in this offering by us at an assumed public offering price of $41.39 per share,
which is the last reported sale price of our common stock on The Nasdaq Capital Market on February 23, 2023, and after deducting
the estimated commissions and estimated offering expenses payable by us, would have been $81.7 million, or $8.08 per share.
This amount represents an immediate increase in net tangible book value of approximately $6.98 per share to our existing shareholders
and an immediate dilution of $33.31 per share to investors participating in this offering. Dilution per share to investors participating
in this offering is determined by subtracting as adjusted net tangible book value per share after this offering from the assumed public
offering price per share paid by investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    public offering price per share</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value per share as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in net tangible book value per share attributable to new investors purchasing shares of common stock in this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.98</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    adjusted net tangible book value per share after giving effect to this offering</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.08</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    per share to investors participating in this offering</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.31</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above assumes for illustrative purposes that an aggregate of 1,812,031 shares of our common stock are sold at a price of
$41.39 per share, the last reported sales price of our common stock on The Nasdaq Capital Market on February 23, 2023,
for aggregate gross proceeds of approximately $75.0 million. The shares sold in this offering, if any, will be sold from time to time
at various prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above discussion and table are based on 8,303,729 outstanding shares of common stock as of September 30, 2022. This number excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155,691 shares of common
    stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $10.36 per share as of September
    30, 2022; </FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,725 shares of common
    stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $10.80 per share as of September
    30, 2022; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,518,805 shares of common
    stock reserved for future issuance under the 2014 Plan as of September 30, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any outstanding options or warrants are exercised, new options, warrants or restricted stock units are issued under our
stock-based compensation plans or we issue additional shares of common stock or other equity or convertible debt securities in the future,
there will be further dilution to investors participating in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN
OF DISTRIBUTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald.
Pursuant to this prospectus supplement, we may offer and sell shares of our common stock having an aggregate gross sales price of up
to $75.0 million from time to time through Cantor Fitzgerald acting as sales agent. A copy of the Sales Agreement will be filed as an
exhibit to a Current Report on Form 8-K and will be incorporated by reference into this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald may sell shares of our
common stock by any method permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) promulgated
under the Securities Act. We may instruct Cantor Fitzgerald not to sell common stock if the sales cannot be effected at or above the
price designated by us from time to time. We or Cantor Fitzgerald may suspend the offering of common stock upon notice and subject to
other conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay Cantor Fitzgerald commissions, in cash, for its service in acting as agent in the sale of our common stock. Cantor Fitzgerald
will be entitled to compensation at a commission rate of 3.0% of the sales price per share sold under the Sales Agreement. Because there
is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and
proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cantor Fitzgerald for certain specified expenses,
including the fees and disbursements of its legal counsel in an amount not to exceed $75,000 and certain ongoing expenses. We estimate
that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor Fitzgerald under the terms of the
Sales Agreement, will be approximately $120,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
for sales of shares of our common stock will occur on the second business day following the date on which any sales are made, or on some
other date that is agreed upon by us and Cantor Fitzgerald in connection with a particular transaction, in return for payment of the
net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of
The Depository Trust Company or by such other means as we and Cantor Fitzgerald may agree upon. There is no arrangement for funds to
be received in an escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase
the common stock shares under the terms and subject to the conditions set forth in the Sales Agreement. In connection with the sale of
the common stock on our behalf, Cantor Fitzgerald will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities
Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification
and contribution to Cantor Fitzgerald with respect to certain civil liabilities, including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of shares of our common stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as
permitted therein. We and Cantor Fitzgerald may each terminate the Sales Agreement at any time upon ten days&rsquo; prior notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald and its affiliates may in the future provide various investment banking, commercial banking and other financial services for
us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor
Fitzgerald will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus may be made available in electronic format on a website maintained by Cantor Fitzgerald,
and Cantor Fitzgerald may distribute this prospectus supplement and the accompanying prospectus electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
MATTERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered hereby will be passed upon for us by Haynes and Boone, LLP, Dallas, Texas. Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., Boston, Massachusetts, is acting as counsel for the sales agent in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of December 31, 2021 and for the year then ended incorporated by reference in this prospectus supplement have
been audited by Weaver and Tidwell, L.L.P., an independent registered public accounting firm, as stated in its report, which is incorporated
by reference in this prospectus supplement, and is incorporated by reference in reliance upon the report of such firm given upon its
authority as experts in accounting and auditing. Our financial statements as of December 31, 2020 and for the year then ended incorporated
by reference in this prospectus supplement have been audited by MaloneBailey, LLP, an independent registered public accounting firm,
as stated in its report, which is incorporated by reference in this prospectus supplement, and is incorporated by reference in reliance
upon the report of such firm given upon its authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the SEC. The
SEC maintains an internet website at <I>www.sec.gov</I> that contains periodic and current reports, proxy and information statements
and other information regarding registrants that are filed electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
documents are also available, free of charge, through the Investor Relations section of our website, which is located at <I>www.sanaramedtech.com</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement under the Securities Act relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus supplement
does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement
for free at <I>www.sec.gov</I>. The registration statement and the documents referred to below under &ldquo;Incorporation of Documents
by Reference&rdquo; are also available on our website, <I>www.sanaramedtech.com</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not incorporated by reference into this prospectus supplement the information on our website, and you should not consider it to
be a part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Ha_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION
OF DOCUMENTS BY REFERENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can disclose important
information to you by referring you to those documents. The information we incorporate by reference is an important part of this prospectus
supplement, and later information that we file with the SEC will automatically update and supersede this information. We specifically
are incorporating by reference the following documents and any future documents we file with the SEC (excluding those portions of any
Current Report on Form 8-K that are furnished and not deemed &ldquo;filed&rdquo; pursuant to the General Instructions of Form 8-K):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222008222/form10-k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K</A> for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the portions of our <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000149315222011478/def14a.htm" STYLE="-sec-extract: exhibit">Definitive Proxy Statement on Schedule 14A</A>, filed with the SEC on April 29, 2022, that were deemed to be filed with the SEC;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Reports on
    Form 10-Q <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222013810/form10-q.htm" STYLE="-sec-extract: exhibit">for the quarter ended March 31, 2022</A>, filed with the SEC on May 16, 2022, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222022851/form10-q.htm" STYLE="-sec-extract: exhibit">for the quarter ended June 30, 2022</A>, filed with
    the SEC on August 15, 2022, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222031983/form10-q.htm" STYLE="-sec-extract: exhibit">for the quarter ended September 30, 2022</A>, filed with the SEC on November 14, 2022;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on
    Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222000557/form8-k.htm" STYLE="-sec-extract: exhibit">January 6, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222007915/form8-k.htm" STYLE="-sec-extract: exhibit">March 28, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222008931/form8-k.htm" STYLE="-sec-extract: exhibit">April 4, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222009477/form8-k.htm" STYLE="-sec-extract: exhibit">April 8, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222011475/form8-k.htm" STYLE="-sec-extract: exhibit">April 29, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222016456/form8-k.htm" STYLE="-sec-extract: exhibit">June 10, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222018458/form8-k.htm" STYLE="-sec-extract: exhibit">July 5, 2022</A> (as amended on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222019436/form8-ka.htm" STYLE="-sec-extract: exhibit">July 15, 2022</A>) and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/714256/000149315222034594/form8-k.htm" STYLE="-sec-extract: exhibit">December 6, 2022</A>; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our
    securities contained in <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495421003520/smti_ex41.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to our Annual Report on Form 10-K, filed with the SEC on March 31, 2022, including all amendments
    and reports filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained herein or in any document incorporated or deemed to be incorporated by reference shall be deemed to be modified or
superseded for purposes of this prospectus supplement to the extent that a statement contained in any other subsequently filed document
which also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed to constitute a part of this prospectus supplement, except as so modified or superseded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person to whom a copy of this prospectus supplement is delivered, upon written or oral request, a
copy of any or all of the information that has been incorporated by reference in this prospectus supplement but not delivered with this
prospectus supplement (other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in
this prospectus supplement). Any such request should be addressed to us at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102 (telephone:
817-529-2300).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access the documents incorporated by reference in this prospectus through our website at <I>www.sanaramedtech.com</I>. Except
for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated
in this prospectus supplement or the registration statement of which it forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="prospectus_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Sanara MedTech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$150,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may offer and sell from time
to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities
described in this prospectus, up to an aggregate amount of $150,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We will provide specific terms
of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in
this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated
or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">These securities may be offered
and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The
names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation and any over-allotment options
held by them will be described in the applicable prospectus supplement. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on
The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo; On December 22, 2020, the last reported sale price of our common stock
was $52.42 per share as reported on The Nasdaq Capital Market. We recommend that you obtain current market quotations for our common stock
prior to making an investment decision. We will provide information in any applicable prospectus supplement regarding any listing of securities
other than shares of our common stock on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>You should carefully read this
prospectus, any prospectus supplement relating to any specific offering of securities, and all information incorporated by reference herein
and therein.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves a high degree of risk. These risks are discussed in this prospectus under &ldquo;Risk Factors&rdquo; beginning on page 4 and
in the documents incorporated by reference in this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities and
Exchange Commission (the &ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">The date of this prospectus is January
4, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_001"><FONT STYLE="font-size: 10pt">About This Prospectus</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_002"><FONT STYLE="font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_003"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_004"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_005"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_006"><FONT STYLE="font-size: 10pt">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_007"><FONT STYLE="font-size: 10pt">Description of Warrants</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_008"><FONT STYLE="font-size: 10pt">Description of Units</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_009"><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_010"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_011"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_012"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Hz_013"><FONT STYLE="font-size: 10pt">Incorporation of Documents by Reference</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of a registration
statement on Form S-3 that we filed with the SEC using a &ldquo;shelf&rdquo; registration process. Under this shelf process, we may, from
time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total amount of $150,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus provides you with
a general description of the securities we may offer. Each time we sell securities under this prospectus, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add to, update
or change information contained in the prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded
by the information in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus may not be used
to sell securities unless it is accompanied by a prospectus supplement that describes those securities. The prospectus supplement to be
attached to the front of this prospectus may describe, as applicable: the terms of the securities offered; the public offering price;
the price paid for the securities; net proceeds; and the other specific terms related to the offering of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">You should only rely on the information
contained or incorporated by reference in this prospectus and any prospectus supplement or issuer free writing prospectus relating to
a particular offering. No person has been authorized to give any information or make any representations in connection with this offering
other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related issuer
free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations
must not be relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement nor any related issuer
free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction
in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the information
included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration
statement, including its exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">You should read the entire prospectus
and any prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference into
this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither
the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under
any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free
writing prospectus is correct as of any date subsequent to the date hereof or of such document incorporated by reference, prospectus supplement
or issuer free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus
supplement, any issuer free writing prospectus, or any document incorporated by reference is accurate only as of the date of the applicable
documents, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results
of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Sanara, Sanara MedTech, our logo
and other trademarks or service marks appearing in this prospectus and the documents incorporated by reference herein are the property
of Sanara MedTech, Inc. Trade names, trademarks and service marks of other companies appearing in this prospectus and the documents incorporated
by reference herein are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names
included in this prospectus and the documents incorporated by reference herein are without the &reg;, &trade; or other applicable symbols,
but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our
rights or the rights of the applicable licensors to these trademarks, service marks and trade names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_002"></A><B>CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and the documents
incorporated by reference herein contain forward-looking statements within the meaning of the federal securities laws. Forward-looking
statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking
statements because they contain words such as &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;continue,&rdquo; &ldquo;contemplates,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predicts,&rdquo; &ldquo;projects,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will&rdquo; or &ldquo;would&rdquo;
or the negative of these words, variations of these words or other similar terms or expressions that concern our expectations, strategy,
plans, or intentions. Such forward-looking statements are subject to certain risks, uncertainties and assumptions relating to factors
that could cause actual results to differ materially from those anticipated in such statements, including, without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="width: 0.25in">&#9679;</TD>
  <TD>unanticipated changes in the markets for the Company&rsquo;s business;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>unanticipated downturns in business relationships with customers or their purchases from us;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>the potential effects on our businesses from natural disasters;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>the availability of credit to customers and suppliers;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>competitive pressures on sales and pricing;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>unanticipated changes in the cost of inventory and other operating costs;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>the introduction of competing products;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>unexpected technical or marketing difficulties;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>unexpected claims, charges, litigation or dispute resolutions;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>new laws and governmental regulations;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>stock market and currency fluctuations;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>war, civil or political unrest or terrorism;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>the course of the COVID-19 pandemic and government responses thereto; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>unanticipated deterioration of economic and financial conditions in the United States and around the world.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We caution you that the foregoing
list may not contain all of the risk factors that may impact the forward-looking statements made in this prospectus and the documents
incorporated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">You should not rely upon forward-looking
statements as predictions of future events. We have based the forward-looking statements contained in this prospectus primarily on our
current expectations and projections about future events and trends that we believe may affect our business, financial condition, results
of operations, and prospects. The outcome of the events described in these forward-looking statements is subject to risks,&nbsp;uncertainties
and other factors described in the section titled &ldquo;Risk Factors&rdquo; in this prospectus<I>&nbsp;</I>and in the documents incorporated
by reference in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties
emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking
statements contained in this prospectus. We cannot assure you that the results, events, and circumstances reflected in the forward-looking
statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the
forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
made, or incorporated by reference, in this prospectus relate only to events as of the date on which the statements are made. We undertake
no obligation to update any forward-looking statements made, or incorporated by reference, in this prospectus to reflect events or circumstances
after the date of this prospectus or the documents incorporated by reference herein or to reflect new information or the occurrence of
unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, statements that &ldquo;we
believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information
available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements,
such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive
inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are
cautioned not to unduly rely upon these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="Hz_003"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary provides an overview
of selected information contained elsewhere or incorporated by reference in this prospectus and does not contain all of the information
you should consider before investing in our securities. You should carefully read the prospectus, the information incorporated by reference
and the registration statement of which this prospectus is a part in their entirety before investing in our securities, including the
information discussed under &ldquo;Risk Factors&rdquo; in this prospectus and the documents incorporated by reference and our financial
statements and notes thereto that are incorporated by reference in this prospectus. Some of the statements in this prospectus and the
documents incorporated by reference herein constitute forward-looking statements that involve risks and uncertainties. See information
set forth under the section &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo; In this prospectus, unless the context
otherwise requires, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Sanara MedTech&rdquo;
refer to Sanara MedTech Inc. and its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We develop, market and distribute
wound and skin care products to physicians, hospitals, clinics and post-acute care settings. Our products are primarily sold in the North
American advanced wound care and surgical tissue repair markets. Sanara MedTech products include CellerateRX Surgical Activated Collagen
Adjuvant (&ldquo;CellerateRX&rdquo;), HYCOL Hydrolyzed Collagen (&ldquo;HYCOL&rdquo;), BIAK&#332;S Antimicrobial Skin &amp; Wound Cleanser
(&ldquo;BIAK&#332;S AWC&rdquo;), BIAK&#332;S Antimicrobial Skin and Wound Irrigation Solution and BIAK&#332;S Antimicrobial Wound Gel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">CellerateRX products are primarily
purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds. HYCOL products are used in skilled nursing
facilities, wound care clinics and other medical facilities, and are intended for the management of full and partial thickness wounds
including pressure ulcers, venous and arterial leg ulcers and diabetic foot ulcers. HYCOL is currently approved for reimbursement under
Medicare Part B. We believe CellerateRX and HYCOL products are unique in composition, superior to other products in clinical performance,
and demonstrate the ability to reduce costs associated with the standards of care for their intended uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">BIAK&#332;S AWC is an FDA cleared,
patented product that effectively disrupts extracellular polymeric substances to eradicate biofilm microbes. BIAK&#332;S AWC also provides
mechanical removal of debris, dirt, foreign materials, and microorganisms from wounds including stage I-IV pressure ulcers, diabetic foot
ulcers, post-surgical wounds, first and second-degree burns as well as grafted and donor sites. BIAK&#332;S AWC is effective in killing
free-floating microbes, immature, and mature bacterial biofilms and fungal biofilms. In addition, safety studies demonstrated that BIAK&#332;S
AWC is biocompatible and supports the wound healing process. Initial sales of BIAK&#332;S AWC occurred in July 2019. BIAK&#332;S AWC
is also available in an irrigation bottle (BIAK&#332;S Antimicrobial Skin and Wound Irrigation Solution) that can be used in conjunction
with negative pressure wound therapy installation and dwell (NPWTi-d) and other wound irrigation needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">BIAKO&#772;S Antimicrobial Wound
Gel is an antimicrobial hydrogel wound dressing that can be used alone or in combination with BIAKO&#772;S AWC. Based on laboratory studies,
when used in conjunction, the products can work together to enhance effectiveness. The cleanser is applied initially to clean a wound
and disrupts biofilm microbes (removing 99% in 10 minutes). The gel can then be applied and will remain in the wound for up to 72 hours
helping to continue to disrupt biofilm microbes. When used in clinical settings, BIAKO&#772;S Antimicrobial Wound Gel is indicated for
the management of partial and full thickness wounds, such as diabetic foot ulcers, post-surgical wounds, pressure ulcers, first and second-degree
burns, grafts and donor sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Texas
on December 14, 2001. On March 15, 2019, we entered into a Share Exchange Agreement with CGI Cellerate RX, LLC, an affiliate of The Catalyst
Group, Inc. (&ldquo;Catalyst&rdquo;), pursuant to which we acquired Catalyst&rsquo;s 50% equity interest in Cellerate, LLC (&ldquo;Cellerate&rdquo;)
in exchange for 1,136,815 shares of our newly created Series F Convertible Preferred Stock (the &ldquo;Cellerate Acquisition&rdquo;).
Prior to the consummation of the Cellerate Acquisition, we and Catalyst each owned a 50% equity interest in Cellerate. The Cellerate Acquisition
was accounted for as a reverse merger, and Cellerate was deemed to be the accounting acquirer. In May 2019, we changed our name to Sanara
MedTech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102, telephone number (817) 529-2300. Our website address is www.sanaramedtech.com.
Information accessed through our website is not incorporated into this prospectus and is not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Offerings Under This Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may offer up to $150,000,000
of common stock, preferred stock, warrants and/or units in one or more offerings and in any combination. This prospectus provides you
with a general description of the securities we may offer. A prospectus supplement, which we will provide each time we offer securities,
will describe the specific amounts, prices and terms of these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may issue shares of our common
stock from time to time. The holders of common stock are entitled to one vote per share. Our Certificate of Formation, as amended (the
&ldquo;Certificate of Formation&rdquo;), does not provide for cumulative voting. All of our directors hold office for one-year terms until
the election and qualification of their successors. The holders of our common stock are entitled to receive ratably such dividends, if
any, as may be declared by the board of directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders
of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common
stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common
stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated
solely by action of the board of directors and issued in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may issue shares of our preferred
stock from time to time, in one or more series. Our board of directors will determine the rights, preferences, privileges and restrictions
of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking
fund terms and the number of shares constituting any series or the designation of such series, without any further vote or action by shareholders.
Convertible preferred stock will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory
or at your option or both and would be at prescribed conversion rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we sell any series of preferred
stock under this prospectus and applicable prospectus supplements, we will fix the rights, preferences, privileges and restrictions of
the preferred stock of such series in the certificate of designation relating to that series. We will file as an exhibit to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any
certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related
series of preferred stock. We urge you to read the applicable prospectus supplement related to the series of preferred stock being offered,
as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants for the
purchase of common stock or preferred stock in one or more series. We may issue warrants independently or together with common stock or
preferred stock, and the warrants may be attached to or separate from these securities. We will evidence each series of warrants by warrant
certificates that we will issue under a separate agreement. We may enter into warrant agreements with a bank or trust company that we
select to be our warrant agent. We will indicate the name and address of any such warrant agent in the applicable prospectus supplement
relating to a particular series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, we have summarized
certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement related to the particular
series of warrants being offered, as well as the warrant agreements and warrant certificates that contain the terms of the warrants. We
will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports
that we file with the SEC, the form of warrant agreement or warrant certificate containing the terms of the warrants we are offering before
the issuance of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units consisting
of common stock, preferred stock and/or warrants for the purchase of common stock or preferred stock in one or more series. In this prospectus,
we have summarized certain general features of the units. We urge you, however, to read the applicable prospectus supplement related to
the series of units being offered, as well as the unit agreements that contain the terms of the units. We will file as exhibits to the
registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the
form of unit agreement and any supplemental agreements that describe the terms of the series of units we are offering before the issuance
of the related series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><I>An investment in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the specific factors
discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement, together with all of the other information
contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You
should also consider the risks, uncertainties and assumptions discussed under Item 1A, &ldquo;Risk Factors,&rdquo; in our most recent
Annual Report on Form 10-K and any updates in our Quarterly Reports on Form 10-Q or in other documents that are filed after the date hereof
and incorporated by reference into this prospectus and any prospectus supplement related to a particular offering. The risks and uncertainties
we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also affect our operations. Past financial performance may not be a reliable indicator of future performance, and historical
trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business
prospects, financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section above entitled &ldquo;Cautionary
Statement Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_005"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that we will
receive any proceeds in connection with securities which may be offered pursuant to this prospectus. Unless otherwise indicated in the
applicable prospectus supplement, we intend to use any net proceeds from the sale of securities under this prospectus for our operations
and for other general corporate purposes, including, but not limited to, general working capital and possible future acquisitions. We
have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our
management will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant
to this prospectus for any purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds
in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations
of the U.S. government, hold the net proceeds as cash or apply the net proceeds to the reduction of short-term indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_006"></A><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following description of common
stock and preferred stock summarizes the material terms and provisions of the common stock and preferred stock that we may offer under
this prospectus, but is not complete. For the complete terms of our common stock and preferred stock, please refer to our Certificate
of Formation, any certificates of designation for our preferred stock and our bylaws. While the terms we have summarized below will apply
generally to any future common stock or preferred stock that we may offer, we will describe the specific terms of any series of preferred
stock in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any preferred
stock we offer under that prospectus supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have authorized 22,000,000
shares of capital stock, 20,000,000 of which are designated as common stock, par value $0.001 per share, and 2,000,000 of which are designated
as &ldquo;blank check&rdquo; preferred stock, par value $10.00 per share, none of which are currently designated as an outstanding series.
On December 21, 2020, there were 6,293,968 shares of common stock issued and outstanding and no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Holders of shares of common stock
are entitled to one vote for each share held of record on all matters to be voted on by shareholders. Except as otherwise provided by
law, matters other than the election of directors require the affirmative vote of the holders of a majority of shares entitled to vote
thereon. Holders of our common stock do not have any cumulative voting rights, which means that a plurality of the shares voted can elect
all of the directors then standing for election. Holders of common stock vote together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Subject to preferential dividend
rights of any other class or series of stock, the holders of shares of common stock are entitled to receive dividends, including dividends
of equity, as and when declared by our board of directors, subject to any limitations applicable by law and to the rights of the holders,
if any, of our preferred stock. Our board of directors is not obligated to declare a dividend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Upon our liquidation, dissolution
or winding-up, the holders of our common stock are entitled to share equally, identically and ratably in all assets remaining, subject
to the prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences,
if any, on any outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Other Rights and Preferences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the preferential rights
of any other class or series of stock, all shares of common stock have equal dividend, distribution, liquidation and other rights, and
have no preference, appraisal or exchange rights, except for any appraisal rights provided by Texas law. Furthermore, holders of common
stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The rights, powers, preferences
and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series
of preferred stock which we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Transfer Agent and Registrar</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is Securities Transfer Corporation, Plano, Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Listing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on
The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors is authorized,
subject to limitations prescribed by Texas law, to issue up to 2,000,000 shares of preferred stock in one or more series, to establish
from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences, and rights of the
shares of each series and any of its qualifications, limitations, or restrictions, in each case without further vote or action by our
shareholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below
the number of shares of that series then outstanding, without any further vote or action by our shareholders. Our board of directors may
authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights
of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions
and other corporate purposes, could, among other things, have the effect of delaying, deferring, or preventing a change in control of
our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we offer shares of preferred
stock, we will file as an exhibit to the registration statement of which this prospectus forms a part, or will incorporate by reference
from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred
stock we are offering. This description and the applicable prospectus supplement will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title and stated value;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares authorized;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the liquidation preference per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase price;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dividend rate, period and payment date, and method of calculation for dividends;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the procedures for any auction and remarketing, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions for a sinking fund, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise such redemption and repurchase rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any listing of the preferred stock on any securities exchange or market;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting rights, if any, of the preferred stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preemptive rights, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on transfer, sale or other assignment, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material United States federal income
  tax considerations applicable to the preferred stock;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative
      ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</FONT></P>
      <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any limitations on issuance of any class or series of
  preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate,
  dissolve or wind up our affairs; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations
  of, or restrictions on, the preferred stock.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent, registrar,
and dividend disbursement agent, if any, for a series of preferred stock will be named in a prospectus supplement. The registrar for shares
of preferred stock will send notices to stockholders of any meetings at which holders of the preferred stock have the right to elect directors
or to vote on any other matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Texas Anti-Takeover Law and Provisions of our Certificate
of Formation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A number of provisions of Texas
law, our Certificate of Formation and our bylaws could have an anti-takeover effect and make more difficult the acquisition of the Company
by means of a tender offer, a proxy contest or otherwise and the removal of our directors or management. These provisions are intended
to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of the Company
to negotiate first with our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the provisions
of Title 2, Chapter 21, Subchapter M of the Texas Business Organizations Code (the &ldquo;TBOC&rdquo;), which provides that a Texas corporation
that qualifies as an &ldquo;issuing public corporation&rdquo; (as defined in the TBOC) may not engage in specified types of business combinations,
including mergers, consolidations and asset sales, with a person, or an affiliate or associate of that person, who is an &ldquo;affiliated
shareholder.&rdquo; The restrictions in Title 2, Chapter 21, Subchapter M of the TBOC do not apply to corporations that have elected,
in the manner provided under the TBOC, not to be subject to such provisions. Our Certificate of Formation affirmatively states that the
Company elects not to be governed by such provisions, and neither our Certificate of Formation nor bylaws provide a similar restriction
on business combinations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">However, provisions of our Certificate
of Formation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management,
including transactions in which shareholders might otherwise receive a premium for their shares, or transactions that our shareholders
might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock.
Among other things, for example, our Certificate of Formation and bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do not provide for cumulative voting rights (therefore
  allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the
  directors standing for election, if they should so choose);</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">empower our board of directors, without shareholder approval,
  to issue our preferred stock, the terms of which, including voting power, are set by our board of directors;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require that special meetings of the shareholders be
  called by the Chairman of the board of directors, the President or the board of directors, or by the holders of not less than ten percent
  (10%) of all the shares issued, outstanding and entitled to vote;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit our board of directors to alter, amend or repeal
  our bylaws or to adopt new bylaws; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enable our board of directors to increase the number
  of persons serving as directors and to fill vacancies created as a result of the increase by a majority vote of the directors present
  at a meeting of directors.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the TBOC, a corporation
has the power to indemnify its directors and officers against judgments and certain expenses other than judgments that are actually and
reasonably incurred in connection with a proceeding, provided that there is a determination that the individual acted in good faith and
in a manner reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal proceeding,
had no reasonable cause to believe the individual&rsquo;s conduct was unlawful. Such determination will be made, in the case of an individual
who is a director or officer at the time of such determination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by a majority of the disinterested and independent directors,
  even though less than a quorum;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by a majority vote of a committee of the directors if
  the committee is designated by a majority vote of the directors, who at the time of the vote are disinterested and independent, even
  though less than a quorum, and is composed solely of one or more directors who are disinterested and independent;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by special legal counsel selected by the directors, or
  selected by a committee of the directors as described in the preceding two subparts above;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the owners or members of the corporation in a vote
  that excludes the ownership or membership interests held by each director who is not disinterested and independent; or</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by a unanimous vote of the owners or members of the corporation.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">No indemnification may be made
in respect of any proceeding in which such individual is liable to the corporation or improperly received a personal benefit and is found
liable for willful misconduct, breach of the duty of loyalty owned to the corporation, or an act or omission deemed not to be committed
in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The TBOC requires indemnification
of directors and officers for reasonable expenses relating to a wholly successful defense on the merits or otherwise in defense of a proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The TBOC permits a corporation
to advance expenses relating to the defense of any proceeding to directors and officers, contingent upon, among other things, such individuals&rsquo;
commitment to repay any advances unless it is determined ultimately that such individuals are entitled to be indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Formation and
bylaws provide for indemnification by us of our directors and officers to the fullest extent permitted by Texas Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Limitation of Personal Liability of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Formation provides
that our directors will not be personally liable to us or any of our shareholders for monetary damages for an act or omission in the director&rsquo;s
capacity as a director to the fullest extent permitted by Texas law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The TBOC provides that a corporation&rsquo;s
certificate of formation may include a provision limiting the personal liability of a director to the corporation or its shareholders
for monetary damages for an act or omission as a director. However, no such provision can eliminate or limit the liability of a director
for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of the director&rsquo;s duty of loyalty to
  the corporation or its shareholders;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acts or omissions not in good faith or that constitute
  a breach of a duty owed to the corporation or involve intentional misconduct or a knowing violation of the law;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">violation of certain provisions of the Texas Law; or</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction from which the director received an improper
  benefit.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_007"></A><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants for the
purchase of common stock or preferred stock in one or more series. We may issue warrants independently or together with common stock or
preferred stock, and the warrants may be attached to or separate from these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We will evidence each series of
warrants by warrant certificates that we may issue under a separate agreement. We may enter into a warrant agreement with a warrant agent.
Each warrant agent may be a bank that we select which has its principal office in the United States. We may also choose to act as our
own warrant agent. We will indicate the name and address of any such warrant agent in the applicable prospectus supplement relating to
a particular series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplement the terms of the series of warrants, including:</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and
    aggregate number of warrants offered;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the designation
    and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each
    principal amount of such security;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the date
    on and after which the warrants and the related securities will be separately transferable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of warrants
    to purchase common stock or preferred stock, the number or amount of shares of common stock or preferred stock, as the case may be,
    purchasable upon the exercise of one warrant and the price at which and currency in which these shares may be purchased upon such
    exercise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manner of exercise
    of the warrants, including any cashless exercise rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any warrant agreement under
    which the warrants will be issued;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of any merger,
    consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">anti-dilution provisions
    of the warrants, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights
    to redeem or call the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for changes
    to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dates on which the
    right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable during that period,
    the specific date or dates on which the warrants will be exercisable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manner in which any
    warrant agreement and warrants may be modified;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the identities of any warrant
    agent and any calculation or other agent for the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal income tax consequences
    of holding or exercising the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the securities
    issuable upon exercise of the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any securities exchange
    or quotation system on which the warrants or any securities deliverable upon exercise of the warrants may be listed or quoted; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms,
    preferences, rights or limitations of or restrictions on the warrants.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Before exercising their warrants,
holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including, in the case
of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution
or winding up or to exercise voting rights, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Each warrant will entitle the
holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the
applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to 5:00 P.M. eastern time, the close of business, on the expiration date that we set forth in the applicable
prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the warrants may exercise
the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and
paying the required exercise price by the methods provided in the applicable prospectus supplement. We will set forth on the reverse side
of the warrant certificate, and in the applicable prospectus supplement, the information that the holder of the warrant will be required
to deliver to the Company or any warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt of the required payment
and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than
all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining
amount of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Enforceability of Rights by Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any warrant agent will act solely
as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the
related warrant agent or the holder of any other warrant, enforce by appropriate legal action the holder&rsquo;s right to exercise, and
receive the securities purchasable upon exercise of, its warrants in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Warrant Agreement Will Not Be Qualified Under Trust
Indenture Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">No warrant agreement will be qualified
as an indenture, and no warrant agent will be required to qualify as a trustee, under the Trust Indenture Act of 1939. Therefore, holders
of warrants issued under a warrant agreement will not have the protection of the Trust Indenture Act of 1939 with respect to their warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Unless we provide otherwise in
the applicable prospectus supplement, each warrant agreement and any warrants issued under the warrant agreements will be governed by
New York law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_008"></A><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units comprised of
one or more of the other securities described in this prospectus or any prospectus supplement in any combination. Each unit will be issued
so that the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit.
The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately,
at any time or at any times before a specified date or upon the occurrence of a specified event or occurrence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus supplement
will describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and the terms of the units and of the
  securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any unit agreement under which the units will be issued;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for the issuance, payment, settlement,
  transfer or exchange of the units or of the securities comprising the units; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the units will be issued in fully registered
  or global form.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="Hz_009"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities offered pursuant to this prospectus from time to time in one or more transactions, including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to or through underwriters;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through broker-dealers (acting as agent or principal);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through agents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directly by us to one or more purchasers (including
    our affiliates and shareholders), through a specific bidding or auction process, a rights offering or otherwise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through a combination of any such methods of sale;
    or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through any other methods described in a prospectus
    supplement or free writing prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of securities may be effected, from time to time, in one or more transactions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block transactions (which may involve crosses) and
    transactions on The Nasdaq Capital Market or any other organized market where the securities may be traded;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale
    by the broker-dealer for its own account pursuant to a prospectus supplement or free writing prospectus;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in
    which a broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales &ldquo;at the market&rdquo; to or through a market
    maker or into an existing trading market, on an exchange or otherwise; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales in other ways not involving market makers or
    established trading markets, including direct sales to purchasers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement or free writing prospectus will describe the terms of the offering of the securities, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name or names of any underwriters, and if required,
    any dealers or agents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase price of the securities and the proceeds
    we will receive from the sale;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any underwriting discounts and other items constituting
    underwriters&rsquo; compensation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any discounts or concessions allowed or re-allowed
    or paid to dealers; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any securities exchange or market on which the securities
    may be listed or traded.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may distribute the securities from time to time in one or more transactions at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fixed price or prices, which may be changed;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market prices prevailing at the time of sale;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prices related to such prevailing market prices; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Only underwriters named in the
prospectus supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters are used in an
offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms
of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers)
in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing
underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing
underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities
will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price
and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. Unless otherwise set forth
in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent,
and the underwriters will be obligated to purchase all of the offered securities, if any are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may grant to the underwriters
options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting
commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth
in the prospectus supplement for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we use a dealer in the sale
of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as
principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.
The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities directly
or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe
any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will
act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may authorize agents or underwriters
to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement
pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale of
the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the securities for whom they act
as agents, in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those
dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers
for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional
investors or others that purchase securities directly for the purpose of resale or distribution, may be deemed to be underwriters, and
any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting
discounts and commissions under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may provide agents, underwriters
and other purchasers with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution
with respect to payments that the agents, underwriters or other purchasers may make with respect to such liabilities. Agents and underwriters
may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">To facilitate the public offering
of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect
the market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons
participating in the offering of more securities than have been sold to them by us. In addition, those persons may stabilize or maintain
the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions
allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection
with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at
a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time.
We make no representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented,
may have on the price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified in
the applicable prospectus supplement, any common stock sold pursuant to a prospectus supplement will be eligible for listing on The Nasdaq
Capital Market, subject to official notice of issuance. Any underwriters to whom securities are sold by us for public offering and sale
may make a market in the securities, but such underwriters will not be obligated to do so and may discontinue any market making at any
time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply with the securities
laws of some states, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered
or licensed brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_010"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered by this prospectus will be passed upon for us by Haynes and Boone, LLP, Dallas, Texas. If legal matters in connection with offerings
made by this prospectus are passed on by counsel for the underwriters, dealers or agents, if any, that counsel will be named in the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_011"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements as of
December 31, 2019 and 2018 and for the years then ended incorporated in this prospectus by reference to our Annual Report on Form 10-K
for the year ended December 31, 2019 have been audited by MaloneBailey, LLP, an independent registered public accounting firm, as stated
in its report appearing in the registration statement, and are incorporated in reliance upon the report of such firm given upon its authority
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_012"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the informational
requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and in accordance therewith file annual,
quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an internet website at www.sec.gov
that contains periodic and current reports, proxy and information statements and other information regarding registrants that are filed
electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">These documents are also available,
free of charge, through the Investor Relations section of our website, which is located at www.sanaramedtech.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC a registration
statement under the Securities Act relating to the offering of these securities. The registration statement, including the attached exhibits,
contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth
in the registration statement. You can obtain a copy of the registration statement for free at www.sec.gov. The registration statement
and the documents referred to below under &ldquo;Incorporation of Documents by Reference&rdquo; are also available on our website, www.sanaramedtech.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have not incorporated by reference
into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="Hz_013"></A><B>INCORPORATION OF DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we have filed with it, which means that we can disclose important information to you by referring
you to those documents. The information we incorporate by reference is an important part of this prospectus, and later information that
we file with the SEC will automatically update and supersede this information. We specifically are incorporating by reference the following
documents filed with the SEC (excluding those portions of any Current Report on Form 8-K that are furnished and not deemed &ldquo;filed&rdquo;
pursuant to the General Instructions of Form 8-K):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420003345/smti_10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K</A> for the fiscal year ended
  December 31, 2019, filed with the SEC on March 26, 2020;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the portions of our <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420006958/smti_def14a.htm" STYLE="-sec-extract: exhibit">Definitive Proxy Statement on Schedule 14A</A>, filed with the SEC on June 25, 2020, that were deemed to be filed with the SEC;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Reports on Form 10-Q <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420005225/smti_10q.htm" STYLE="-sec-extract: exhibit">for the quarter ended March 31, 2020</A>, filed with the SEC on May 12, 2020, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420009006/smti_10q.htm" STYLE="-sec-extract: exhibit">for the quarter ended June 30, 2020</A>, filed with the SEC on August 13, 2020, and
  <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420012356/smti_10q.htm" STYLE="-sec-extract: exhibit">for the quarter ended September 30, 2020</A>, filed with the SEC on November 13, 2020;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on Form
  8-K filed on <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420001419/smti_8k.htm" STYLE="-sec-extract: exhibit">February
  13, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420004644/smti_8k.htm" STYLE="-sec-extract: exhibit">April
  29, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420005087/smti_8k.htm" STYLE="-sec-extract: exhibit">May
  8, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420005876/smti_8k.htm" STYLE="-sec-extract: exhibit">May 21, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420007672/smti_8k.htm" STYLE="-sec-extract: exhibit">July 14, 2020</A> (as amended on <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420011158/smti_8ka.htm" STYLE="-sec-extract: exhibit">October 14, 2020</A>), <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420011236/smti_8k.htm" STYLE="-sec-extract: exhibit">October 16, 2020</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420013880/smti_8k.htm" STYLE="-sec-extract: exhibit">December 23, 2020</A>; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our securities contained in our registration
  statement on <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420011574/smti_8ka.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>, filed with the SEC on October 29, 2020, including all amendments and reports filed for the purpose of updating
  such description.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">All reports and definitive proxy
or information statements subsequently filed after the date of the initial registration statement of which this prospectus forms a part
and prior to effectiveness of such registration statement by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange
Act, but excluding information furnished to, rather than filed with, the SEC, shall be deemed to be incorporated by reference herein and
to be a part hereof from the date such documents are filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained herein
or in any document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for purposes of
the registration statement of which this prospectus forms a part to the extent that a statement contained in any other subsequently filed
document which also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed to constitute a part of the registration statement of which this prospectus forms a part, except as
so modified or superseded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the information
incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information.
You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus or the
date of the documents incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We will provide without charge
to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the information that
has been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings,
unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to us at
1200 Summit Ave, Suite 414, Fort Worth, Texas 76102 (telephone: 817-529-2300).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">You may also access the documents
incorporated by reference in this prospectus through our website at www.sanaramedtech.com. Except for the specific incorporated documents
listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration
statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b5_006.jpg" ALT="" STYLE="height: 66px; width: 198px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to $75,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Sanara
MedTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_002.jpg" ALT="LOGO" STYLE="height: 49px; width: 257px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>February
24, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 -P# 2(  A$! Q$!_\0
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M4+12<T$X&:5P%HI@8^M'F+G!89],TUKL'J/HI,^]'/K0(6BDS1S0,6BBBE<
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b5_002.jpg
<TEXT>
begin 644 form424b5_002.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #$! 0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H Q_$'B'0O"FC7_B'Q-K&F^']"TJ'[1J.KZO>0:?IUE"
M72)'N+NY=(X]TTD<: MEWD1%!9U!VH8>OBJU/#X:C.O7JNT*=.+G.3M?2,4V
M[)-OLDV]$95Z]'"4IU\15A0H4E>4YR4(16RO)M)7;27=M):L_,CXJ?\ !4'P
M1H5Y=:5\*/!=_P"-WMIO)'B;7[I_#F@S>7*I>?3--6WGU+4;:2$.BM=KI#J[
M;_+=$ F_2,K\-,;6A"KFF,C@E)7]C2C[6JM-%.=XTX-/5\GM4UI=-Z?G>9>(
MV#H3E2RS"2QCB[>UJR]E2=GO"%G4DFM%S>R:>MFEK\PR?\%0?V@GDC=/#'PD
MA2,DM"GA[Q8R3 ]%E:7QR[@#'_+-H^O/M]*O#3($FOK..;>S]K0T]+89+[TS
MYQ^(^>75L-@HJ/3V5?7UOB+_ '6.]\&?\%4?&]M=*GQ"^&'A75[)I6#S^#+_
M %?P[=6T#>0$=;76[K6TO94VW)*&XM1)YL0#1^4QFX<9X88)Q_V#,JU&:6BQ
M$:=6+>OVJ<:+BGIKRRM9Z.ZMVX3Q*QD9+Z]EU&K"^KP\ITFEI;W:CK*36NG-
M&]UJK._ZH?!?XZ?#KX]>%V\4?#W59;F.TEBMM9T74H4LO$'AZ]FB,L5IK.GI
M-*L9=%D\NXMYKFUF,,P@N)3!*(_S'.,DS#(L2L+CZ2BY)NG4@^:E5BG9RIRL
MKVTO&2C.-US1CS*_Z5E&<X#.L-]9P-5R46E4IS7+5I2:NHU(W=K])1<H2L^6
M3L[>P5Y!ZIX1^T5\>- _9W^'-UX[UBP;6[Q[^ST?P_X;BOETZ?7=7NR\OV9;
MYK6Y^Q6\%C;WEU-<&WFVI:E0C221H_N</Y'7X@S".!HS]A",95*M5QYU2IQL
MK\O-'F<I.,8QYHW;O=)-KQ<^SJAD.7RQM6'MI<T:=*DI<CJ3>MN:TN51BI2E
M+E=E&UFVD_SP_P"'L/\ U0/_ ,RG_P#BYK[_ /XA9_U/?_++_P"^SX/_ (B=
M_P!23_R\_P#O4]W_ &<?V^K3X^_$ZQ^&US\,T\%3:EI.KW^GZHWCJ+7C<W>D
M6POGTZ/3I/"FEL[O817L^^.>1E6S8F(IO>+P^(>!9Y#EL\QCF7UQ4ITX2A]6
M=+EC-\JGSJO5M:3C&SBD^;XKV3]O(.-X9WF,,OEEWU1SA.49_6%4O*FN;E4'
M1I;Q4G=2;7+\-KM?H?7P!]V? W[3W[<MK^SE\0=/\ P?#J/QS/<^%M/\1WM_
M'XVC\/G3)M0U'5[./2I[%?"VJMYXM=,@N][RQ$QZC#B/;AW^ZX:X)EQ#@*F.
M>8/ QC6E1C!X9U>=0A3DYJ7MJ6EYN%DGK!ZWT7Q'$?&4>'\=3P,< L8Y48U9
M26(5+D<ISBH./L:FMH*5VUI):6U?SE_P]A_ZH'_YE/\ _%S7T/\ Q"S_ *GO
M_EE_]]G@?\1._P"I)_Y>?_>I^GGP?^)VB?&/X;^%/B-H"B"R\2::ES/IYG6Y
MET?5('>UU?1IYUBB\Z:RU*"YM_-\J(2K$LJHJ2J*_-<VRVMD^8XK+J_O3PT[
M*5K*I!^]3J)7=E.#4K7?+?E;;3/T;*LQHYKE^%Q]!<L*\$W&]W3FO=G3;LKN
M$TXWLKVO9)FW\0?%T'@#P%XU\=7%H;^#P9X3\0^*9-/6X2T?4%T#2;O5/L$=
MR\<BP2W)M1 CF-]K2J=K8VG' 826.QV#P,9>S>+KTJ*E:ZA[2<8<SBFKJ-[M
M76BW1MCL5' X+%XV4>>.$HU:SC>W-[*$I\J;3LY<MD[/5[,_*C_A[#_U0/\
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MPZW<W?B"/QV^NIH]MH^AZCJRSSZ<O@FQ$D4]U9VUB&:[A"R:A&<L<1R>/GW
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MIWACBZT<QQ^ YG]6J8;ZPXWT52E5I4U)+HY1JM2:MS<L+WY8V_-?$G"47E^
MQW*EB*6(5!22U=.I3JU'%OJHRI)Q3OR\TK6YI7_$*OVD_'C[0\(^-[O1OV%/
MBWX49_\ 0O$WQR\%:9 BV\;L+BZT6W\3WC2S,X:*(Q_#NPVLH<ADV8VSNR_'
M8O!0J\;Y3BK6GALMQ$V[M:1J.C&RV;3Q4K[:._V4CZW"XR5'@O-,+M#$9CAX
M)66[IJM*[Z*V%C;S5OM,\-^$'QU^)WP-UP:U\._$MUI:2R1OJFA7#/>>&M=2
M,%%CUG1))!!=.L;.B7*B.Y@$C_9YXF8FO;S;(\MSJA[#'X:-3E7N5%:-:E_U
M[J)<T=;-QUA*RYHRL>-E6=9CDM;VN Q#IIM<]-WE2J6TM4IM\LK+125IQN^6
M43]Z/V8?VQ_ G[0UK%H5P(?"/Q,MK9I+WPC=7!>'5X[6VBEO-4\+7DBJ+^S!
M\]VLF8WEND$C2))!']ID_#.)>$,=P_)UHWQ>6R=HUXK6FVVHPK17PRV2FOW<
MFTDU)\B_;.'.+,%GL51=L+F,5[U"3TFDDY3HR?Q1W;A\<4FVG%<[Z3]H?]K'
MX>?LY);6/B;3_$NK^)=6TFZU/P_H^EZ/=16&IF"=+58I/$M[''IT(6>16N%@
MEN[BVB"R26V;BU2ZY^'^%<PXA<IX6I1HX:C.,*M2=2+E"ZYKJC%NH]%[O,H0
MG+13]V;CT9[Q/@.'U&&)IU:N(J0<Z5.$&HRLU&SJR2IJS?O6<I1CJX>]!2_F
MGUG5+C7-8U76KM(8[K6-2OM4N8[=72W2XU"ZENYD@2221UA629@H9W8* "S'
MD_T91I1P]&E1@VX4(1A%O>T(J*O9)7LM;)>B/Y[JU)5JM6K)*,JLY3:6B3DW
M)VNVTDWI=OU/U6_X)J_L_:[)XGN/CYXDTV6PT#3-,U'1_ +7ENJ3:SJVIJVG
MZOKNGF0^8NFV6E_;]/\ /6,)<2ZK,D4I^PW"-^7^(V?4(X:.18:HIUYSA4Q7
M*]*<(>_3I2MISSGRU.6]X1@FX^_%GZ7X>Y%6^L/.\13=.A3A*GAN96<YS]R=
M2-]5"$.:GS6M)S:3]R2/VDK\=/UP_#O_ (*H7\\GQ1^&FEM;W"VUEX!NK^*Z
M8G[+-/J7B+4+>XMX5S@7$,>DVSRGNMW!Z<?M7AA3C'+,QJJ2YI8J,7'[24*4
M6F_)N;2\XR/QSQ*FWF.74N5J,,-*2?V;RJR32\XJ";\I1/RWK]-/S<_IS_8W
MMK>S_9B^#<5K!%;1MX5^TM'#&D2&XO=4U&\NYRJ  RS7<\TTC]7DE=V)9B3_
M #9Q?*4N)<W<I.35?E3;OI&$(Q7I&*22Z))+0_HKA.,8<.92HQ45[&]DK:RG
M*4GIU<FVWU;;/I9W2)'EE=(XXT9Y)'8(B(@+.[NQ 5%4$DD@ #)KYQ)MI)7;
MT27X:'T#:BFV^51W>UK?E8^%;C_@HU^S+:W$]O\ VSXJG^SS2P^?;>%;N6WF
M\IV3S8)?.'F0MMW*V!E2#CFOMX^'O$DHQE[&A'F2=G6BFKJ]FK:-=5W/C)<?
M<.PE*/MJTN5M75&33MI=.^J?1]CMOAI^VQ\#/BOXML_!GA*_\2MJMW9ZKJ+W
M&I^';C3M(T[3]%TRZU6_OM5U.68PZ;9QVUHZ^=,53S988]P:5<\68\&9WE6$
MGC,53HJE&4(*,*JG.4JDXPA&$$KRDW*_*KNR;M9,[,OXOR;,L5#"86=7VDHS
ME>=)PA"-.#G*4YMVA%*-KNRNTMVC\/?VK?CC+\>OC%KWBNTGN&\)Z9M\/>"+
M6821>3X=TYY!'>FVDP8+C4KM[G4)%=1(GVQ(6)%NH'[3PMDJR+**&%E%+%5/
MWN(:L_WLTKQNMU3BHTU;1\KDOB9^.<39R\ZS:OB8-_5:7[K#Q=U:E!NTK/9U
M)7F[ZKF47\*-/]CKX;:!\1_CCX:B\87NE6'@[PGN\8>(6UF]L["ROX](F@_L
MO13)?2QQ7#7NL36*RVP)=[2*]8#$3%<^+LQKY=DF(>$A.>,Q7^STE3C*4H<Z
M?/4M%-KDIJ7++93<%U1IPGE]#'YSAUBIPAA,)^_J^TE&,9>S:Y*=Y-)\\W&\
M=W!3[,_1O_@ICJ/A/Q-\%_"%_H6O:%K6J:%\1[ /%I6NZ=>S6NCZIX>\10WL
M\EG;7;L\9U&VT6/S C%#(!P'8U^>>&]/%87.,73K4*E"E7PDK.=*<4ZD*M)Q
M2DXJSY'4=KZV\D??^(<\+B<HPLZ%:G6J4,5&ZA4A)QISI55)\JD].=4U>VE^
MS9^'U?M1^.'] 'PX^*?E_P#!.I_&'VDMJ'ASX0>*_!T&UK&ZFL=5T/\ M7P/
MX=2ZA9HXTC7R]&N/)E!D-K-&=LS.OF_@^899_P ;!6#Y;4Z^/H8A_$E*%3DQ
M-7E>KOK4C=:<Z>L4M/W#+\RMP%]:YO?P^!K4%\+<9T^?#TKK1):4Y6>O(UI)
MO7^?^OW@_#S]*?V&/@1I_P :OAA^TMHVK(L']N:-X3\-^%]5F>-[?3?$EM)K
MGB"#4)8(@UR!9ZG:>&G<IY?G6US>6ZLWFR>7^<\;9Y4R;,N'*M)\WL*E>M6@
MD[RHM4Z3@F[1]^$JR5[\LU"3M97_ $'@S):>;9=Q#2JKE]M3HTJ,W:T*J]I5
M4FE>7N3C2;M:\7.*O=V_.G6M&U/PYK&K>'M:LYM.UG0M3O\ 1M6T^X $]AJ>
MEW4MC?V<X4D":&Z@EC8 D;D.#7Z#1K4\11I5Z,U.C7A&I3DMI0G%2C)>3BTT
M?!5J-3#U:M"K!TZM"<J<XO>,X-QE%^<6FGZ%FY\1ZO>>'='\*W%V\NAZ#JNO
M:UI5FW(M+_Q+;:#::Q)&QY"31>&M)^084-"[ ;I&)F.'HT\15Q48<M:O"E3G
M+O&BZLJ:?G%UIZ[V:6R14L15EAZ6%E*]&A.I4A'^6554HSMY-4H:=TWU9AUO
MMY6,3^MOX=^&O^$+^'_@;P=T_P"$3\'>&?#6/-\_']A:+9:7_K]B>=_QZ_?V
MKNZX&<#^4\?B/KF/QN+_ .@K$5JVUOXE24]M;?%MK8_J# 8?ZG@<%A-OJM"C
M1WO_  Z<8;Z7^'?0Y?X\^)QX+^"GQ6\3B1(Y]'^'_BJ>P,B7$D;ZK)HUW;Z1
M#(MJ5E$<NJ36D3,K)L$A8NBJ77JR+#?7,YRO"VO&KBJ"E:U^15(N;7-I=04F
MDT[VM9['-G6(^IY1F>)ORNCAJSC>]N?V<E!/EULYN*NK6O>ZW/Y3*_J(_F@_
M0_\ X)G>%?[;_:%O-?DA#0>"_ FO:I%</:I.L6I:K<:=X<MX(YV<&RN9=.U7
M5W65 S-':SQ8VRLR_G_B/BO89!##IVEB\32@X\UO<IJ=5MK[24H4U9VLY1EN
MDC[OP\PWM<]G7M[N$PU2:?+>TYN%))/[+<9S=UT4ELV?>'_!336;G2_V<["Q
MMP/*\1_$KPSHU[EY$Q:P:3XE\0H0J,!(?MF@V@VR!EP2P&]5*_#^&]&-3B&<
MWH\/@ZU2.BW<Z-+Y>[5EMKTV;/M?$.M*ED$*<=J^+HTY;[*%6JMO[U*.^G7=
M(_ "OW@_#S]M_P#@E7_R3_XK?]CCHO\ Z97K\8\3_P#?\K_[!ZG_ *</V#PT
M_P!QS/\ Z_T__39^JM?EY^EGY)?\%4?'=K#X?^&'PQ@N$>]O=9O_ !WJ5HJK
MYEK:Z797/A_0[B1FCW!+J75_$"((WP3ILOF+D1&OU7PPP,GB,RS)QM"G3AAH
M2Z.4Y*K42U^RJ=)NZ^VK/<_+_$K&QC0R[+HRO.526)G'^6,(NE3;_P 3G52L
M_L._0_&"OV(_)#Z.\<Z;-X3_ &<O@II,]L(+OX@>+/B3\3KII[+R+P:3:IX:
M\#>%XUN3M>2S=M$\2WJ1NK#9J4,T3!)\O\[@:D<5Q#G-6,KPP%#"8.-I7CSO
MVV)K.VJ4E[2C!M=8.+5XZ>_C*;PF09/2<>66.K8O%N\;2Y(^RP]%7T?*_9U9
MI/I-26DM?G&OHCP#TGPQX+^+MG)I'C/P?X0^(<+V4L.L:'XG\/\ ASQ&5MY;
M23S8-1T[5K"R*@Q21%A-%+@%#SP:\[$XS*9*K@\7B\(U).G4HU:M+5-6<)PE
M*^J>S1Z&&P>:TW2Q>$PF*BX-5*=:E2JZ.+NIPG&-M&MTS];_ (=^/=!_;6^$
M^J_L_?'2+_A%?CEH]DVJ>&]1U#2VTF]U.YL;21M,\8:18W,46;Z)#+%J^EP+
M$+BSEN)[3RXI)/[+_*,PP-?@S-*6>Y(_K6259<E6$)^TC!2DN?#U))OW7HZ%
M65^6HHQG=I>U_4<!C:'%V65<CSE?5<YHQYZ4I0]G*3C%\E>G%I>\M57IJW-!
MRE"R;]G^3WV/6?@/\5KK3/&O@GPSXCUKP+K,]CJWA3Q?:W&J^&K^2(862:WM
M;NV&H64]K*EQ;2.SQ.D\,QC<;17ZGST<\RN%7!8VMAJ.-IJ5.O0DJ=:"[)RC
M+DE&2Y9I6DFG&ZU/S'DJY)F<J6+P=&O6P51QG1KQ<Z4FNK491YHRB^:#=XM-
M2LS^D?\ 9V^+>A_&SX2>%O'6A:/_ ,(Y#/!-I%[X<15%OH.IZ)(=/NM-L9(H
M8XI],58HI+62)$'V:>!7CAF62&'^=^(,IK9+FN)P-:K[=Q:G&KUJ0J+FC.2;
M;4]6IIM^^I6<HM2?] 9#FE'-\KPV-HTOJZ:<)4NE*=-\KA%I)."LG!I+W&KJ
M,DXKVZO%/8/R=_X*D?#34-3\-?#_ .*NFP33VOA6ZU#POXEV*TBVMEKTEI<:
M%?R '%O;IJ5K=VCR$'?+JUFF5( ?]3\,LRIT<3C\KJ-1EB8PK4>EY4E)5(KN
MW!QFETC3F]>GYCXD9=4J8? YE3BW'"N5&KY1J.+IR?9*<90;ZN<%Z_BK7[(?
MD1^B/[,7[?6L? WP=8_#?Q7X0;QGX3TF>_ET*_L-573->T6WOII[^33C'<VL
MUOJUC_:4TSQAY+22!;N4"26.*&!/S[B3@2CG6+GF&%Q?U/%5%%5(2ASTJCBE
M%3NI*5.7(DG924G%:1;E)_><.<;U<EPD,OQ6%^MX6DY>SE&?)4IJ3<G"S3C.
M/,VU=Q<5)ZR2C%;OQ_\ ^"C7BCXF^%M7\"_#OPI_P@FAZ]82Z9K>N:AJ0U3Q
M+>:==Q+'?6&GI;006NBPSQ-<6LLF;Z5X928GMG;Y<<A\/<-EN)I8W,,5]=K8
M>2G3I0AR48SB[QE+F<I5'%VE%>Y%26JFC;/./L3F&&JX+ 87ZE1KQ<*E24^>
MJX-6E&*24::DKQ;]^3B]'!GYHU^CGYZ?85_H&J?LX?!.675A)H_Q<_:%T:73
M(](D*)J?A+X'L\,VI37\ ;S+'4?%^I0P69@F7*:?I=Y$WEW$D\4/R-.O2XAS
ME*E:KE/#]13=17Y*^9)-047M*&$@W/F3UJS@U>*BY?5SH5.'\G?M;TLTSVFX
M*#^.AE^CFY+>,L5-*'*]J4)+27,E\>U]<?*!0 4 % 'W#X:^*!M/V!?B1\/9
M)_,N+GXW>%-*BB'V:5K?2=;T^+QE:PM""LMI VJ?#K6I5N6$GF/*\*?*C^7\
M5B,LYN.LNQZCRQCEU>;>JO.E)X>3OJI-0Q=-.*M9)2>K5_L</F/)P1F&!;O*
M6848):.T*D57BK:.*Y\+4:D[W;<5L[?#U?:GQQ^_G_!,SPVNC_L\W^M/$@G\
M6?$#7]22X^R>1,UAIECH^@6]L;DY-Y;Q7NEZG*C A$>\G0 .)"WX1XD8CVN?
MTZ*?NX3"TH6YKKFG*I5;M]EN,X)]6HQ>UK?M_AWA_8Y%.K:SQ6)JS3Y;/EA&
MG22O]I*4)M=$Y26][_('_!2[X(?\(GX]TCXRZ'9^5H7Q"V:3XF\E-L%EXVTN
MS_T>X?:%2+^V-!M1*J(K,]QH.IW$K;[D9^L\.,Z^M8&KD]:=Z^7^_1N]98><
MM5U;]C5E9MZ*-6E&*M$^5\0LF^JXVEFU&%J./M"K9:1Q$(Z/HE[6G&Z2U<J=
M24G>1^85?I9^='KWP \,GQA\</A+X;P_DZG\0?"B7IBEC@E33+?6+2[U62"2
M9'03IIMO=.@9'RZJ-K9P?)S[$_4\ES7$;.EA:_+=-KG=.48)I6=G-Q3U6E]4
M>ID>'^M9SE>'Z5,51YK-)\BG&4[-W5U!2:T>O0_JNK^7C^ESX7_X**^*!X=_
M9B\0Z<)1#+XS\2^%/"T!_P!($CF/4O\ A*9XH7@^5"]EX8NE?SB(VB:5.7=
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K?^Z5_P#K[_[9 ^GJ^:/H@H * "@ H * "@ H * /_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b5_005.jpg
<TEXT>
begin 644 form424b5_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
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M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'JQ0'&?>IYXWV->25MS8L)7GTZUFD.7DB1F.,<D FK%,AB2"".&,82-0JCV
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M[]32C2[81M&WF.&0QDO(6.TXXY^E>,_\+]O?^@!;_P#@0?\ XFC_ (7[>_\
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M;6-KJMM-/):RWENL<-W&I)B(<,0<<X8#&12=-I:294:J;LXHZ\P?"$$@W.N
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M_K^@:2(-;UDWK$#9#C<(?;>>376UYTJM1.RE<]&-*#5W$\X_X4CX1]=1_P#
MC_ZU'_"D?"/KJ/\ X$?_ %J]'HJ?;5/YA^QI]@HHHK(U"BBB@ HHHH ****
M"BBB@ HHHH **** (I+:WF;=+!$[8QED!-,^P6?_ #Z0?]^Q5BB@"O\ 8+/_
M )](/^_8H^P6?_/I!_W[%6** *_V"S_Y](/^_8H^P6?_ #Z0?]^Q5BB@"O\
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M$*J6^RVAP,_ZD4-';_:)HQ9VOR% "8AW!/\ 2I9/]4_TJ,_\?US_ +T?\C0
MA@@4$M;68 Y),( %1L;%'V.--5_[K*H/Y9JIXH@>Z\):Q;QXWS64L:Y!ZLA
MZ9/>O/?$,QUM-+>WL5MYXK66RN'N+=V*HXB7>"J$GY5< 9R* /3V2T0(7BL%
M#G"%HU 8^W/-*(K8G @L23D8$0[=>_:O,=+==.:V2\LH]3MK6WDLK>!H)0L<
M?F[T<;T./EPIZL-@ZYJ?1V2Q\1VE_/<S&WBNM1E,0M9"(UF8%"N(\DGOD\4
M>D_9H?\ GUM/^_(IJQV_VB&-K.UP[,I(B'89J2">.YMXYXBQCD4,I92IQ]#R
M/QIG_+[;?]=7_P#0: !8(64-]EM!G_IB*1H[5)%C:*P5V!*J8P"0.I S4T?^
MJ7Z5P>IW%O;^(-96>R6]:Y9?*N'A?-KB+;M'R'//(V\'<<D4 =ND-O)G9!9/
MCKMB!Q^M"P0."5M[)@#@D1 \UY%&FJ0V2PP7UU"8XQY:Q>>@#K;Q(N<+R Z/
MUX_.M?3M0N;;6$FNYKR:V^T32(L9GC$.Z9F#,H3YP4*C;@XQVZT >C_9HO\
MGUM/^_(IDL4,4;L;2T.$9A^Z Y S7-?#\:BNEWJZA=37(%S^ZDN&<R$;1G.[
M Z]-H ]@:ZBZ_P!1)_UR?^5 !Y$!V[;2U&45CF('DT?9H?\ GUM/^_(J1/X/
M^N2?RIU %<QVRN$:&Q#D9"F, D>N,]*:_P!BC7<ZZ<BX!W,J@8/3O7#>(_D\
M=K>P[P!;?9[DR0-*C#9)MV83*."X&5)!#'/2N2T;1)[.XL8;N\=[2W^R!)#:
MO(\:(DN],-&0VUY,+QTQZ4 >TK! RAEM[,J1D$0@@TOV>''_ !ZVG_?D4EG+
M%-90R0$F(H-I*;#C_=P,?3 J<]#0!5B6"1)3]CM05D5!^Z'< _UJ3[-#_P ^
MMI_WY%1VWW)_^NR?^@BK5 %?RK;./(L<YQCRAG/IUZT_[+%_SZ6G_?D5YCK-
MM=IK=_);:A+!,-4EN(A]F=ECS;&-7R(R2V[MDC'-5'DU2>;=_:&HP6PV^5!Y
MUP6B_>PE\L%^;*+-CKC=CZ 'K'V:+_GUM/\ OR*/LT/_ #ZVG_?D5YOH5UJJ
M>(-,-WJMX]LBK&4V2D=9!M;<OS9W1G=U&.HQSZ=0!7$=OY\$9L[7YW921$.P
MS2K!"R!OLMH 1G_4CBC_ )?K7_KJ_P#Z!4=V0-(N2>GD..A/\)[#F@"18;=S
MA8+)CC/$0/'KUI?LT7_/K:?]^17DMM'=V*6Q6\NYU6RM;>:)(Y(7;RUD!175
M!A0S(<GK@C-)<WVO6\.I.=2O[MY;&.-2B3JWG#RP?+ 4;0</DD9YX)SB@#UK
MR(-^S[/9[\9V^4,X]<5-$# #Y4<$8/79'C/ZUY,+G4A=/,UU>&U.T?90TXD,
M0F=O*\W;G(5D^;/;&:WO#\^H7?C0RM?7;67V?Y87\PJ (U!1BZC+!P6W8!.>
MO:@#T".:4S*K;"#GH"/ZU9JG'_Q\1_C_ "JY0 4444 %%%% !69?ZREA<^2T
M+.=H;((K3KE/$/\ R$_^V8_K0!>_X2:+_GVD_P"^A5?Q/XSL_"VAV^JW=M/+
M%.ZH$BQD$@GO]*Q*QOC%_P DZTS_ *^8_P#T%JTI14II,SJ2<8-HD_X7OH/_
M $#-0_)/\:/^%[Z#_P! S4/R3_&O :*]+ZI3/-^MU#W[_A>^@_\ 0,U#\D_Q
MH_X7OH/_ $#-0_)/\:\!HH^J4P^MU#W[_A>^@_\ 0,U#\D_QH_X7OH/_ $#-
M0_)/\:\!HH^J4P^MU#W[_A>^@_\ 0,U#\D_QJUIGQIT75-4M+"+3KY9+F58E
M9@N 6..>:^=ZVO"'_(YZ)_U^Q?\ H0J986FDV5'%5')(^LI+ADE*+'NP!SNQ
M3?M+_P#/(?\ ??\ ]:F2?\?+_04@((R""*\L]0D^TO\ \\A_WW_]:C[2_P#S
MR'_??_UJCHH D^TO_P \A_WW_P#6H^TO_P \A_WW_P#6J,$'H0?H:KRWUI!<
MPVTMQ&D\^?*C)Y?'I0!<^TO_ ,\A_P!]_P#UJ/M+_P#/(?\ ??\ ]:HZ* )4
MN6:15:/&[ONSVIRR2NH81+@C(^?_ .M4"?Z^+ZG^1J:&6,0H#(H.T=Z '[IO
M^>2_]]__ %J-TW_/)?\ OO\ ^M2^=%_ST3_OJCSHO^>B?]]4 )NF_P">2_\
M??\ ]:J-EK5IJ,;R6<\$J(Q1F$F!D?4<CWZ5?\Z+_GHG_?5<9+\/-%FEED;4
M+L&9BT@5XP&&0P& N!RH.1@D]2: .J.HQ#:/,@)8@ ++GJ<#H*9)JMO$8P\]
MN#*RH@$N=Q8X &!W-<@?AU82ZI(\M\JZ?Y2I%#"JI(I"QCEQU'[L''N<8[W+
M;P#H]OJUIJ)U"Z>6T(,:;HU08.<;54#&1F@#<M/$.GWTTD-M=0/)&<,I<K_$
M5XR!GYE(XSR*GNM5M[* SW4]O%$,?,TO'\O<5A3^!] FMTB5C&PEDD>52F^3
M>6+ D@_WC@C!'8BJ#?#+P[]M>Y2\O$9RVY/.1E + X 93MP J@CD!0,T =DM
MT'<(IA9CD!1*">.OY5+NF_YY+_WW_P#6KF] \':+X<U"6^LY7>>1#'F5PV 3
MG@XSGMGOWKI?.B_YZ)_WU0 FZ;_GDO\ WW_]:C=-_P \E_[[_P#K4OG1?\]$
M_P"^J/.B_P">B?\ ?5 #1(_F*CH!D'!#9KEO$?BN#1-5^S/:32L8U?<D@4=3
MV(KJ"ZO<1[6!P#T/TKS?Q]87ESXC62"TGE3R%&Y(RPSD^E;48QE*TCR\UKUJ
M&'YZ.]UTN6A\1+8'BPN?^_R_X4O_  L:#_GQNO\ O^/\*XO^R-3_ .@==_\
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MT;_T$T 2"T4# DD ^H_PIWV?'_+:7\Q_A4U% $/V<_\ /:7_ +Z_^M1]G/\
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M +Z_^M4U% $/V<_\]I?^^O\ ZU(;;/6:4_B/\*GHH A2W5'#[W8CIDU-110
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M$0I3M9^7KYGJ%O\ \>T7^X/Y5)4=O_Q[1?[@_E4E<1]<%%%% !1110!3LO\
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MH& >>.6#QY<P:7/=77AX.\/58&8[V,DBA5S'UVQY).!\P]: .[VQ_P#/9O\
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MKY'TC_PAG@O_ *!>G?F/\:/^$,\%_P#0+T[\Q_C7S=@>E&!Z4>P?\P?7H?\
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M !1110 5R?B1E34&=CA5B!)] ,UUE<;XN1Y)+A(YGA<VYQ(BAF7@\@'@GVH
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MN2&&#Z)@\<[JL7.H>/'TZ51ID$4\BG8]N@8QG]X  &?G[J'<>F[H: .VW?\
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M/SJAY\O_ #T;\Z//E_YZ-^=/V3%[5&@9" W[MSM/H.?I1O.2-C\#.?7VK/\
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MYO[@_.F3W)G@DB*@!U*YSTS1>H%J8B6LCHK#&&&1S3OL<O\ L_G1'=M'&J!
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MYB2(QEF*HQ*EVQN8 ],[1Q2>$/\ D<]$_P"OV+_T(5BUM>$/^1ST3_K]B_\
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M1[5U_F2?\\3_ -]"CS)/^>)_[Z% &!H_AC1=#O1=V7G"4(R?,2<A@@.>.?\
M5K],FM[[1%_>/_?)I?,D_P">)_[Z%'F2?\\3_P!]"@!C2I))&%))W9Z'T-17
M43O+E5)&*L"4^8$:,KD'!R*DJHRY7<F4>96,SR)?^>9H\B7_ )YFM.BK]JR/
M9(S/(E_YYFCR)?\ GF:TZ*/:L/9(S/(E_P">9IH1F=D"DLN-P],UJUE7%XFG
MRZC=R*S)&L9(7J>U-5)-V2$Z<4KMCO(E_P">9H\B7_GF:RO^$YL?^?6X_3_&
MC_A.;'_GUN/T_P :W]G6_E.?VM#^8U?(E_YYFCR)?^>9K*_X3FQ_Y];C]/\
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M98XSCBK@VI)HB:3BTSS+R)O^>,G_ 'P:/(F_YXR?]\&O1?\ A+-&_P"?H_\
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M\9/^^#1Y$W_/&3_O@UZ+_P )9HW_ #]'_OAO\*/^$LT;_GZ/_?#?X4?6:O\
MS[#ZM2_Y^(\Y\F4$#RI,GI\AI?(F_P">,G_?!KO)_$VDO>6LBW)VQEBQV'C(
MQ5G_ (2S1O\ GZ/_ 'PW^%'UFK_S[#ZM2_Y^(\Z\B;_GC)_WP:/(F_YXR?\
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MKC'/SGK0+887,:YSS\YZ4 <-+\-[*XM&M)]2NW@\YIUXQ(LA5@&W9QD%L@@
MY'-==8VBV.GVUFCLZV\21!F'+!0!D_E5LVPPV(USGCYSTH-LN6Q&N,<?.>M
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M?_0PZC_W_-'_  G/BO\ Z&'4?^_YKGZ*]CDAV/']I/N=!_PG/BO_ *&'4?\
MO^:/^$Y\5_\ 0PZC_P!_S7/T4<D.P>TGW.@_X3GQ7_T,.H_]_P T?\)SXK_Z
M&'4?^_YKGZ*.2'8/:3[G0?\ "<^*_P#H8=1_[_FM7POXR\2W7BO2+>?7;^2&
M2[C5T:8D,"PR#7%5M>$/^1ST3_K]B_\ 0A4SA'E>A4)RYEJ?62IYCR$N_#8
M#8["G^2/[\G_ 'V:39*K.4*$,<\YH_?_ /3/]:\0]L7R1_?D_P"^S1Y(_OR?
M]]FD_?\ _3/]:/W_ /TS_6@ ,0"D[Y./]LUYGI'Q+O;J1OM^DF&..!2[+,RC
MSC(!C<_ 38R'<>YQ7IG[_P#Z9_K01,>HC_6@#SR3XC/Y-YY>G2^;'(1"K.?N
MX!'F+G*'D?7!QTJY)XXEN= EO-+TN\>]^U_98+>;<?,(!9CA<GA5;CMQ7;XF
M](_UHQ,.@B_6@#S^+XHZ;/;">*SNF1F*J3<(.F_(.3\K?NSA3R<BI8?B%"LL
MZ7EI/$L<C@.7* *#@9W'ENF5 SU/:NQ738$*%;2T'ERM.F$^[(V<L/<[CS[F
MK7[_ /Z9_K0!Y_:?$F.ZW2?V;<1P>8(TW3#<<@_,W("*"/O'(QS6G9^-;>]D
MF5;"^14MY)E=W&'*(CE0 ?1Q@]#76XF](O3O01,RE2(B",$'- 'GS^.=475H
MM/72T=G:"(RK))L#SJK1<^F!+D_[*^M:%SX]L+1KCS;2]"PR.F[>,94/P>?E
M8F,X4\G*GO770Q/;PI#"D*1HH5$4$!0.@%/Q-Z1?K0!PE[\0XX+">6+3;H3+
MGRA/,%1A\X!)!ZDQG"]35O6/'5KI.O3:0ME>75Q&A?,4H"\)O8$GH<?G788F
M/:/]:,3>D?ZT <G8^+?[3N=42UMF6*SM#.AGF*LS!F&' ^X/ESSS@YZ&L&#X
MG.JS_:]-G/E!3O@W;9.NX*2V">.Q(QSDUZ5^_P#^F?ZT8F](_P!: ,#1-?\
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M+M5&S#@B1MJD<YR>W&: .'\'Q3PK<1S6-M:J%7;Y2HI8$L> K'*\\$]>:O\
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MG;1@"/3H% .0%11SD'/Y@'ZB@#E[GX@6UC<7"7D%S''!)-&9%B+;V258P%X
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M%K>-_P#H/2_]^D_PH_X6MXW_ .@]+_WZ3_"NJ_X9^U[_ *#.F_\ ?+_X4?\
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M_0>E_P"_2?X4V3XI>-98VC?792K#!'E)_A76?\,_:]_T&=-_[Y?_  ID_P
M]<@@DE;6-.(12Q 5_P#"CVF&\ON_X <M4YC_ (6MXW'_ #'I?^_2?X4?\+6\
M;_\ 0>E_[])_A74K^S_KK*&&L:=@C/W7_P *7_AG[7O^@SIO_?+_ .%'M,-Y
M?=_P Y:IRO\ PM;QO_T'I?\ OTG^%'_"UO&__0>E_P"_2?X5U7_#/VO?]!G3
M?^^7_P */^&?M>_Z#.F_]\O_ (4>TPWE]W_ #EJG*_\ "UO&_P#T'I?^_2?X
M4U_BGXUD1D;792K#!'E)T_*NL_X9^U[_ *#.F_\ ?+_X4R;X!:[#"\IUC3B$
M4L0%?M^%'M,-Y?=_P Y:IRX^*OC95"C79< 8'[I/\*7_ (6MXW_Z#TO_ 'Z3
M_"NI3X :Z\:N-8T[# '[K_X4O_#/VO?]!G3?^^7_ ,*/:8;R^[_@!RU3E?\
MA:WC?_H/2_\ ?I/\*/\ A:WC?_H/2_\ ?I/\*ZK_ (9^U[_H,Z;_ -\O_A1_
MPS]KW_09TW_OE_\ "CVF&\ON_P" '+5.5_X6MXW_ .@]+_WZ3_"C_A:WC?\
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MN_K7-44<D>P>TEW+FJ:E/J^J7&H7(033MN<(,+G&.!^%7O"'_(YZ)_U^Q?\
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MAF"29(62+.Q_7//?K@4 ,M_%VEW%O'/]LABCDD:.-ILKO*X!(]LD#/KQ3_\
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M110 56U#_D'7'_7-OY59JO?_ /(/N/\ KFW\J )8?]1'_NC^5/J.W_X]HO\
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M>%\OO#FJG6_\-"WG_0NP?^!)_P#B:/\ AH6\_P"A=@_\"3_\37)?\*<\<?\
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M ,\G_P"^365\6;*[O?A_IL-K:SSRBX0E(HRQ VMS@5K1_B(RK?PV?/U%:?\
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MXO\ GHOYT>?%_P ]%_.@ \R3_GB?^^A1YDG_ #Q/_?0H\^+_ )Z+^='GQ?\
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M"17NU>=B(1A.T=CIIMN-V%%%%8&@@.0#ZTM(GW%^E+0 4444 %%%% !1110
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5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b5_006.jpg
<TEXT>
begin 644 form424b5_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" ,8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BL"_N[:
MQM+FYU"Y%G;6MFU[>7K,,6. 2QX#$ !6/3HI_O"JU]JUCI$#75_/]FM%4?:[
MPG&F6)"_Q$X52QP 3GU8CI7)>)/$NFVNGZ4TVFW7B'2_$5]I.G$:+8+J^F)I
MGB)74:YKZDF-?#*[G\R4Y!7"@2(^Z/6,;7U_3;^OZ1R8K%?4_*W](T?^$FTR
M?3]-UFVNK.\T/5U5CK(OQ_96&)"L,D#!96 .,9!!/!K&C^)_@=?B%<_"B'74
M'CJT\*KXK;1"H+'1GD$2ZUD9SF5@I]SCJ<U\;>/_ !I'\._$6J_ ;Q1XF\/>
M*/&7QH_MK4/V;/!6O> =OPZ\-+X9\/JV@>'_ !(?#B#]TWBE%/F;1N3#JR\$
M?.ND_'_XP:G\4/@AX@U#]H7]CK3O /@W1/%_PQ_;!T+PUX@,OB_4?C-X9T-7
M30OAT\I9CY;@2CP@S/("H9,LJBO8^I\W5-:M-=5=<NFK=E>+M;RZGRO^L-M&
MG>]K76_76]NS7E\C[Z\;_%7P[#\/O#-QJ'B=/!&I^.?%&B^$="N/&_A/Y]2U
MJ21O+T1O#O4!_*D5<\95\%N<?3$05%MU)XZ'CI_GD=/TYK\F_!'Q1UK4_AW\
M&_B_X1^-.@>(/V;? ][XWU+XZ>-OVAK&33/%KQQ!6\/,S^7'#;R>"Y)2HWNO
MF?*PD8@K%ZD_[0^L7V@^&OASJ/Q,\$Z)\6OVA!XSU/\ 9W\9_#K0=<\7>$F\
M(^2?$'AS7]>\UEC!DB)B;<Z1DGYMI:5C6*RO73HW?>Z?:UMTK-K=)K377R<K
MXJ37U^6THI):6:>CUOJM6KZ:IZZ:??VE:]HGB**YGTC4K35+:SO&L;[["<_\
M392H8$C@'++QDCW.#73LN>1].:\W\$6MMI_AO338W6DZM=7FU]=UC12BZ7J&
MLOA-?UP$-L8RRHY4ER22$Z=.AL=<L+Z9K>PN4U,63C3[XV/S?8-4 YW9"[2<
MMP"0H //(KQ_3[OZ_JWR/T#"XJZLSJN!CMV%9-]J%KI\%Q<WMQ:VMK:*#>WE
MW@  #.>H4*!CJ>XP#S6BQ/E ^J\>V,_X&OYR?^#BWXM>/O!_[/7P&^&'A_Q;
MJGP^\"?'?X[:-\/OBQXZL&_LP^&_!;[6.'(!PS+G&<,%5O116"POU_&QP*TY
MOT>OY:?/L1FF-6"P,L=_);2_?;S/T7\5?\%6/^">O@CQ#<^%/$W[6'PFLO$%
MHO\ Q,-.M?$(U,@\<,T8F3(XSM+C(X)K[$^&/QF^%GQM\-VOBWX1>//"OQ&\
M*77RC7?"^NQ:M&1G@AHV;;UZ2>7GLIQ7YO?!#_@D!_P3(T+X6Z!IGA?]G_X4
M_$W0+W0M)8>.=;5/%>K^(]B@+KC^(C*2S.2SJT>T87:Y&&+?/WP:_P""3GC;
M]C+]N70OCC^Q9X_TCX?_ +,'CS3]7L/CO\ _%%YK>JZ1YL>UTE\++(TBH\<H
M5XMY8I(JDDA0QZWAL"T^5V:6G-%)-]N_3\O-'AX3%9[I=+?H]5KYWO;^M;,_
MH!4 #@Y!YI2 >#7Y9_\ !1+_ (*=_!W_ ()[Z%X7M/%.EZ_\3?C!\1[\Z=\-
M/@YX( /B_P 3,.X7H%4C@L"2W0* "WYX^'O^"O/_  4-\'PVOQ(^.W_!*OXF
M^'/@3=_Z??Z]X3UY-7\7^&M%X)U[Q%X=8,,' R /0C! (G"Y!C\9@;I+7W5>
M48N36MHJ32=^GS:TU?3B^(<#@\>LO;UW;6OS[_\  _#^E9@H['GT_P#KT*%/
M8\>O_P!:OQ6_92_X*T?#K]K7]L_Q7^S5\*/#5GX@^&NC?!?1_BGH'Q<L-;BV
M:C/*_A\S:#KWAP(LGAFX\*R7#(X:1A)(RA$6223S?-?B?_P6[\$?!_\ :P_:
M8_9H\8_"_5[S5/@KI^ACX:Z=X6OUUCXA?&OQIXA;PRR^ _#7AP@_O-WB),,2
M0!&A RF:?]@9C]<^H*+Y^5/V=TGKLGT3ONKZ._9W/]8<C^H_VAS+EVM9_/6^
MW78_?>FE@.H/Z?XU_+_\0O\ @M#_ ,%!/@9 ?BA\>/\ @EKXY\ ?LZ"^"ZAX
MJLO%XU;Q;X:T4<#7O$4:!8EXX^2-<CD@GFOWC^!?[2?PN_:#^!W@_P#:0^'_
M (BM;WX9>+_"9\2IK%Y)'I+:?I";FU]=>\P (?",:R))DJH(D(89,K&+RO&X
M-)R4;-M*S4U>[5KQNKW35K[IK=-+JPF?X#&W47MKK_D]3Z<W'^X?U_PHW'^X
M?U_PK^;'Q?\ \%S?B[\8OB7XP\ _\$Y?V,O&O[4NB> ];73_ !%\4KO43I'@
MW47Q\W_"-,0'=<\ O]X -M4D@7M9_P""ZFM_"#X;?$^R_:C_ &5_&W[//[1_
M@/P@WC#P?\*_&M\J>$_C+HT8B36HO"?Q"C18AXBB19/W<BN-Q3.X%P:_U>SO
M1<FK5^6_O)/1-QO=*^C=K)Z-LX_]:LC_ )UZ\JM\G;[NY_2'17Y8^,O^"A=Q
MX5_X)GVG_!0@_#C[9=7GPBT?XI#X7'7DW9\0^6!H(\0%=I(+JP(&U6'W1Q7Y
M]>(_^"Z?CKXB^&?ASH7[&'[(/C;]IOXU^(_ >A^,/B5H?A6^5?"/PDU;Q!HA
MFC\-^(_$:@#_ (22,\*G"A/E.X$DSA<AQ^.3Y5S)2<9/F45%Q^*[ET76WY:J
M\7Q!@,%N[7_KH?TG#E#GL1C_ #CW^OTILB^8@ [<?C@?GCVK\DOC]_P4\\,_
ML>_LC?#'X^?M4>"=6\$_&+XCZ#HXL/V=-"/]K^+M2\:,#N\.^'5!(+ 8;+#^
M,8R0U?"'AS_@KS_P4GO;*T^*^K_\$F/B:/@/=XOQ>:%KRZK\11HHSC7AX;
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MP5(; \K^('_"1:7\'/C;IOA@6EIX%7]NXZ!XZ/V[^R=(TSX9G0/#(;_A(3C
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M -8;UM^ONKY_\-V./%8;ZY_S)+W>EVONTWZI]6M[H]8\$?!O]G+X9:E<:YX
M\*?#7PIJEV#8'6=/\H:JYQPIW9<8]5D _O,0<4WQ5\!OV=?&/BN3QMXN\!^
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M^F_V[]JUO;I65. 1B0A3@8R68 @'@Y&>SE\4^&X!IHN-;TM?[7(&G9OEQJ'
MYCX(QSWR <CJ"!\@:C^S7K^HKJNGZGJWANYTG^WO!^H6%DUCC'_",^&F\/\
MAX-TV[?$RO(0<80;L5C?#/X4^.-*^)OA4>,?"#76E^$M"TG3-.UVQOO^)38:
MWX6T*2.77DX^9O&3Z[*C@9*/%(K %&Q3PF!Z/Y?\.^MSI^LXWLON7^7_  UM
M#]":*KU8KE.P**** "BBB@ HHHH **** $P/0?D*,#T'Y"BB@!:*** *]/0
MDY&>/ZBBB@"3 ]!^0I:** "DP/0?D*** %I,#T'Y"BB@!:***32L]%L^B[>@
/!1113 **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>prospectus_001.jpg
<TEXT>
begin 644 prospectus_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != 1@# 2(  A$! Q$!_\0
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98D4<9)1%4GJ0*DH;N"5@HHHI#"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Y IX# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^5^BBBO\
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MA[[X>_\ !-KP)X,_X)[Z'_P4H_:W^(_Q<\-?"#XC^/8? 'PD\ ?L\_#;P?\
M$#QMJ$8U7Q%H<_C?XA>(?B'XV\"^"? WA6;6?#.J:;IL4E[=WTTJV&XG4-4M
MM'3RUQ-E;RS*<U<L2L-GE3"4\KI0PTJN88FIB?;2]E#+X58S=7V="4U#ZQ!1
M@G5=5Q7*_37"N9_VIF.4J-"6(RA8B685Y8A4\!AX4?91]I+&2IN*IRJ5804O
M8R;FXTU",GS'Y#$'.3QGC#$!LCU&<C((//;!Z<T $G Y.T'"\\9QG@<]OY^M
M?H#^UQ^RU^SY\(?@'^RI^TA^SG\<_&WQH\!_M0ZS\>;)M*^(WP\\/?#GQ?\
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ME:?IFO:?J7AOPI/X\\1:>/%.J:=--)-H>G7$-V?,_AU_P4:_:3^/P_9.\,_
MO]G'X8W/CG]I[]D'5/VHKZ_^)'Q3\0^'_!'P@&D>-_#WA*?0_$C:'X,USQ+X
MB@E37H;:V71+&/4'UI)1(8=,M9;IO2M3_8Z_:+^&FI_&W1O@%^UUX9^$7[-/
MQW\;?$+XK^,?#OBOX*CQ_P#%KX/>)_B5=ZCKWQ9NO@!\26\<Z#X4T?3_ !;K
M=[J_B:PMOB3\._B+#X.UO4;Z;1K6]LS#I\/+_L8_LZ?##X(?$O\ 9Y\.^'_V
MA=.^(WBC]G#]B[4?V6+[P\/"VIZ=J_B."X\<Z!X['Q$U&]N;F:#3%>#0&MI-
M.=KB/49KB>\M;R(0FSKTITLC^IX^M0P%#$K"QE'!1IX;.)U*<'EU.5*6;5$J
M>&^LTLTK1G.,*E.'/1IV<L&X*KYG]HYA#'8'!X[,_J%;'U:,)QQ6-R2C+%5?
MKE2K4ADM)5:E6M1EE6'E*--PG5]E5Q$I-XBC7E3AT_\ X*/?&34/"4'PPM_V
M>/"E]^W)-^U3XU_9''PHL_B7J:?!,>)_ G@+3OB_K?Q=D^*,OA+_ (2,_"FT
M^$>M^'_%-Q:S^#AXP&LZHGA'^RFNT&HO+K_[?7[3WP?^)7CSX,_M"?L[?"W2
M?%?@;]COXU?M7Z?X\^&?Q4\1^(OAI\0H/A??6%I8>%=#77O!&@>+?#=_%/=7
M%OXO@UFPNY-/^T:+?Z)=:G:7\T5OI_$S]@6ZTS4_C)\=O"W[04/PH^,$/[5V
ML?MG_"?XFW7@2+Q'X=^&\=]\"O!?P1\<?#;Q_P"$[CQ':GX@_#_QKX2\(7X\
M4MI5]X7UJW;4=.NM#O[/4='BGNJ&H_\ !/SX]_%WX@>/OC1^T!^U-X7\7^.O
MB'^R+\9/V4K7PU\/O@W/X%^$7P_T;XGW.GWUAXF\$:+J7C7Q3XRO]0MYX+F[
M\77/C#QEK-QK]P]C9Z.?#&DZ=#8RJFN&7)U9TJ,,#.G*-6%2GCGBH8]K+YI8
M.4>;#_5>5YC[U2K4G";7/%_[.RY5^(FWAH5:M3,*;56BJ6)RJ5!Y?SXZ'M<?
M"-7ZU2Q$ZCP$8*&'4*L7*$'2G&O:E9_M\_M6#X7?"+QQK7[+OPUTGQ_^V'JO
MPS\.?L9_!4?%_7+KQ1-<>)_!>J>.O'?C+]HWQ%#X'_L7P+X,\#^$K*'Q9-:^
M"(/''B 6#KI%S FLS*8/6?AM^UC^U'IG[7OPI_9#_:0^ WPP\*:A\2/@I\;?
MC#8_%OX1_$WQ)XO^'^LVOPOU[X2Z+;^'= TKQ5X,\+>([+7[*;XB7?\ PEUK
MK< M;.V7PQJ'A_4=2CUK4[/2>[^,'[&&I_$'X(_LY^#_  1\5[GX9_'']DU_
M 7B#X*?&BV\+6/B+3[+QEX+\#KX U:W\5^!-2O88_$'P_P#B#X9GU?0_%WAB
MTUS2-4&GZE#=:5K]EJFG6UV.*^&/['G[0I_:T^&/[7W[1W[2?A/XC^+_  !\
M&OB_\&K7X9_#3X27OPS^%6@:1\3=<^%^MQZGX1L];\>>//%HURYNOA_+=>,]
M5\5>*->_MGS/#ECH%CX9L=!G75N"5;(JU+$3AA\+1YZ&9Q<''%^WAB55G'+?
MJK]M./LGA(T)5Y5^:53$2J5*S<I47#THT\[IU:$)U\55C"OE[4U/#?5YX9T:
M<L?]:_=1ESQQ4L13HQI.*IX>%.$>91GS?I?">J@D[3AB1C/WNF>2 > 3S@#/
M?$]58OE)/3G!YR-H=OK@$G'/.1[U:KYR"M"'^%;IIZ76J;;6W4^G3O?;XI;-
M/JNVG7[C_%GHI,CW_(_X49'O^1_PK_0*TOY7_7_;Q_ ?LWW7X?\ R0M&??W/
M!_#.1SGGUQSG%)D>_P"1_P *4=>0W)[*PSGE@?8^AXX.<]0-2?V9?)7_ /;O
M\BE!K_AU_P#)>I^M?_!(F']M;P5\5/CG^TY^P@OASQ'\9/V6/@D?''B#X.>)
M/#>M>+++XZ?"OQAXLT3PWXT\$1:+H>L^']3OY]#MH+7XAVNGZ5K^B:]J&K>$
MK&TT6YFU$VVGWG]&7P)_:@_8I_X+K?"S]J+1_P!K#]BJP_9K^,?P#^#&K_$'
M7_VFO#DR-'X/MKRR\0Z)+K&E?&0>&_!GB[P]K]BT%QJ$WP\\<VVN:1XET2+Q
M)9R_VY8Z3JHE_BP^&WQK^,GP;.OO\(/BK\2/A5=>*8O#UMXBOOASXR\1^"-1
MUJT\)^(++Q9X;MM1U'PWJ.F:A<P:+XGL+77+&(W0@AU*(3K"$>6.7UOXK_MR
M_MH?'3PA<?#WXR_M4?'_ .)W@"^G@N=3\#^,OBEXNU?PKK%Q;!_L\VN:++JB
M6.NM!([2QC6(;Z/[01<,C7"12)^<\0\$XS.\UJYC3KX/!XIUL%_9^<4'F>#S
MC+,)AZE!U\/B(X1RP&;1:CB'AJ>(IQC155<SFH*F_P!-X?XRP62Y73P%2EB\
M715+,98S+:U/ 8G+,;B\1'EPM:A.ORXS+U!2BL3[&?-5=)\KCS\Q^Q?_  3Q
M_:1D_8X_97_X)Z_M(SSW@^'/AO\ X*]?%;P1\1O$L6F77]FM\-OBG^S7X$^'
MGBV\#6MG.)9K/0)]5\5V.EVL7GZAJOA8:5:LD\<@C_8SXQZ#\(_V=O\ @NQ^
MRK^SS\';X7>M_M-?M3^(OV^OCW8VT&GPP:!X@/[./C_X2?#3PC:KIMM")]*2
MZN_C/\59WO+DWZ:O\41<WL=[:'298_XX[[]MW]L/4_A')\ M0_:6^,M[\#9?
M#*^"G^#]UXROI?AJOA&* 6\.@1^#P!HT=E&BJ^Z.V2Y2X4W<<R7Q-R6>&_VV
MOVPO!_CS6_BIX5_:8^-/A_XH^)- \.^%=?\ B/IGCG5X/'>J^%_"6G1:-X9\
M.7'BDS2:U'HFB:3##86&G6]Y!!':PQ1N)%7#<&8< YEF&,S+,)5LOI5<9A<Z
MP\L/3>-JT<9]?J4IY;4Q<JV'BU5RZO+%8V7(I*=5T_9N,HVCZ&$X[RS"87 8
M*%''5*>$KY17A6E#!TJF&>"4UCJ>%4:M1<N+HPH86FY2C.--5.=--,^X/^"^
MXC/_  5Q_:_\V,@V^N_#6Y224QJT:-\&/A^IGC:1 40[9(S*#C;'(!(P5]OZ
M1?MX+,G_  ;0_P#!+*X\J[")\4-$E>94DC\I+FQ^.QMY9I&7$:7#R1""1RJ3
MM-$L)<RIN_G+^+W[2O[07[0/B7P_XT^.GQB^(7QA\7^$XH[?PUXG^(OB"Z\5
MZ]HEM!?C5+>UL]3U,SW;6L%_FZM[6YDGMX92P2$1O-$WK7B[_@HC^WGX_P#!
MNN?#CQS^UY^T%XO^'OB;0[WPOX@\"^(OB)J^J>#M4\-:C8RZ;>:'/X:N6?2H
M].DT^>2SCAM;: VL)7[&T#QQ/'Z\^&,V^J<"TJ<\ ZO"F(PM?%N7UF*Q7U3!
MUL!"&&E&C>*E"O.M!U>5P<7!VE+F/&CQ-E;Q?&E><<<H<2X?$4,)&*P\G0^L
MXFEC'+$?O8Q]R=+V;5-/67.KZL_>C_@TE6&+]KG]KF"W14,7[-GA)FCB$96-
MKCXFQ,"5CX1Y"IFZAI2ID7?DD_R]?$#:/B/\1' E0Q?$#QO%(A"NT4T?BG5%
MEB97P\,J.-LB. ZXYP=M>W?!S]M#]K;]GCP]<>$/@%^T;\8O@MX8N[^;5+W1
MOAEXSU+P?:ZAJ$X/FW6I/I#6]SJ,N[<\0O9IX[<M-]F2$3N3X]\4?B;\1/C7
MXNU?X@?%WQAK_P 1?'7B".VC\1>,/%%VVH^(->6RM$L;>35]1(CDO;B.TBCA
M:[G\RZN=@DNIII,LWI9;D688+B?B#.JJP?U3-:&6T\-1HQK+$4)96IPIWYJ<
M:7LJRKSJ37.I1=)<JG)IGF9CG6!QG#>1Y13^NQQ65UL=/$3JJDZ%6&/E"<W%
MJM*?M*?LE!)QY9J>LK7O_7E8^+O W@G_ (-5/@WXI^(?P?\ #'QU\)6/Q0\-
MRW7P[\:>*OB%X-\*ZQ+=_M?ZW;Z9?:QKGPQ\0^&/%<^GZ??S0W[Z?:ZU;:=J
MT:K87Y:SN'9?ST_98_X*Q?MC?M<_\%-_^"9^G>,?$G@_X4> /AY\7O ?P9\%
M_!SX#^'=5\$?"?3/ ?BZ/1O!WBG2SHGB;Q1X\\0ZU+K7AC1;'2%N=<\3ZF=&
MTU+BU\-)HD-Q?+/^6%__ ,%&_P!OK4O"=QX"O_VO_P!H&[\ W>C_ /".W'@.
M3X@ZJW@>3PZ;=;4:%_PB88:$FDBV40BPBL4ME0C8B-&K#YU^$WQ?^*7P(\86
M7Q"^#/CWQ;\,?'VFV=_8:;XS\%ZK+H?B+3K/4XDBOXM.U2W1KS3Y+I%$4UU9
M36]QY.^&)XDDD#?/8'@&I0PG$/URAE>*S+,<7GN)RO$R>,GA<#'/*#H5*?U:
MO%TZ=?#JI.3Q5##.KB%!TX3H>[)_18WCNE4Q.00P=7,J&6Y;A\HH9E04,+'$
M8Z65UX5E)5:<U*=*7LX\E"O6]E"4N=4Y2A%Q_J)_X+&_\%3?VDO@S^V__P %
M"_V"3=?"S4_V7_CI;_ OP-XY3Q?X&O[CQO\ #_P1X\_9S^%MO\1=>^''B/0_
M$>AV,/B'5-+US5;@^(_&WA;XAW>F76C:#)X;32X?#T<)^LO^"D'B7QQ\ _\
M@I9_P0\^$?[%.J:KX-_9\%AX#B^%O@SX6:I=V'@#Q7H'BKXE:;H'Q'U.?1=(
MOK71/&G]I_!RZ2?7[_5K>]GFTC6M0UB\FEFU*>23^.OXU_M)_M!_M)7VA:K^
MT)\9?B+\:]9\,6^H6F@:W\2O$5YXJU?2K#4VLGOM.M=3OR][]AN);"UE:TEN
M)84EMXGCC1Q(9>Q^'W[;G[8WPH\,>'_!GPU_:B^/'@?PKX.;4V\%Z%X=^)/B
M6QL?! UNWGM];7P,QO'NO!::S!<S0:DGABYTJ&[MIIK:6)HIB*YX^'4Z.#R;
MZK3RNGB\)E6.P&9490Q,\OS#%XC*(9/0SBI3G1K-8ZC&*JJ$*"A*FZC5>EBN
M2L]7Q]2JXO-HXFIF-3"8K,,'BLOQ$%0AC\'A,-F_]HU<LA.-2FGA<0IU%*<J
MKDIQA"4)4'R1_N1_9G^!_P"QAI7_  7I_P""@&J_#'PW\.4^,WPY_9U^%GC#
MX9^&-%@T=]*\+_%GQC:^)-/^/?B/0=&6)=.TKQS'!+\-[#7GTY[2YTVU\;>)
M8YHHVU_5C%\+_L,^+OVU?BG_ ,$;/^"X5I^UC>?M#>-/','@WX_V/A2P^,]E
MXXU37UO[SX#:W/XTT'PI:^)K)]1.D6WBA9K:Y\/Z DFB:-*K66E6%E"/(;^/
MGP1\7/BO\,OB#9_%OX=?$SXA>!OBKI^H7^J67Q+\+^+_ !!H_CN#4=4BF@U:
M\?Q9:ZA'K=W/K$%U<P:S)>WMP=7CFDCU+[5&\BO](77_  4@_P""A-Y)XADN
M/VX_VM2WBN.!->:+X]_$>W;4A9V!TZT$YMM=B6)+>R(@>*S%K%,/WLR--ATY
M<1X;YNX4Z5+,\#CN7#<*4HXK-*.-GB\-/AK$NO5H8:=)5E2P>8RBI34*D*UZ
ME.-;ZRZ<SOP?B1E=*HJ\\MQ>$<,3G]9X/+YX2G@\2LYAR4*^)YG3E+%82/+!
M/EJ04'5E0=)N,3^C?]K/QY^T[\4_^#=#_@F5\6/ FM_%?QW\?O#?[3/A>_L/
M&W@.SUOQ!\0]&O/!LO[4'@+PGJZ7'ABPEU.VO=$MK3PYX:MM1EM9)VNFLK&\
MGNK^^\ZX^[/^"OWPN^$OQ9_X*X_\$=?"W[26E07GP.\1IX]TCQ&-?MY(_!6O
M>,(IUUKP-X&U^^FL9=%EM?%GC?3_  SI&H:#/);C6--NY-/D$5I=^9%_$[X#
M_;)_:Z^%7P\U[X2?#+]IWX__  ]^&7B:;7+G6O 7@KXL>-?#?AB^N?%"2)XH
MN9-,TO5H%CN/$:22MK=S;26]QJ4TDD]Y--+(\AR?BM^U;^U%\=='T3P]\:?V
MBOCA\5] \,7%C=>&= \??$[QAXET#PW=Z9 ;;3+[1-#U'5IM*TS4-.AS'INI
M6MI%?6"/)]EN(C+(S;4_#S,Z>.]M2QN74<+'$\95*%6A0Q\<PI4N)J-2%&/+
M>-"E/+JLO:X.=.J^=24JGU:2=*/%/CO*98-TY8/,*V(JT>%88FE6G@Y8.K4X
M=G34^9\TZDZ6,H1Y*D73CR-.*A53YW_63^W+^U3^W;^RO_P45_X*!_"CPS^R
M%XN_:0\ _M(? SX<>#_@2M_+\0[/X<_![X5_#[X7ZAJ,?BSP#IOA_1=3\!1Z
M+X0\377C+Q'XDL[>^\!:GIGB_07U&3Q?IMT('?&_X*D^+_VK?'?_  2!_P""
M)DWPL\8?''QAK7QJ^!/P7T+XZW_ACQCXW6#XK/X\_9<^'G]KV/QV\2V.J?9=
M3T7Q=K]SK3^)M3^(VH3Z2+B[UB^UJ[+17LY_F!\9_MX?MN_$7X=S_"3Q[^U[
M^TSXQ^%][I=AH>I> ?$?QF\=ZQX<U72-,,1M=)UBQO=9E.KZ9&8( ;#5)+N"
M58(5N5N$C5!0\*?MO?ME^!?AE9_!7P3^U9^T/X1^$.FK/!I?PT\.?%GQEHW@
MK2M/N=3?6KC2M-T*PU6"VLM+EU6:XO)=,MA#ITLEQ.DMG(DUR)GAO#[,,*\B
MKTX</1Q>3XN-3$R]CFD\-F\*>23RI8G$TJCE[+%)RIU8PHT53J5XU*]:M.?)
M4CI6X_RVO#.<//\ MIX;-</)85MY;'$Y94GF7]H/"TJD;*MA/:7BG4FG"E&%
M*%))R2_N.^'_ ,0?V:OVU/VHOA[X3^#'QK_:,_X)[_\ !2?]D/X,ZQ\-M2_8
MB\::)K5Q^S8GA#P7<VL'B/P?\1_AOHL5M\*OBU\)7>_M9=-U[X(_&CX;>+]=
M\%WGA?Q/%J%K_9.DQ:;_  L_ GX9^.O&G[5/PF^$W@.S^'&N?$'6/CYX7\(^
M&X/%<,6N_";6O%)\?P6%A_;T4S3/K/PXNKV!&OK;,]YJ7ALO:PM<7,ZJW9^(
MO^"@'[<_B[3M=TKQ-^UY^T7K-OXIT*Y\)>)KJ_\ BMXJGUOQ#X0NCNN?!^L>
M(S?+XBU'PI<M+(;CP[<ZJ^C2JP1K()O5_D_3[Z^TF^L=3TB^U+2-2TJ\MM3T
MC4M)NY].U+2=3L)5GT_4=,O[-XKJPO+"XCCN;.YM7AN;6YCCFMY8WC##U^%N
M#\PX?CFT98BA66,P.'PV$HSE/$0P]:,,=5Q/-BJN%PV.JX*IC\5&M2PDYRJQ
MI*5&KC:D9KV?C\3\6X#/9Y5*&$JPE@L54K8JJU"C+$TN?"0HN&'HUZV%I8Q8
M7#SC.M!>S=2:DJ34$Y?Z3OP%\,^++O\ X*#?MI> ?VB)/&7Q3\;R?L)?"G1?
MB7<>#_AAJ?PC_8!N_#<UYK#>'? /PL^#OC;QC\;?%&O^/[&PU'7E\4^/]5^*
M]MI>IZ;=WGAK3OAKH\ND7E_)^(O_  14^,/Q(T/_ ((T_P#!:NPL]<NKVT^
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MBU&>WEN;>":Z2!HQ<2 ]?!_P4&_;P@\ 2?"J/]LS]J%?ALV@/X4_X0M?C?\
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MH/\ B#/#?_0;FW_@[#?_ #.?Y:W_  Y:_P""K?\ T8E\<O\ P(^'O_S;T?\
M#EK_ (*M_P#1B7QR_P# CX>__-O7^I3_ ,+$\#?]#3HW_@9'1_PL3P-_T-.C
M?^!D='_$:.)/^A7D7_A/BO\ YJ#_ (@SPW_T&YM_X.PW_P SG^6K_P .6O\
M@JWG/_#"7QRSZ_:/A[G_ -3:E_X<M?\ !5O_ *,2^.7_ ($?#W_YMZ_U*3\1
M/ __ $-.C>_^F1C^9 _,@5IV?BKP]J,!N;#6-/O(!--;M+!<QR1QSP6LE]+%
M*ZDB-H[.)[AR^ (49P2  5_Q&CB3_H59%_X3XK_YJ#_B#/#?_0;FW_@[#?\
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MY%_X3XK_ .:@_P"(,\-_]!N;?^#L-_\ ,Y_EK?\ #EK_ (*M_P#1B7QR_P#
MCX>__-O1_P .6O\ @JW_ -&)?'+_ ,"/A[_\V]?ZE/\ PL3P-_T-.C?^!D='
M_"Q/ W_0TZ-_X&1T_P#B-'$G_0KR+_PGQ7_S4'_$&>&_^@W-O_!V&_\ F<_R
MUO\ ARU_P5;_ .C$OCE_X$?#W_YMZ/\ ARU_P5;_ .C$OCE_X$?#W_YMZ_U*
M?^%B>!O^AIT;_P #(Z/^%B>!O^AIT;_P,CH_XC1Q)_T*\B_\)\5_\U!_Q!GA
MO_H-S;_P=AO_ )G/\M;_ (<M?\%6_P#HQ+XY?^!'P]_^;>C_ (<M?\%6_P#H
MQ+XY?^!'P]_^;>O]2G_A8G@;_H:=&_\  R.C_A8G@;_H:=&_\#(Z/^(T<2?]
M"O(O_"?%?_-0?\09X;_Z#<V_\'8;_P"9S_+6_P"'+7_!5O\ Z,2^.7_@1\/?
M_FWH_P"'+7_!5O\ Z,2^.7_@1\/?_FWK_4I_X6)X&_Z&G1O_  ,CJY8>,_"N
MJW<=AIFO:7?7LP<PVMO=Q//+Y:/*XCCR&<K'&[L%!(52W0$@_P"(T<2?]"O(
MO_"?%?\ S4'_ !!GAO\ Z#<V_P#!V&_^9S_+*_X<M?\ !5O_ *,2^.7_ ($?
M#W_YMZ/^'+7_  5;_P"C$OCE_P"!'P]_^;>O]32\\9^%]->*/4-=TNSDFA%S
M''/=I'*T#336Z3"-P&\MYH)HPQQEXG5=Q4XJ?\+$\#?]#3HW_@9'1_Q&CB3_
M *%>1?\ A/BO_FH/^(,\-_\ 0;FW_@[#?_,Y_EK?\.6O^"K?_1B7QR_\"/A[
M_P#-O1_PY:_X*M_]&)?'+_P(^'O_ ,V]?ZE0^(?@AB OBC1F8G 47B9)]  "
M2?0 $D\"FCXB>"6^[XFT=L<DK>QE=NUFW!N-Z_+M^0,0V00 "P/^(T<2?]"O
M(O\ PGQ7_P U!_Q!GAO_ *#<V_\ !V&_^9S_ "U_^'+7_!5O_HQ+XY?^!'P]
M_P#FWH_X<M?\%6_^C$OCE_X$?#W_ .;>O]2C_A8?@K) \2Z0=H8MB\CRJK@D
MLI^8#&6)P1M"X),D0=#\1?!0SCQ+HY QR+V+:> 3M)QO)!^0(&W$?-L'S _X
MC1Q)_P!"O(O_  GQ7_S4'_$&>&_^@W-O_!V&_P#F<_RV/^'+7_!5O_HQ+XY?
M^!'P]_\ FWH_X<M?\%6_^C$OCE_X$?#W_P";>O\ 4H;XB>"A@+XETAB2PP;Q
M 3MR#M&"S#/&Y5*\,-VX!6&^(7@P %?$>CL"0 WVZ(*6+J@7<3C+DD1\_.PV
MCD@$_P"(T<2?]"O(O_"?%?\ S4'_ !!GAO\ Z#<V_P#!V&_^9S_+7_X<M?\
M!5O_ *,2^.7_ ($?#W_YMZ/^'+7_  5;_P"C$OCE_P"!'P]_^;>O]2C_ (6)
MX*_Z&;1AUP3>QA3CEL-C.5 <N-N5*.&Q@FD_X6+X*P__ !4VC$QJS-_IT050
MF?,+,<!?+VMYA;"H5(9AMDV'_$:.)/\ H5Y%_P"$^*_^:@_X@SPW_P!!N;?^
M#L-_\SG^6Q_PY:_X*M_]&)?'+_P(^'O_ ,V]'_#EK_@JW_T8E\<O_ CX>_\
MS;U_J4CXA>"LX/B?1@<9P+Z,G_EH#QTX,3@@D,I4JZHPVT@^(?@S<$_X232
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MY&3^A/48(SSZBC_B-'$G_0KR+_PGQ7_S4'_$&>&_^@W-O_!V&_\ F<_RUO\
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MOOY?W_,_,YUZJY?WD]81?QRZKU*_V.T_YX0_^ \/_P 31]CM/^>$/_@/#_\
M$U8HI>RCVC]S_P#DB/;U?^?D_P#P.7^97^QVG_/"'_P'A_\ B:/L=I_SPA_\
M!X?_ (FK%%'LH]H_<_\ Y(/;U?\ GY/_ ,#E_F5_L=I_SPA_\!X?_B::UG:$
M8^S6[ L!\]O"1SCD?(P],\=>>HYM4-]T?[W]5H]G%-.RW73Y]6TUILTT^J:T
M*A7JN<5[2>KU]^7^:_->I_:__P &A-O;P>#OV^7@@AA>3Q5^SNTABB2/>?[
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M$6[UK6+&&XN+2U-Q>6_@WBO]NCX&?#'P'J'B[XW7GB[X!>*M,\/_ !/\2R?
MOXP6&A>'_CMJVE_"1PWB^Y\%>$-*\6:_X>^)^FK;RV4WAWQ1\+_&GC+P7XI7
M5].L='\37.M6VLZ?8^^?%;X8>!?C7\//%'PM^(^D2:[X+\86=I::O8V]]J.D
M:A#-IFJZ=XAT'6M%UK2IK35-#\0^&O$NC:-XD\.:YIEW!?Z-K^DZ;JML[36J
MHWQ=\2?^"7O[)7QJU3PIXF^-FC>/OC5X[\*^$OB#X*A^(_Q?\6V/Q,^(-[H'
MQ&U0:U?6EIXI\:^%=<O/AW<>%=2\Z?X>:C\$H_A3>>"5U#5;?19(K?6-5BO
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M/[)NB^--"^ /BU=)G\51ZMJ>H_\ !06;QQI'BCX@Z>\,%UX8U3X9Z/#XXM/
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MO%WBCXQP?!K8DL'@72/C1K_Q!\=:E\4]-2+48O$T_B>^6*33+:*QMK+B;?\
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M_:7_ /3-\#J_CQ^$'_)7OA'_ -E/\!?^IGHE?V'?\'>7_( _X)Z?]A']I?\
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M\1ZCX>^+NK?#?Q&EEJ%]X5TCXE>!-&U+X<V/Q!^&OASX@^-)/AW8>-:AXO\
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MT7PKX>UG3?\ A-M?\$W>N?$32K_6?$NC?"S3?A_:7VNQ_$;4?$6D?\(U=O\
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M_P -[SPCXV^,FL^$)?"/CG0-&E\6Z#X2N[#6]3T_6_&.D#3HKB\]G^!W@_\
MX*4Z#^T)JNA?&GXD7WC?]G&T^ WC7P]X8UZZ3]GS2-6USXBIXET*#P1XF\9Z
MM\.?AYX*\6>'_C!=V$GBJ2\U+P5X!G^ :^ I?#%J/ASHWQ-T;5=7\3_GEX3^
M'/QK\0_ [P]X'TO4[#Q+YOB#6_"OACX36W[0D6M^*OBCXH\,^+=-U#49/%GA
M:^_:X_X0CXEZE;W?@#QEXI\:6'P[_:6_9]TWQ>O@[Q!XRL+'X;:S!>_!'Q0
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MC%M2G*,5)K\[PN'6*Q.%PWM(4GB*M"C[6:<J=-5&J;G*,8RFU%RO[J>FFYX
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M_9W_ /3#\5:_LR7H/H/Y5_(WB3_R77$?_850_P#4+!G]:^'/_)&9%_V#5/\
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M=\*_BAJNM^)6T/3;;3=;UKQ=K.D?M6>'=/U#X]0V.GVWA?X5?&S0_#?AG3O
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M;ZC9?GS^S-^S1^SS\&?BM\-OBU8?MK?LZ^(_@[XE\8_%W]JSQ9'X6NOA_P#
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M=_R)O[?'_8T_L[_^F'XJU_9DO0?0?RK^.?$G_DNN(_\ L*H?^H6#/[#\.?\
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MIIX9M98FD$2ZCKHT;4Y=-TJ.:74[FUM&O(K22TDAFD] AE,N3QT'3<,=0.&
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M>$/#O@OPA>Z)\<+G6M?T7X=:9X/A\9>//!'AKQ_XLFU[Q5K?Q"U7QEYCHO\
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M?X?'VNXTO1["+5X;Z[T/Q5H?V?\ >+_@[O)_X1__ ()['GG4OVEP<\8/]C?
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MDND^+/$GBG7_ !!_Q/Y@#]6D;>BL,'<,\$$<^A!(/X&L+5_^0EX=_P"O^_\
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M/W5^SKK/[6/BWQ[\&Y/CS^SSH?P[BU/X=^*/$>M37/PR\,^,K;P%XW\66/\
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M1110 4444 %'OZ?Y_I110!&X  XZNG?'.Y0#U&>@!'<<5_G+_L.>,?B=H/\
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M^-\7A_QAXGU#3IO'%CX0^$/A-/AUXET.\U_4+ZR -^?X#?\ !7N#X7O=Z/\
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M[XE>%IQHWCWQ1<ZGI[^ _%W@#0YY+35^'U[_ ()N?$>WN_'R> OVQOB9X?\
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M>%'\1^'?&]]%=Z_!I/C74OB#!8ZG>:Q^E7[)'@+6_@A:^(;;XD?$"7QMJ3>
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MN/$4FIV>WX _:3_X+*7T'@K0K[]DCP1INKV7@;QUJ?C2U\;_  =\=)!INO>
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MSLU:^]M5V:;3_(]2+4HQ:N[QBVVN5MM7>FMEJK:OJ<]YGM^O_P!:CS/;]?\
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M@_Q#QLJ&%PKQ-?*:KP^#I2HX>$GB$YRA"=2HTY2<FTYMWE)Z)V7\5C?ZYO\
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M[^''Q&\'>,K;2[O0[/4+C0];M;N&VN?$GPT\#?&+0HXY0XBN6U+X5?$WX?\
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M_@CS\9OV:=1\=Z/H_P 2_"WQVUK1?C+X5^&W@*Q\!>'#H%K\1_!,_P"SK/\
MM%?$[X\7OB3Q'XR/A#X9?#3X):)<>'- \>:SXJU^X\+VBZ]<>*M9\:^%M'TE
M[>_^RQ/$^28+,/[-QF/I8;&*,*E2E54H0C3J4I5HU)5I)4Z<%346Y2E)12FW
M9Q<5\CAN%\ZQ^"CF&%P-2OA9-TZ4J<H2J3G3G&E*$:2]^4^=N*BN5MN&KO<_
M(C</;/ Q_$220 5X(.0>...2 #DN/!P>H8K@$'D8'.#@#D8).#GKZ?6>@?L(
M?MA>*M>;PQX=_9]\=:MKR?$73?A5'I]G+X29+OQ]KOPJU#XZZ!HFE:C-XGBT
MS7+3Q%\&],O?B?X:\4Z/=WO@WQ)X-6/5M \1:FEW9)/DS_L7?M71^!? _P 3
M;?X%^-=:\%_$EOA@G@6_\-2^&/%6L^(F^-VN:KX9^"SP>"?"OB'6O'UG#\6/
M$V@:UX:^'T^K^%-,A\5^(]&U/0-(DN=8LKFSAZ?[;R=N*_M7*TYSA"%LPP4F
MY.$JC2C'$.;E&$7*4;1E!<W,ERR1S?ZOYNTY+*\P:C%SE_LM=-+F44[^SY;2
ME*-FN9-.+CHTSYBZ''?+ 8YY0_..#P5_7C&>R9^4N<[0Q4D@Y#8)P0?FY R,
M#C\17W%\:?V!_BY\$](_9!MM8U/0];^*7[7^J>/?#6A_"W2[WPQ>'P%X\\)?
M'23X"VG@W4_B+X6\:^,_ ?B>]UOQ.UD^H7NDW]A#X*U":_\ "OB:VM_$&A:M
M!;X_Q/\ V3_#WAWXI:E\!O@O\:9?VB_CKX9^)OB?X5^,O 6A_"'5OA_X=N==
M\$V6I/XQ\7?##XG:OX\\2^%?&/PM\,:MH'B;2]:\8_$J+X#ZO9:=I<7BQO!K
M^&9]2OM$SIY_E5>.'E0Q4:E/%T<3B*->$*D\/2PV'K3PL\7BJT(N%'"QQ%&K
M!UZDH0E>/++[3TJ<.9G0=95\-*G+#5J&'G1G5A"O5Q%>G3Q$<-AZ<K.IB%0J
MPFZ:?NNZO)M(^-N0P7C=D#:749+<J,D@$$')*G"]SR,M/3/RG!SRZYP&4< G
M.-WU/\0^49'U3K'[#_[6FA:%XC\3ZU\#O$6F:-X:^(GA7X5W=W=Z]\/Q-K'Q
M*\=^$_"_C[P'X(\ :=%XSEU7XLZ[X\\#>,_#/C/P/;_">P\;V_BWPIK$'B+0
M;N^TNSU*:T\P^,WP*^+/P!\1:?X3^,7@B]\":_J%A?ZEIMI<ZEX;UVSU2STG
MQ1K_ ((UU]/U_P (ZWXD\-W]SX;\;>$O%O@OQ1IMKK,^J^$_&'AK7?"OB2RT
MO7-*O[&#HH9QE.+J4Z6%S+ 8BK5E5]E1HXJE5JUX4XTZSE14)OG]E0JT:U9I
M27LZL7%1V65?),TP<)5L5EN88>G2Y/:U:N%J0I493E.$(U9.+Y55JTJM*GS-
M-R@U)_"Y?V&?\&AH_P"*+_;W/;_A*OV=P?K_ ,(_\5/UQ[8X'?@?V9KT'T'\
MJ_C,_P"#0X_\47^WN,G'_"4_L[\D]3_8'Q5_7GG^7K_9FO0?0?RK^2/$C_DN
M>(G_ -1.'_\ 4'!?U_P#^K?#JW^IF16_Z!JG_J5BQ:_,+XX_\$L_@C\>/VA?
M$7[1OBCQ-X\L?%OB#Q?^R7XL?2-)F\/_ /"/V*?LM?$:Y\>ZGX?L(+[2KBZB
MT?\ :*L[;P;X'^.ZB=;CQ/X.^'?@O28;JVBTHF7]/:.^?_U<9_QY_"OB3[8_
MGT\5?\&_?PE\2>&/&OA%/VGOCUH^B_$?P-;_  Y\=0:3X:^"]O)XDT#P_I^K
MV7@?6[J;_A!$8?$FRGUK4]:^)/Q+8OXK^-/B2[_M[X@W>H7Z><OU9^SC_P $
MF_A!^S%^U3<_M.?#_P ;^(I#M^._]C_#NX\"?"?3M*\,VWQV\<6OBV]\(>'/
M%^A^#]+\<Z1\)_AY8:7I/A_X7_"*SUF'P)X2":WKMKI;ZWXDU2Y?]7Z0@'&>
MW2@#\5O'/_!&GPQ\1/@9X1_9V\1_M1_'23X7_"+P+9?"CX$>'[30OA5IZ?#K
MX5:')X?MO#G@?7;_ $[PC9ZS\4;.T\/>&=$\*:[>>--3N)?%F@Z;"^KPG6KC
M4]6U+GKS_@AE\$]8\:_$WQ?XF^-'Q<\5V_CW0?A[H&@^'?$6B_#+7[7X>I\)
M/A5\1/A/\+?$.B:OK_A;4_$&N_$#X>Z7\1M0U?PY\3?%NI:S\1$UO1]%U;4/
M$VH:T-2U74?W+HQSG_/?_&@%_6M_Z]#\&K[_ ((+?!#6(!8:S\=/C3>:%!H_
MQC\/:7X4MT\+Z=X4\,:+\7[.TMKNR\-Z':VGDXLI#K=SX@'BJ3Q;!X_.O-9>
M*[6\TW0O#5GI'[G:%HNE>'-(TWP_H&DZ=H.@Z%8V.D:'HND6-II>D:3I&FV<
M%EI^F:7I>GQ6]CING6-K#':V=C9PQ6MI#%'%!#'$B1KKT@&/U_7K0 M<_IG_
M "&-?_[A'_I!6\Y*J2H!(YP<].^, \^@[GCO6186L\6I:O<NH$-T=/$#!@2W
MV>T\J4,H^9"LG&&Y/4<4 ;-%%% !7RW^U]^RCX _;+^$MI\'/B3?:[IGAF/X
M@_#WQO=W?AN>SM]3O;/P=XGL=2\1^#IY;ZTO(1X:^*'@IO%/PJ\=0I#Y]YX$
M\;^);"!TENU8?4E&,>O0#J3T^O?U/4]Z /P_\9_\$-/@)XG\/6?A;2_BQ\6/
M"VFP:E\5=1.H6>G?#S7?%6G-XT^('_":?#^U\'>+/$WA?5M:^'VG_##PUI/P
M_P#@E?6/A"XT^W^+GP)^%O@#X9_%-/$.BZ% %X3Q+_P0%^"GBZW\:ZMXA^.O
MQ&UGXE_$/QS\1?'_ (T^(VJ?#'X ZFWBR]^)/@OX1>$-2\*>*?"5_P##F?PY
MXG^''AW4?A./B!X*\":[;:AH?A;X@^*;_P 6Z3'!J^DZ+<VO[]T8Q_G\/Z4
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M97UM#I7C;1['6/ 'BY$A%S<^#O%.OV5K<6\]\)X/J>DP/?OW/?KW_+T' P*
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MLM?!WQ?:^ O'WC?Q98^,=2\&^%?'V@>'M ^"7QZ\<ZAXQ\.>-_$^B^#/"J^
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M!WA3PUXX379/ WB3XD7J_"WP_K^J?$:XLO"]T ?HZ5# @@$'@@C/J/Y$_F:
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MA7M]#_:2_P""@U[=77Q4C_8R\'KXB@TM?!?B&XN/@_\ $[0OB!<:==>&-?\
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M@#_@GI_V$?VE_P#TS? ZOX\?@^"?B[\)3S\GQ/\ A\225Q\_C+1<8..0W4G
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MR]X,U"SL?"W@8Z'H^O>&M)B_:"7QA:>.+Z\^)>DZ[XY,>NZ98ZEX3L_#,5V
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M?3?&%=+^%WP\\+3^)?%G@KQU#X-^'6I?#_XZ?$#X&V,?A?3'UG1YM4T+1]&
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ME,[);R1PDQ5Y+H?_  4B_9L\0Z?\ ?%?A.Y\?>(_AW\?]2\<Z!HOC&Q^&GQ
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M  H ZC_A8EK_ -"_XF_\ =-_^752Q>/4G)6#PSXKF8 L5BTVPD; X)PFL,<
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M7_9O2YTCQAXE\9_$J.W@^,"?MF>-/VR(I_AE:ZC+X/\ $'[,^L:[9W>L:U8
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M"_XF_P# '3?_ )=5RV]/[I_[XHWI_=/_ 'Q0!U/_  L2U_Z%_P 3?^ .F_\
MRZH_X6):_P#0O^)O_ '3?_EU7+;T_NG_ +XHWI_=/_?% '4_\+$M?^A?\3?^
M .F__+JE7XAV320I+H_B"T2:XMK;[3<65BMO%)=W$5K 9GBU.YD2-YYHHRZ0
M2%=X)7 ..5WI_=/_ 'Q5#4F4V\.%/&K>'V^Z0<#Q!I9/Y#)QW]J />(V+ [L
M9!QP?4 \CMC.WKR1G"YVB2HXR#OQTWGCCC(!Z#IGJ/4'/>I* "BBB@ HHHH
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M77A?_GAJ?_A0>(?_ ):5W-% '#?\*Z\+_P#/#4__  H/$/\ \M*/^%=>%_\
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M_%5]X7CU]+&WU80:9JKP07EAJ,%E!%J5D;JU-PL,4L<J7-O Z_ST_P##G_\
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M%C4(K+PO\0_'2V.A7>I>)/BCIO@&Z#M\-+ZX^!L%O=^#/BOHNJW_ (IT35W
M/VX_KTH_SZ?SK\GM)_:H_;WO_C1\)O"VJ?LEV7A_X3>*?C;X[^&?C7Q?JFG>
M/!JVF^&/A[=Z1X4U#XAVO]@+XHL?#?A7QMX@MO%GQ#^%6O>+1::'XK^',OA#
M1]1O="U^]U:[L/UAH **** ,*/\ Y&2\_P"P-IO_ *6:K6[6%'_R,EY_V!M-
M_P#2S5:W: "BBHI WE,%+ E2%*\D,>A'0XR?7L!ZT!_7];_D2 @]/IGW_P F
ME_S_ )_SQWKSJZO_ !['X^T33K/0=&N/A[/X;URZU_Q-/XHGM?$&F>)[:\TE
M?#^E:?X1'AZ>'5M-U2RGUF?4-;D\2:;)H\^G65NNDZHNHM<V7YQ_\%!_$'[<
M7PU\;_#/XI_LH:E\8O&^@Z#X*UR;QM\!/"WA7X6Z_P#"WQ-KNE_%OX*Z5I>M
M>-)[OX)>-?C]>32?#SXA?%36+_P?\*_B3X0U#Q1:?#;28M"DT&]M-=U/5JG!
MPY;RC+FC=\KORM_9V6JZN]E=?+"C7C6=9*G6A[&K.C)U:52DJC@HR=3#NII7
MP[4TH8BF_93E&<(^]2G;]8,GCCKC\/7\OUI:_'2?]HW_ (*,:S<:#XET?X(6
M>BMX0URZOOB/\*'^%_Q DTO7-!N_#_@^8> _"_Q%\3S:#JGC;Q-%=:AJOB'P
MU\4_"VB>&/"^FPRW'A?QG\.M2\2:!JNBV>?K'[1/_!2J;5?"'@>\^"D&D:GJ
MNM_#B?6_&7P^^$OBM["]\-ZSXT\):OXZO['6O&?B'QCX,\"+\./"5U=> _$/
MA_Q?:ZKXF^)4^JZQXR\ S>$1X6NDLI-S]FZ*_GX^)O\ P5(_:>^$6MZ;X8^)
MG@KX(_"GQ;KD?Q7\3>#O#'QCT;QO\+V^(7A+X5>#-;\??$F+3M<\5>.].TWP
MEH?P>L/#C:)KOQM\0+<_#'X@V_B"U\>:,/"7A30;T:G] _&_]K_]L.#P=\!=
M)^%/PE_L_P"*_P"T'\$OB[\6$\"?\*X\9:U\1_ MA!?>%8OA[I>KQ:E-+X0^
M&'CKP'X0\?Z=XC^("_$[3?$OA?6?B9X1O?A-H%A=W?BC1[B@#]8/$.AQZWH^
MKZ1)<7-K'JUA=Z<U]9N(KVS%Y!]G^U64S"01W5H=D]N[JP6XC$A4G-?.\7[.
MNJP:0VC0?'3XUK:I;);6MU/K^EW6H6RQVL=H7MKVYTR6ZMI)(XU-TT$\0N9G
M=\(&VK^8?Q#_ &CO^"JOQ%^)'Q$^'OPO^$_B3X1> _!GQFL/!WA7XCW7P!N)
M_%WQ5\':7XPU:T\1S:5K/C'Q#XH^'?@VVO-&\#RS:5\5-1\):QX2UWPS\3]%
MU73O#V@>(K>#3=%]"TO]J'_@J#XG6*]\._LX?#_2]&L7M87U+QG\(OC)H%_X
MW_M236FO+_2?"=]X^LM?^'UMX"U+33X)O-/\2PZ[/X]%C#\4-%N]#\(>,O"]
M@W30QV-PL)T\-6A3A.4*K4Z-&M^_I-*E42JTJB2C!SC*":C44K34HJQYV,RG
M+LPJ1K8S#*M5IT)X>G/VV*I.-&K4IU:L']7Q5!2YJE*G*,Y1E.DXWIRBV?H-
MI_[.MQ8QV\*?&#XM2P6L^B2VMO<:UI\\-O!H^SSM.87-C.9[+52K+?Q3O*_D
ML(898U1,?2MM$(V=@-HV(FQ5PJJHP@51PNP J%0!0NU0/DW-^.W[4W[;G[9_
MP \+?"GQ)H?[.D.OV5Q\'/%_BWX\>(=1^'/CU_!7P]\3:*NJ:=I&H0:IHOBR
MZN;*SN=8L+._G^'MU!J7B6]T;7]*CTKQ'=R#4+^QX33_ -L/]OSXE:M\0_#'
MAKX4WFFW7PN\06NA>(&\$?"#Q9H6NS'_ (4OX'^(^@7>L:A\3V\9Z!H^K?$Z
M3XE0W<GP9T_29_B=\&;'PUX?NO&^O:@OC6/3DBOB*^*E&6(FJC@Y.-J5"DH.
M5^9QC1I4TG)MWT5E[J]VR6F#R_"8#VGU2E['VUG5_>UZLIN/P\TZU6I)\O2[
M;>[=[M_NB?PY/<X^OXXR<>W;K2 YYX[]#GH?\Y]#Q7XQ?%#]KS_@H=HL7AW2
M/A[^S!J.O>*?$/Q^\5?#_51-\$/B3<>'/AW\,=-E\&::OB/5O%UQXXT/2?&F
MJ>'X/%.J>,]/\;^&=.@^&?Q8TGPKXET#PL^C^)M'LM)\0YVE_M._\%,(U^'7
MA33?V?H=8UWQ<_@[3-:\:^.OA)X]T_1O#]MXO^(,7AGQ'\7M6@T77/#6G^'_
M  [\.M/GL+I?@%?RM\2]2T367\63^.9-"\)^(;^3$[3]KL\XXSWYY''I^(_,
M4N?U_P _Y/T'4BOR,^)_QF_X*-+XS^ .M_#;X>:;9^&[KX6^'O'?QA^&U[\)
M]?UJUO/$]EX,^.EWX\\"MX]77DG\/ZGK&O:3\)-,\ :1!+IVJZ!KNK6^LZ]J
M'CCP\=4\(ZIV7[(7[0/[9_QC^,?C6W^/'P>O_A#\(M(MOB;IW@:'5?A!XN\(
M:WXNN-#\:^$X_!_BO5M<UCQGXCL= DN/"^L:MI,GA4HZ^(-1T?4O$&B7\^E0
MP*X!^H-%1QY"@'.1D<G.,'& 222/0D[F R>34E !1110 4444 %%%% !2'^?
M'O\ YZTM']* &,>@..73'/494@_7/3UQZFO\X;]F7]HG]H_X9?\ !6;]JKX8
M_!Z^L=4\"^+OVE?VDO'_ ,1?!>N?%_1/@!X>A3P*?B?9-\3;[XOZCX7\33^'
M-0^&OAS6];UNPL)-,U?0M=(-EK/AW6;?=;U_H\,!\HZ$,F.YQN''T_EZ=!7^
M:S^RG;?&'4/^"[WQATSX')\(7\9:I\</VR=.U#_A>GAWQAXS^&H\&7</Q&'C
MU=:\!^!/$_A#Q-\0+FX\'IJ=CI?@JPU5H]>OKJ&TOK"ZL$NMGZAX<0I3P?':
MK0HSIPX8]ORXARA152AB*DJ=:4H0J3@Z+E-TZM.+J4JM2#BN255K\Q\1)5(8
MS@QTG64Y<0.E>A&$JKA5P]-3I)5)0IR]LDE[.<HPJJ#4W:$3AO\ @I5\<_ G
MQN_;1_9C'PW_ &X/B/\ MQ>%? FL^%-&3Q+\0_!?AG0;?X7:OK7Q"\,ZEJG@
MSPCXV\*_##X-Z9\6-%OIHDN9?&<?P^T13<Z=:P1B6WN%@A_9O_@[N&-!_P""
M>_/_ #%/VEL9QT_L?X(8Z?CU)XZ\\G\G_P#@J]^S+??LP?MF_LB>%U^&O[(G
MPX\.>)]0AUGPO_PRE\'?&OP'7Q+8:%\=K3PG<ZC\3OAMXW^+7QAN+._B.E6]
MYX$UC1M>M-(U#1-5U33H%N)O#LR0?J__ ,'=X_XD7_!/;K@:E^TN2 .0?['^
M"!(SG/\ @0<<<U]U0EAYY]X2RPCE]7^J\0\CG/!U'*:I8A5&JF"PF#P\TI)V
M4,/3G%*U2=2:DW\+BXUX9+XF0Q5G5]MD3:]GB*34'.FX.5/%XC%5H-QLVWB)
MP;;=.,82B?QL^ ?'&N_#'X@^!?B5X8O+S3?$WPZ\9^$?'WAW4-.?RM0L->\%
M^(-*\2Z1=V$W'E7MOJ&F6\EK)D!)D1B>A']BOQS_ &VOV(/!ND?M%7_P-^+O
MA"U\??LP>!_C-^W7^S;XFT/Q'X5N-;\:_M._\%!OA]^U5X9^)GPT\+:L-6GT
MC7]7^$6L?&?X(>(H= \/Z3!XF\*WWPL>&^N9O,U..'^+]L^:<'JG!/J1'@D'
MIVSG&>1ZTT*WRNBQ@LV$(5%,3=Y4(&Y-Q!?<""25).0K5^E<1<*87B+$86M6
MQ6*PTL+"=%QPVBK4ZF(H5G&HW..T5B\-RM23IYC7YM4G'\[X>XJQ'#]'$4:>
M%P^*AB)TJW[^4HNG.%"M27)RPF]9O#U[O6-7 T>5-\T:G] .K?LT_P#!+:U^
M*/@+PC8:Q\)-+^'^K?&3]H3P!\(_$&B_M3>*=>/QJ_9WT_\ 8.\6^(_@%\;O
MVBM0OOB"]I\"_B=<_MCCP/X>.DQ0? #PQ=F]U#PEXL^$LGA?1K[7-0Z7X/\
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M_L>:'#^TIX8T:W\ ?LW>!?AW^UIXXT/XA?&+0O''Q9^*2:1H&E_%7Q1X*M-
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M=J@$G)/<G&,D]>@ ^@QTH =1110!SZ?\C-?_ /8#T7_TYZU705SZ?\C-?_\
M8#T7_P!.>M5T% !4<N2C<XX.">F??J?IQCN<U)44PS$P]NV>G0].>F?4^Q-'
MS:\TKM>:7=;KOL&G6RCUNKJW6ZNM+>:]5NJ1?.[)90'*D @C.!D8P3@DG(/.
M "1C-9VL0ZK=>&=<@T V\6MW&CZK#HK7UU=6=FFK2V=S'I[7=[I\5Q>VELMX
MT+3W-E#-=V\6Z6WB>9$1K-TCRK-"C21,T<J+(BY>-V1ECD02QO$6C^\NX2+E
M06C<?(>/\&>$-:\-?#FT\'ZG\1?&7BG6;72]7L9/B-XD_P"$7;QG-+>SZA-:
MZO=?V7X9T;PH^H:1%=00V)_X1E+)XM.M#J%K?.;J:ZT<8VG+2,W*"Y=>9PY6
MU.Z235]&F]+JR.93J+$0IO#S<)4:E26)YZ,(0G"K3ITZ"HSJ2Q4_:TY2K*M"
M"PT52E"<G4E21^,7@3]FS]OFTT#1O#?C']M'PCJOQPCF\5SV7PQ\(_M&_&'3
M]$\2?!2'Q;\6YOB)X9M[KQ?<?$3XG0>+]-UWQ1\)OAQ9?'F]OO%OBSX6MX>O
M)- N]"4V7@VX]<T3]ES]M+P]X0_9?\-?"WXQ>"K#P;\.?V1->^%7Q'@@^*/Q
M/^R^)_B5-X;OH-!UGP#J/A&W\.Z"M[>ZR-)L-4^,'C7P9XO\1Z+HWVG7/A_X
M;\&^*[>YN/$?E_P+_P"">/B_X.>.?A?<^&_VPM*U7PYX'UOXPWNB?%<W/PFO
M?C39ZQ\9/C;^T7\0-&\,6?A-_A#/\*/$^L^,[+XU^(SKWC/48+2\LM?L_'>E
M>%_ >L6_B/P[K7PQ\\N/V4OB9\-/^%<?!?P/_P %%;#P@_CK7-2T;X6:;_PT
MQ\>CK/A/Q$/@5X5/BVR\!^"[?Q[J>C>.=!\?^(_V=_VD+>P\&^,;O2_ /[.>
MD^(_$7CCX$:1IGQ/\,0>'SF=)[-=_L??\% ->^-O@[X@ZO\ %7X>77@#X:>$
M9[WP/X'\2?&CX[>-]??XGM^SK\4_A+H_B/6?&+Z5X=T>VU#1-:^(=QIVI^-O
MA[X!^&_BOQ5H5[J'BKQ)?>(O&$=I+8<?\,/V"/V_+#5/#^H_%#XX^ K_ ,1Q
M:CX$\7:_XW@^(OQ:\=:+/K_P_P!:M[CP1I]M\)_B+IFOSW^M^#I%T_6H/BIX
ML^*_BGQEXALO#L'P\UJ>3PUKMQ?Z7Z-XN_9Y_:-UK]GWX^:7J_[8&D:!\<OV
MD/C3X)T/PCK'AO\ :G^/OA_PC\*K73?&,&OZA\%/@KXSM-3^W^%_&>E3KXR=
M+_PU\*[;7/'F@60\"^/-'L/"MKI-UX$D\/\ [*W[4UI>_##5-4_:TT[Q-!)\
M5]#\0-XGE_:?_:EL$^)]I)IOA2>Y^(]GX.TCQW:>!K[5='T_0_$/P_T#]E3P
MT+/]FSQ58>-+WXS^.FU;XB:)I&C@ ]"^%O[.?[?WA[X2?LM>'_&/[2NEZK\1
M/!GQ<U=?VD]2A\1>,[[1/$_P%U+Q9I_CR2V\#ZGXDB\7>-M7^)-EJ7@3PKX+
MT*Y\>^++RTTSX??$SXOZ5)J<T">%-.T_Q?P'^Q'^WM\*)/AKJG@_X^Z3JFL6
MGP4^$7P7\=:+<?&3XC>'_AIX?C\$Z=;^'=9\1_#+X66/P^U#X>:2^@V@DU;0
M=/TOPMX6O=;OEN-'U/5M+L;Q)+'@=9_95_:V\:G3?%-Q^W[H.B^-/!OC;X/>
M.=?MO!'[7_[2%AX+\&_"7PG>:K8QZAJ^FP>((?!OCJR^+M]X/MI?&&@_$#X=
MZ=IFO7M[XGT31?B!ING>'-8A^(W>_!S]CO\ : ^#.@_M":*/VQ/%FK>$M3^!
M7@_X>?#C2H/VF?BW\0M%^%^LQOX?M=$2R\*WG@F]^+/@34/$NEV%\)OC?H7Q
MVU_XA:@/B!K&I?\ "-7&I^%O#'B1 #7_ &=/V7OVV;*P_:7\5_$OX_?";Q'\
M6O%W@?XE_#'X:ZG\.OB-\6/%I^$E_JUQX3UO2O ]QXZ^(]YXV\;Z0-#\2VOB
MS4H=<ENY[SPU+XJT^^T/X>Z/9Z79^$[?S;PG^P+_ ,%&= LO&/AG3/VH[3X>
M_#_Q1HWQHUO0O#O@SXL?%:Z\3^%O'WQ,^-/Q:^,&@VFM?$N^TRWN/%][HNO^
M--!OO%7Q2TGP)X&\=_$"XD\2Z/XQO->\)_V9H,>&O[#G[7_A;X9^ M*^%G[7
MNE^'+K1OC#^TC\2X?#/@/]I;XUS_ &K5OBAH-M/I?P&L_$?B[62/C[)H_BJ?
MQ.9O&OQ:G\)^,CXSOC\9M7N#XT\1>([6WC^%O[)G[56O?![PMXD\3_M0^+_A
MS\4_&/B#Q^MC\"/%?_!07]J#QOI5Y\+KKXQ^)]:\#_ <_&WPO\6=7UT^(+#2
MGT7PKJ'[1'@70=5^.5G::<GA)]=O[%-5T:Z /2?&_P"Q[_P4,M9_!WA+P=^V
M!I\6F>(?BUXVU'7-=\?_ !S_ &@9O'__  K;2OB-\9%^'OA7P#9^&M;\)Z3?
M>(;;]EVZ^#_A_P >7FMV7B2PF^)G@WQ;\2Y_#VK>+]:O/B(8]-_8N_;E@_L*
MWU?X\:&^K^#_  _<GP?87GQ\^(OB#Q'K$X\":UX+U >"?%^M_#C_ (2+X+OI
M/@SQ+IOPJUGQAX9A\6:KXFOKU/CIK:V7Q 2R@NU7]C;]J_4?"OQ%\-0_MGZ]
MXJUOQ=XV\1ZKX,^P_MD_&/P_XI\0MIWPK\2?#?Q-/X9\>:?X!\47_P !=.L/
M'5[I_BN;X5>#? _Q@T[P9?:%=6MUXWU?4;Z.ZTGVSXK_  .^-/Q%\8_L^ZEX
M(_:F\/:#KO@?P-X1^&GQ,\?Z!XTUO2['Q,WA748K;]I'PM!X=T?XAQ^*9?%'
MQ%\ ^))?%O@_4M0\1:U?_"SQ]\-?!7BK6]0=T/\ :P!\EZ-\+?\ @J5!\6;'
MP9=>./C;&F@W7PK^&WC7XQ3_ !#L]<^%?Q \,^-K+P_IOCSXA^#?"-Y'X=MO
M!^J_!?X;Z'\0+^P\7VVFS:Y\0_C$W@"Y\4>%]'OO&>JW%A];_M/?L[_M[>.O
M$'QXG^ _QET3PQ8^.K'PG9_#&[\4_&/XQ>'="\&PZ=_P@)VK\/\ X8Z9X4UK
M2O$?@[4-#^)NLOXHT'XQV>G_ !8L_BI!X?\ BMX-\7:?\/?!JZ!U7P=\ ?&/
MX<_L^?$;X5^+_CUIFN>)OB'J/Q9UCX=^/;GX_?%#XX>/_ :?%KQAHOAOX'6D
M/Q"U/P=X9\5:QX137]2UM;OQ)8:1X8TWX=/_ &)X3T!/$MGI>I>+1\]_"7X,
M?'W7OB'\<X/C3^TYX)N].\=_"+QAX7N+3PE^UY\<?&.E0M\<M U#2_#7AOPS
M\,-:\0Z/X/\  OA#PAXFT3QG<^$?C?X<T_PA^T'KNJ>#]5\.:/+HG@F/4+6^
M /;/V8?V;?VY?A=^TG/\0/C=^TJOQ6^#VL_"WQ?::KX/F\2>--8O+?XIZ[XO
M\/:CI3:;I&K3Z=X%L?#.DZ/I^O7>C7OA?P3X3UO2E\0S^$)[G5_#=EIR6?Z=
MVNL6-]]H-E=VEXMI=W%A=-9W,-T+6^M<?:+*Z,#O]GO+=F"W%K*%N(2R"6-#
M(HK\8/"'[*'[0WA+]FGX_P#P:N?VK4O_ !MX[T#X/>"?ACXCT7]LSX\^&=7T
M/6+>X?5['Q%IOQ%\4:5\3_$?P/U3Q+X=O-,\!:+X(^$WA74-#\>>&? EEXSU
M29O%WQ#\23:)[%\(/AM\1M(^-OPT^,/B']KGP_\ $3X81^%/$":GHVG?$OXN
MP>!/'FK>(;2\\.Z3\0--M9?'^H_"N74_!OB5-4\'Z=X$U.+Q);^+K7QE?^.]
M5U"S\=?";X=1( ?J=')Y@)QC#$#W& 0<]#UYP3@\5)5>W)*$,NT@CY<YQA5X
M)  R!@'H2020#D58H PH_P#D9+S_ + VF_\ I9JM;M84?_(R7G_8&TW_ -+-
M5K=H *CD7<C* #N&.2<=\'J.,]ABI*0G )]*!/U:\T[->:?0K"%@ZMV"D8W-
MC.>"1NVGC_9/3&<';7Y)?MW?"GX[_%7]H#X0Z/X0^/\ \$_A?\%+'X<_$"]^
M)WP[\>_%7QWH'BSXFVL7@WXIV5P\/P[AUH_#6^\*>"_$.J?#+XA3^-]5\'ZY
MXGTF?P+J]K9>(O!]C L>O_KKD$9/3'(ZCG'!_E^-?C[^VE\(/V;/'O[34&O?
M'GXV)X>Q\(OAIX1TKX-:-I_PZL?$GB;5KA/VP?$NDZ_JOCGQMX(UG5=%\-7'
M@C0OC3=1:)X?\:^$?#WB./P%XEL?B+9^(=-D\/Z/=G;1*R2T5M%?_,22N]6[
MW=KJVMNR6BZ=KR[L\"B^#W[35MJ'A[3_ (9_\%!_A#X)\#RZ;JO@BQL_#OQZ
MM;S1]=\+:+X5T;P?\5+;P)X.E\*W.E^#?B-^S/8:MXU^*^G^,M*U77#XP\;Z
MQX*L?BWH>CZ'X<TN\TOT?X*Z!^U1:?#;X^>&_'7[:?P-\=_$/XNWGP[M_AC?
M>'OVA_%-YJ.L>/O"N@Z7X[_:D^%'@[Q$UXEK\%?#WB7PYJ.L>%_AIK'PD^'@
M^(_P-\$^(-!^*WB*+QYXI\-Z->3_  KXA^#_ .P[JOQN^'_AK1/VQ=#T3X26
M6O\ QS\*?$VV^(_A?X;^&?%7B#2?AK\"?']MX<TOX-FV^ $?AY?#_@KPI\5]
M=M[SXKSW/P^\3?&63PY=W/C3Q7^U6'\/6?@GZQ\)_L;_ +#NA^*?A;\3?!O[
M7/QUL-,^-7C/XV>,?A7X4?48O$.@Z_8>(?"_B+POXO\ A5KOA_Q7\-];U+_A
M47@6]U?4K7_A37Q.M;;P<WC4V?AK7?#FH^(Y(-*F"A_B_P#9N^/VL_##5O&/
MPT_;-^%WPVU?XSWFO:U\//BSH/QU>:\\6>/8/V2?$/A'X<:=)\8M*\&:#+\4
M-*T_XZ>"? 'Q!\<:=8:8FG^/O!GP_P!<O]=\,W_FZQH-_J?#;0?B!\5[?PAX
ML^%/[2/P<\1^#OBQX:UC]H[]G73-3^)?B7X=VGB#X1>)=;^(OBGPO=:/^SM>
M_"O0_$WA<Z1<^+],\6W_ .TMX5U+PU\0+^U\5S^%-1A^R^"/">OW/,:=JW_!
M-JX^#G[)?@=_VT?BK\2=$^"NJVU[X8U[Q#I-Y\2_'_Q+T?QU^T)X<TM?"7Q"
MO_%?P?\ $&O^&C%\5=,\*:*E_P"&E\ _%#0_ASX8UFVN=?'P\;QC>W'?V2_\
M$\OA!\7/V+/$^H_MP>*;;_AFKX">!/@'\'?AIJ7BW3$^%7C;P[K/PXD\ ^'?
M&?Q#TS1? -KH^I^)_$7@CQCI^ISZK/?:-HFD65M;:UI=AX=T&+7_ +6 >=6W
MP$_;KTCX2-INN?MV?#:X^.?B6V;P-X&TI/VE?C#I7PWFCFUS7?'>C^'UAU+Q
M1J7Q5\2Z_9:?>Z%9:QXCTSXFP?%_Q#X7T*:TL?B;I'AS4+K29_<?VB?AY\<=
M2^.GAKQYX _:Y^''PXEM_@Q\"9/B7X>N?VF/%G@G3K&+X*^(/BCXH^(_Q3M/
MAY=6_BS1=7\#6EC\4_!>K:Y%KCZ7;^/=(TVQ\-_$7Q%::1/INHNS0/\ @BA^
MS9X7ETLVGQ.^/FH0Z;I/@#PK-%KNI?"KQ!=WO@?X=7NB76F^%;?6-3^%%QK^
M@7.L67@?X2Z+K_CGPKJFC?$C4M-^%'A:6/Q9:ZSJ'B_5O$G?VG_!*#X1):>)
M;S5OB[\8?$7C_P 1:O\ #36U^)FK:'\ 1KVFS_!_PAX@\#_#[3(/#]A\%+/P
M+JOA?3O#>LZ39:]X2\2>%]8\.^-Y?"&B3^+]/UB6YUMM8 /B_P"/WA_XM:U\
M4_'OB[X"?M\_##P+:_M'?$SX8?$O]G_PU\1_VH?CUHFF+X!\7>"?">A^*?%T
M/@/PGKG@N2(:QXO^#VK^#_A9H.J^)-7^$0M;K5#!X>NO$WB<>#]4]Z^#OPB^
M/J_M&?#CXB^*_P!K'X4>.[WX8:Y\2[3XT>#;3X[/XD\5^,? _P 0;OX9QZ'K
MND7NF^#O#>K?!_P;8?%/X5_$+X@0_L[7_P#PF'@8W6IZW\-=-\>6?A#1?#_A
MSP1](:G_ ,$U/@SKEE\*K#7O%7CO6(/A1\(=*^$6F_:M#^#P_MV+0H?&:^&_
M%^H+%\+5AT'Q'H4OC_Q5=Z=8^"8_#'@V"[O],N!X8#Z%I(L?.(O^"2?PATBZ
MN[WP;\9/C3X(O&MM/_L.^T/2/@'>7V@>()=,\$>'O''BK[3KWP1U9_%&H_$#
MPOX!TK0-2TOQR/%/ACPM)?:SXB^'^C>%?$EY#J=H ?''B+]G[XZ>&_$_QB\+
M_ _]O+X>^$?CA\=?B_X\M- \->)OVC?BEXYB\8^$_AOJ7PQDNO!%Y-;:KX>\
M3^#/C7;PZUIND:I_PC?C:V^('A7P7JNG^'?#.H7GA'3+VRL?6?C5\%?VA-2\
M2:AXG^%'[;7P[^&?QR\6^!_@]\*?&^F^,?B%XB\)67Q)N/ 7AKQ=\-_%XE\#
MZ'/X(UJT\4_$']H/7_AUX6\)_%#P%K?A[Q1HFEZKJ&G^ /$&G:EK-KIVM^E?
ML\?\$L+#P#XO\2>+?BSXPM=>O/#?Q9\+ZY\#5\&:3X)M9]"^'_P[\?? ;XA>
M#)?&&L7/PHT3Q+J?CW6-1^ FB>'_ !?K&I^(/&GBNZ\(>(_%FFZA\5/%MYJV
MF:CX>]Q\6_\ !-+X#>,/%OB3Q_JFK^.XO&'B+QSX@\?VWB6UM?AQ)X@\*:OK
M^F_%:R:V\*ZUJ/P[U#5-,TS2+[XNZUXCT>UFNKMK?Q%H/AC59Y+J6PNUO@#\
M]O#_ ,%_VG/'OB[0?%?Q0_;7_94\>^"M'/A[QKX/1_C'KOC-=4O/@K\,?$WP
M^^/7Q$;3?%.I^)?A[IK:9?>*9K3Q9:^ /#'A;POX4^R-K'C :EXONG\0/WFF
M:9^T_P#"+]IW]C3P]K?[1.K_ !&^$GCW6O%GQ9\0^-;K]IZP/A%?!FD_!WQG
MXB^*0U70?%UX-<^+W@O7]7@\$ZWX#T?1K<>&_A#I.EW7B/PU?VNAZIXZMK6+
M6?\ @BM'=^/O"FFM^T1\5_$GP8N-5^(?Q#^)GB7QIXJTZ^_:'NOBEXF^'_QM
M\ >&+WP%XVTOX=VNI^"M.\/M\;[WQ/I.H>$?&W@S3] D\)3>%]2\!^/M/\9Z
M5J?PR^F_&O\ P2J^%WCWP[^SMX2U_P".'[2S>&/V</"/BWPQI'ANR\:>&3HG
MQ&O/&F@>-?#.L^)OBI8ZKX2U6'QIKTFB_$#Q-9J-5>728)+F"\M;"WNQ<W%Z
M ?>^B_'/X/Z]XN\*^ /#WQ*\&>)/%_C;P/??$WPKHOAWQ#I_B&YUSX=V%YH]
MC-XWLY='FOK0>&9KK7=,MM-U>:X@L=9FFF31I+[[%>BV]<KX(^#'[ GPP^!/
MQWU3XZ^#O&'CRXGU$?&J6T^'VJ:;\,%\'Z%J/QX\<>&O&OB^?1=5TCX<Z-\0
MX-$TJ/P;X7\,>#_!DOC:7P7X>T/2GGM_#\NO7UYJLOWO0 4444 %%%% !111
M0 4444 ,?G Y^\AR,#&'7N01SG&.I!.*_P Y7X+?#[]BKQ1^VC_P4,\9_M%?
MM)Z;^S)\8/AO^VQ:^(?AI\0-5^,'B[X.Z[X4^%6E_&'QYXA^-7BCX(W7@R>P
MU+QY\>-4L=#TGX>>&?"]U>SP:-IGC.^\46&C:IJUE9K#_HU/V//WD^GWO3\>
MOL/3-?Y"7[=+L/VVOVOL=?\ AI#XWXX&,GXD^(P"0>K ,0I/S+EMI )!_7?"
M; 3S.KQ)@88W$Y>ZN!RR3Q.$5%UHTZ68UJE6DXXF%6C.E7IITJU*=*2JQE3Y
M[QH3IU_R7Q5Q\,KI<.XZI@\/CHTL;F*^KXEUE3E.>!H*G44J%2G4A5HR49TJ
ML9<T'&:37M&X_H=_P4A^+/P0^/\ ^U=^P]\>?ACK>KR^/?BSX&^'7B#XQ> ]
M3^.7CC]H23X86J?'C6Q\"_#6O>._B%XN\<Z_H/Q.O/A)/I&H?%3X<PZU;Z+X
M6\1+:ZE::)I][XNU/4-1_9K_ (.\,G0/^">QQR=3_:7[GK_8WP/QT/JQY/?'
MH*_CP^#ZJ/BY\)<+MW?%#P 3@#.1XST?+9Y.27+,22&8AR"PR/[$/^#O+_D
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M -.>M5T%<^G_ ",U_P#]@/1?_3GK5=!0 4A /7_/^?Y\]0*6HW?:K'YAMZG
M]>O/88(SCH?6CT5WT7=] ]-7T2W;Z+[[#BH((&><]^I)Y![>W/0<5R/CS3=+
MU3P'XUTG6+RXTK1M2\)>(]/U74+.)KJZT_3+S1KVWOKVUMEAN3/<6EK++/#
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M5\,O$]QXC\ V'@>X\"^%_$?P<\0_##X;_$$^.GU#6]'\/ZGX:\0_?OBO2?\
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MA7&E>,?!7C_0UL;+2/B9IC>'M O[*[\)GX?^(_[3TZR^F_@S_P $U?A=\$O
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M_P .R6NCZ#:^%)-9\1WD%SXN\&ZM=66@66IWEGX0\8^%?'ES$G@?Q-H/B"\
M/G'2/^"1WP]L-6AUFX^+_BI;I]7\->+=1B\-> OA?X,MG\6:)XT^'GBK4-/T
M0:#X9BE\-?"+4;;X:Z/9:=\$]+E7P5X=U_5_%/CJPCE\3ZV]S!.O_!'G]F\^
M))=7EEMY-%75?"^N6'A4?#;X70:9I>J>%==\=ZQI_P!AFM_"L4Z:8EM\0=>T
MRUTM@8--%_K-[8-#=>(=7:X^E/$/_!0[]CWPI?WVE:Y\;-+MM1T[Q0_A*XM;
M3PE\0M5DN-0%S?:9#J&E#2O"-\-7\)7^O:5J_A71O'NE&_\  VM^--%U_P %
M:3XBO_%FA:KH]KF/_P %)_V*8I_$D,WQ\T*$>$8M8E\03R^%O'T5C9-HOVB-
M[&+4I?"2:??ZOJVI:?K/AWPQHVFW5[JOC/Q9X=\4>#/!UIK7BWPKXBTK30#Y
M,B_X(K?!,:KXGOKOXL?%35;77?$NE^+]-M-=U.[\1P^&==T;]F+]HK]FG1)?
M#VA^)=7UKX?^%[3PA:_M#ZC\0_A]'X%\">#;WPGXL\#^#HQJ.J:=:2POZ[X_
M_P""6GPF^(_PZ^'/PQUWQOXBM_#/PRTKXG:3H6GZ7X7\!VFENGQ \#?M&^"=
M'OFT(^'Y=(L]3^';?M#W'BOPC>Z?:VLUOXO^'O@[7)#]H74/M77>/O\ @J5^
MQ?X&^'/Q'^(]O\6_^$\M/AMX=D\07/ASX>^%?$>M>)/%T@^'_CKXFVN@?#\Z
MCIVC^'/$VKW7A3X:^-KJ_N_[?LO#/@J7P_JI^(WB'P?::9J-U:_HD.@!() &
M<>O?]: *>G69L+&ULC,]Q]EMK>V^T2G,TXM[>*#SIB  9I?+WR$9!8DC .!=
MHHH PH_^1DO/^P-IO_I9JM;M84?_ ",EY_V!M-_]+-5K=H *BE8)$[$\*I)Y
M.>_IS^7OZ5+36&Y6'4,"",GD'@CVR"1D8/O1U^:_,/6]NMG9VZV=GKVT=G9V
M=K/B;GQYX/LO&6C_  \O/$VBVOCGQ!H>L>)=!\(3ZA;1>(=7\.^'KG3+#7=:
MT_36D%U=Z;I%]K6DVFHWL4;PV<^IV"S.&G0-\"_M5Z_^Q)IGQ[\(7_[2_@?Q
M%??$"V^$NH_#WP=XUT_3OB?XCTD>!OC+K/B3Q3XW\.7>@?#74+QM.M=(T?\
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MGA/X"^&OBEX^^"\7@KXD^*)_$?C;P/\ L_V_B?\ 9B\.:;?> K[X6>!]*N?
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MBS2I/@=H<_B;]IG3O%5MJ-OH6KZO\*-8UUI='RM7_:,_9-\#?#O_ (2G3/V
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M%_C6;1;K1?&>BWNM?#_XMZ<]UXM^'6G7B>&K#P5JVGV^C?\ ".^N_!3]C?\
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M^(OA%[+X]W?PD^('P\\/VNAZT;S4?! ]+^+'QL_X**_!OX<'QE\9_"=IX3\
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M+_$OC_59+GXC?#6Z?I?"'QY_X*)?'?X#?M8Z5J7P^M_@C\63HGPH7X'S:?\
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MI(#&@#\1/A%^UI_P4=^(=CH</Q&^ J:#-J.IQ-IT/AS]EK]IGX<3^.O"MO\
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M]/N\_IQ7H+Q&XYW?$6.3?GA__F(XGX><&?\ 1/X)^D:VE]6M<<MOZL?R%_\
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MP>'BX4:,&^2*D^=V4G*7Q-K63=A:***Y3L"D(!ZC/U_'\CR>1S2T4 )@>@Z
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MK5Y9_ V\GDT)O&_Q,T:SMYF_=*HI(A(NUF(XP2I*G'4C*D$9(4Y!!&/E(."
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ IX# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^5^BBBO\
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MTPHWP1PI_P!$]E?_ (21_P#FA'^+91_3D^PY.3[<=?PZD44A(0AS@Y!X&<@
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MO+\NRO,\3.A'#YM*K##1C.HJT)T.7VBQ-.K1HNC&/-K/WXZ7CS)Q;I%E R2
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MR\3\4_#G_!-'P'XB_P""<EU^PU\1]"D\9^-/VR_V9)=;@^$GQ3\0>-Y_B?\
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M]_MJS^+;I%O7IO%Z72OI?9WT/X'A&47?;1KJGJK:6UO]VE[Z'[V_\&U# _\
M!67X7QHS$_\ "H?C:VWDHH_X12$$@=EY4 D@9.,Y-=1^TU_P5)^(/[&?[3__
M  47^&/[(OP3^''P*^(7Q=^._P 4/"_Q<_:%N]5\=?$#XN^(;+3O$^OI;3^&
MT\4ZQ'X8^'H!U;4;^QM](T*\MK*:]BN[7;=VEE>0?E3^RW^WE^U1^Q6OBH_L
MR?$Z'X8S^-9]/N/$>HV_A+P7K^KW+Z7:W%G:1VNJ^(]"U34-,MO(N9OM%IIU
MQ:V]VQB>Y29HXRO#?M*_M5?'7]KOQ[;_ !,_:#\:6GCSQS!H<7AT^(!X=\+>
M&KNXTJ&\NKV-;Z/PKI&C6NIWWVF[N&;5-0@N;]T986N&CBB6/X6MPS6S#BO&
MYGFF&P&)RC$Y;A<'&C*KBYS=; XF>-H5<3@^6G3Q,)U9JDXU*M6-%TX5E0J/
ME2_0,+Q-1RWA/#9;E>,QV&SBGF%;%U)QPU*,%1Q%'ZM5I4<8_:3I2]G%3YH4
MHSJ*;I.<8W;_ *2X/B;XZ\:?\&N6L^//%/B6[\0>,?!/[1V@^%?#/BV[LM,.
MN:3X?\"_&3PS:^$;+^T+>PB:ZCT*)(H8+R^-S<21J/M=U<DMO]T_:Z_:W_:G
M^&W_  0C_P"":G[3_P ,/&5\GQ]U[XL^$+;Q/\3K;P#X1\0^(-2230OB]:6%
MI>SS^%[VVT]/$6H:1H/AV[GL(--NM=MKC^P9+B1-5FM[C^=+1_\ @J3^WA)\
M$;+]D^'X]Z=HG[/^H>$(/A3<^#[[X=_#^/PO8^#+VT319IM7O+/P;J&N/)9V
M4GVR]\1VL=[XD\VW&H6KS:@D9;]P_'7_  4;^&OP4_X)-?LI?LS?LC_\% _@
MEH7[4/[,[6VJ^.[:/P#\3]?\'?$OP[I>G>.[M_!/@6[\=? ZYTC4O$C:]K'A
M6_T*Y\3:3X;L8[_2IKC^W;!H[>:Y^,S+AO'8'$Y>JN6Y?C5C..\;FU##4Z>/
MKX*EEF/RW$4)8;'2PV%J5:6'AB50C**C)1DTW!04Y1^ZROB#+\QP^+J4,QQ>
M%EA.#\#EF)K3E@J&*GC\'CJ.(=?!QK8FG[>LZ/M79*+E!R2DYV1^JWQB^!7[
M'/Q;_P""L/\ P3"U_P#:$\'_  QT[]H/QW^RAXW^(GQ'^%M]8Z#I^C^)OBCX
M?TSP-JGPWD\7>'98EMM>UO3=;U/XH)X8L-9BN+K5$\+Q0+'?6^B)!%^7_P"T
MK^T/XB\.Z+_P5=_8M^,W[&W[:?[1%SXW\4_M!?%GPIX_^-*^ =-^%?[,&A^&
M],\31^"?B/\ !WQ'>VBV7AKX2Z3!9Z%K_@NST;6-/NK^RM8?#>D6%QK&K:G;
MWO\ +_\ $G]I3X[?%WXW3?M(?$;XH>+_ !)\;[C6]'\1Q_$6YO\ [%X@TS6/
M#SP2:#)I,U@MK;Z1;:*UO$FGV&FP6UE @>,0,KN9/HWX_P#_  5)_;Z_:D\
M:1\+_CS^TGXL\?> =)U[1/$O_",W=EX9TO3]4U?PY+Y^BW'B+^Q-%TZX\0QV
M=P%N6M-9GO+.YN?WUQ:R.%->AA_#_-,-4RA5L9',*6%P6#HXBGBL5CL/_9V*
MPF;5LU4LNE@^:K7PC6*^J?5:N)RZK4AAHO$5JN&C'"S\ZMX@Y+B*.:1C@:F
MJ5\1B9T9X?!X3$2Q]+$X&.!G]?C5E"E0Q494OK#KJEC(1G-JA&%;]^?T'?\
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MX>\*>./!6HZY9Q6\%MK8\->-M$U[2K75X;>U@@.H6D$$\R1I]H:1E5CYV7\
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MP\&^$OA#%\1]-_9-\1?%S_A5.FKH$O@JR_:&C^)]KI4GB-?"<:2:1IGQ!M/
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MU"2VTKP9;01Z?HSZC)91Z;9IX>-II4XDU2\>\O+"""YO7DC:ZDE%O;K'XO\
M!+_@IC^W3^SGIGQ7T?X-?M&^,O!>G_&[Q=X@^('Q*CMH_#^H2:[X[\5PFW\2
M>+HIM5TB\DTC7]701M=ZAHIL&EFB@GVK-;Q/54>"<^C5Q&-5/A[#XF6><.YQ
M0PU+ZY##0>49?5P.+P_-3P3E&CBH-2;2FY5)M.%E&02XYX?Y:.$<\\JX=91G
MN5UL54IT)XFV98V&+PU90G5M*I2Y>2S:2C&,6Y*\5_2=_P %L/!S>./V:_\
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M7_L==_\ FGOQ:[]_^2U8SD9SCZY%+_Q%9_\ !1\<#X8?L=#_ +I[\6CTP/\
MHM8ST]<=Z)>%/']1<M2& G&\I6GQ$ZJ3J-NI+DG2<7*;<G+2+FY/F<KMLI^)
M'AY1DYT54I3:IQ<J60>RDXT7%T8N5/#TY.-)PINE%MQI.$'3C!PCR_Z%6T\$
M;AC..4[G)/W3R3R>U+A^F6QTZIT[#[G0#CZ5_GI_\167_!1[_HF'['/_ (;K
MXL__ #[:/^(K+_@H]_T3#]CG_P -U\6?_GVUC_Q!_C7;ZME?_ASPW_RDZ_\
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MO@__ ,^N'_EEE7?_ ,$_\.?97_$*O_P33_Z'7]K+_P .SX(_^=-1_P 0J_\
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M]K/TQ_PMKP/_ /.FQ^O>C_B%8_X)J<?\5I^UF.__ "5KP/P?7_DDW\J^-?\
MB+J^'W_1D'C3_P /%X?_ /F1H_XBZOA]_P!&0>-/_#Q>'_\ YD:/[(\:_P#H
M+SK_ ,.67?\ R8?VKX/_ //K(/\ PV5?_E/]?>?91_X-6/\ @FI_T.G[69XQ
M_P E9\#]/3_DDP^M'_$*Q_P34_Z'7]K/CI_Q=KP/^G_%IO\ "OC7_B+J^'W_
M $9!XT_\/%X?_P#F1H_XBZOA]_T9!XT_\/%X?_\ F1H_LCQK_P"@O.O_  Y9
M=_\ )A_:G@__ ,^L@_\ #95_^4GV4?\ @U8_X)J?]#I^UF?^ZM>!_P O^23?
MCZ>]'_$*O_P33_Z'3]K+_P .SX'_ /G3?_7KXU_XBZOA]_T9!XT_\/%X?_\
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M,FY14DV/,?"17:H9&N67+)QRG$R4)^\E"<H4$DY-.T)-7M:UUI]>+_P:L_\
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MUFO@_;^%D'I_9E73_P HZGV5_P 0J_\ P33_ .AU_:S'7_FK7@?_ .=-W_\
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M_P 1=7P^_P"C(/&G_AXO#_\ \R-'_$75\/O^C(/&G_AXO#__ ,R-']D>-?\
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MO#__ ,R-']D>-?\ T&9UO?\ Y&67;_\ @8?VIX/_ //K(/\ PV5?_E)]E?\
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M $%YU_X<LN_^3#^U/!__ )]9!_X;*O\ \I/LG_B%7_X)I_\ 0Y_M9_\ AVO
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M/&?[69/7_DK'@C_YTM.'_!JK_P $U1_S./[6?X_%?P2?_>35_2NC[CD CDY
M.>I(!/KQ@XS\ISQ4U?-1XWXSE%27$^:V>J_?QV>W_,/NUK^5SZ+_ %-X3=T^
M'<GNFT[8*ENM^OF@JN^3)@'T(^N1_,<?GZU8JNW^M)ST"CL.>H_'VYST^OS,
MG9>;V^Z3?X7OY'T<MO*^OSLE^+5O,_@__P"#MM /VG?V1\97_BPGC5>"1\I^
M(0)'7OM&2.< #..*_DN*CC&?^^B?48X(YZ=O_K?UH_\ !VXX3]I[]D?/_1!/
M&CYSQC_A8:KZ'G+C'4<'/;/\EN]/[R\9[]??]?Q_.O['\-(_\81D%E*WU;$6
M45*U_K^.NDE9+I?Y:]OY!\2>9\:9VTI/]]A];/K@L':[2=]+[^??5<#W_,_X
MT8]S_P!]-_C3?,3^\*/,3^\*^ZY?*?\ Y4/@[5?[WX?Y#L>Y_P"^F_QHP/?\
MS_C3?,3^\*/,3^\*?+Y3_P#*@6J_WOP_R'8'O^9_QHX!!.<;AN&XY*YP=HY&
M1G).#\H/0@&F^8G]X4;X\KE@5RP<#&=I SC((^F<@G^Z?F!RNZTEJTGK42LV
MEJ];)7NW;9/YW!3YES<UM;I=='IHNO3SL?;EM_P3W_:=U/X4:#\7_#GASP9X
MSTWQ+\*_"WQNTCX<^"O'VC^)_CC=_"OQEXU'PZ\/^,X?A!I/G^,;C3+CQI+!
MH4T=C:7EXEY/"JV[@@UX'XA_9[_: \(Z-XG\2>+O@'\</"_AKP5JJ:%XS\0^
M(OA3X_T31O"&MM8VNIIH_BG6-4\/V^FZ!J\FEWMCJ TO5+JSN_LEW!=/&EO=
M02R_:?AC_@J'\9O"6J_L3V>A7'BG2OA5^R%X4^"N@:M\']+^(%[IOA+XU:K\
M&_B9KOQ+M/$'B,VNBPRZ.VK7VJZ?;?V9-'X@M+";1;*^C\ZX"&'TSX?_ /!7
M[XA> /AWJ^B#X;+XN^)4_P -_P!H'X.Z/XS\6?%7Q?J/@&?P%^T)\0+GXC:]
MJ7Q!^#TEA)I/Q$^)OAO5;VXTG0?'FIZ]9--H,.EZ?J6E74>E6I'Q<,3QO04I
M3RW+<:JE>I6A"->K1G1HO$8BE3HU+<T;^QI4*LI+VWNUX/V$VI<GW\\#P-7L
MJ>9YC@?9T*=.;E1=>->LL/AZE2K#FH\T5[:I6I15HN;HRCI:$CX:\5_L;_M-
M>!/A5X0^-'C/X*_$7P]X%\<7OB*#0Y-0\*^);'7X],\-#PN;OQ;JWAJ\TF+5
MM&\#ZA)XT\-6F@>,+]$T'7[[4[:STN]N9YH8W/AU^QI^U5\5?&GAWX?>#_V>
M/C')XB\5_$=OA!ID^O?#_P 7>&O#-E\3$2:6]\&^(?$^N:18Z+X>US1[:UNK
MW6-,U34+;4-+M;:YDNK96C=!^F_B_P#X+-^&O'NF>*/#OBS]EO6M8\+_ !)O
M_C%XB^*&E77[2GBFYO+_ ,2_%_QM\*/B->1_#O5+_P !7H^&W@?P_P"*/A/I
M\&C>"K:SURVM-!U:ZLH;^*[@BO9:WC#_ (+6:GXN^,7@+XZ2_ 75M*\:?#;X
MU:]\0M T71/VB?'NA_#?5/ _B/XUZY\;]1\,>+OA]H^@V&A>+/'HU?Q'J/AZ
MV^)6MB[CCT>#3+J7PK-JNGVEU!RK,N.G"I!\-X6%:?UB4<0\5[2%.+A46$BJ
M:QB]K4A6]ZM+DASTW"])75.GK+*>!56IU%Q#C)T8JA[6@J$H3J3C*FZG+)X)
MJ,*D>:+M)*+4K2=KGXH>(= UGPIK^N^%O$6F7VB>(O#6IW^@Z]HVHV]S97VE
MZQI-[)I^I65Y:WD<-U!/:W<$L<L5Q''*A4!HT8[!C*/E7[W0=2P_J._7M73>
M-==TKQ)XS\8^)-'L]4TO2O$?B37=<T[3->UT^*-:T^UU?4KC4HK+5?$AL-*;
M7;^W\\PW.KMIUD]_(IN&M8"Y1>9WIUWKUQU.?KC'3\Z^WHJM*E2E6BXUI4X.
MLDIJ,:KC3<HQ2NE%2YTE=I6:N]W\'BU%5ZT</S.C&K-49<KO*DI553<GRJ\G
M#D;T3U6W1V![_F?\:,#W_,_XTWS$_O"CS$_O"MN7RG_Y4.6U7^]_7R'8'O\
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MX_Z&]+_PV9?_ /*@_P"(:\%?]"2E_P"%.,_^:3\!_P#B$4^+G_1[WPZ.<?\
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M-CT[0?'&J7NL_$+5;Z33M%.G7&H6,4>2\1N+%HL9@4FTY?\ ")DMY-)*+O\
MV<W=*,5VM%+32VSX!X9EO@\39KE:6:9HTU=NWO8V3^*4I;M7E>U[M_BE%_P:
MT_M50)J,-I_P4NFMH=7O-%U+6(8/"/Q+@BU;4?#:V4?AS4=3CB^)R)?W_A^/
M3=.CT.]NA+=:/'86":?-;BRM?+Y_4_\ @TY^/NOQVD&N?M_^&M=BTV34YK*'
M6_A=XRU:.QGUR^EU36)[./4/B#.EI+J^IRS:EJCVZQM?W\KW=V9IV,C?U _L
ME_M&?%WXHZGX)T+XR:'\.HM0^)W[-GP[_::\'ZO\-$\1Z9I^E:)XTDLK'5O
M7B'1/%.H:SJ$VJ^';[4+&:P\66>HVMAXBM+VX@FT#1[K21)?_?=:+Q+XQC)S
MAF.$A-_:ADV40:?5IT\#3E%M73<91NFT[K04_#[A.I#V=3+JU6G9+DJ9CF,X
M.VUXRQ;32LG%6M%ZI(_AL_XA$_BX#N_X;=^'7&?^:*^(!CKCG_A.N ,\_CTK
MT[Q3_P &K?Q2\2_"_P"#7P^A_;+\ VMQ\+!\3#=:H_P>U^2+5_\ A8/BBQ\0
MPBVMAXT5[0:='9FVE$LDQN)'$BB-/E/]H4F-CYZ;3GKZ>V?Q[8Z\5^9?[3_[
M9OB?X,_M3_"?]GO2+[PSX>TWXA_#B#QK!X@U7X)?&_XV7VHZY<?$BQ\"IX=\
MKX0SVEAX&TD6EZ+YO%/C&Y&G1W+KE#!9W0HEXF\;2E2F\VHN5*?/"^69>[2Y
M7&ZM25G9O4RCX;\&1C.,<FII5(<DU]9QGO1OS6?^T/2Z3\[+L?S0C_@T4^+>
M,?\ #;WP[.6/_-%?$.<G) _Y'KH!GV//3FC_ (A$OBY_T>[\.N.O_%E/$'_S
M=U_0!XH_X*VZ#I_B#P0_A_\ 9\^+>I>#]3L_B)XR\4S:E#X2MO%!^$?@CPE\
M7M8;XH^#M/MO%TMA<:5'K'P-^(>GZAH^O7NF^(;FQLM(N-(TRZD\1:>I]?U;
M_@II\,[+XL:G\#](^%GQ1\7?%+^W_!^D>#_"?A;4?ACJ]WXMM_&ND?$#6=&U
MB\>W\>F+P+:/I7PWUG4YM/\ '1T/74TG4=#U-=)*WEQ'96O%'C=:+-Z*71++
M,N_^4D_\0UX+_P"A)2_\*<;_ /-!_,__ ,0B7Q<_Z/=^'7_AE/$'IG_H>_3G
MZ4O_ !")?%S_ */=^'7X?!3Q ?\ W>Z_I$G_ ."JOP;3P)+\48/AO\4!\.G\
M1^"_AU9>,]5N?AYX:\/W'QJ\;:?X5U2U^$E_>Z_XXL$T/5M%T_Q=:SZYXJU3
M[/X)M9=+UFT@\07%W;06]QL?![_@HWX8_:)^+WP>\'_"'X>>*[OX6_$NR^)L
M5_\ %GQ.FFZ9ID7BOX>_#SP3\0;WP9HFFV.M7^JW&I:=%XYTRQUC4]1TV+0;
MR2SU6/PYJFI&QEED?_$4>./^AO2_\-F7_P#RH/\ B&O!?_0DI?\ A3C?_F@_
MFB_XA$OBWQ_QF]\.N>G_ !93Q!_\W?\ ^JC_ (A$OBY_T>]\.>, _P#%E/$'
M!/0?\CWW[>M?T._!K_@K#X#\7?#KP#KWQ;^%?Q$^&/C?Q9X'\-^+O[$2TT2_
MT/57\7CPQ#X4M_#5_P#\)#)J('BIO$%[-HEGKMIINHQ6GAS6I-7M[1ULA<U9
M/^"KV@V7CS2[;7?@!\5]!^%_C+X:^&_B#\._$^IP^%8/$7BKPYJ*?&?Q/K/C
MZ33(?%TMMH_@+2?AI\&-8\510ZDUMXSO;F^TO2XM!:YU.WCC/^(H\<?]#>E_
MX;,O_P#E0?\ $->"_P#H24O_  IQO_S2?SV?\0B?Q;_Z/>^'/3/_ "13Q!T/
M0_\ (]]#1_Q")?%SI_PV[\.O7_DBGB#IZ_\ (]U_0[)_P5=\$Z7\78/ WCGX
M5^//AWX>TSP#KVO^,T\2V^BS>-?!_B.+PSH?Q(\#+?VNBZ_J/AR7POXZ^&FK
MPW&F7EMJD^JVOC34+#PG?V%E=Q7[P]'\0_\ @J?\+OA+?^(-.^)OPH^)?@V^
MT;_A"181ZMX@^$\=KK4GC;P)XH^*":7%J7_"P/L&D>*=(^'WA*^\0WWA+6KN
MRUJZ74?#FGZ5:WU[KMFCG_$4>./^AO2_\-F7_P#RH/\ B&O!?_0DI?\ A3C?
M_F@_G _XA$OBY_T>[\.O_#*>(/\ YNZ3_B$2^+G_ $>[\.O0?\64\0<]^/\
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M%K@TKP]8V^MZ@L?F2(.F\8_\%B?@!\-TO(?B7\-_BYX%UW1M27_A(?"FM_\
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M> M$\3V.CZSXQ\/^*=>U+Q'J6JR:C)X/\(Z'KFLZ'I%A+/J*B2XLOM>5<_\
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MXAKP5_T)*?\ X4XS_P":#^&K_B$1^+G_ $>[\.O_  RGB#_YNZ/^(1'XN?\
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MG1^(M2MH9-,T.>[T+7]-U?28-1N[::]TV\-U8I+ D[( ?-?C+_@GG^QKX_\
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MBD\3U7_@B9JFM3P:[=?MC_$+1_%/PR\3>/O'_P"SG=>$/"*>'?#G@[XC>/\
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M)OAK1OBUX;\-ZQ^S1\)K;X17WCR\^'&HZ_KOB'1U\.6/AS5DT30=0\;R^$M
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M+ -6S=>.;SPIJZ-+#X-DM?$'[3O::HP;;KJ#?]JVD:7 <"8QF''[[GR<;<C
M<-AL=Y/L>JB1G&LQ$9F=5&G0,5#QQ>21F<@>44=U9AF02;6Q\A(!^+^G_P#!
M'R"QNK#5;3XP>%-,UT^(?"7B76)M$^#:V%B&\.^.#XWB\(Z"%\;F\TSP1H[&
M/PSX*T>ZO;\>&?#VGZ3;!IVM$4^T_LV?\$S/"?[./Q(^'WQ$\.>*?"'G^#[;
MP[8ZW;:'\*['PU=^*K/2/V:-#^!&OV5UJ4/B"\FBMO%OBK1X?BIJ<+V]W!=:
ML8K6\74-2A373^FT>G:L -VMQLNZ(N/[+@ D41&.=21,0HGEVS@#)1P4 *_,
M#['JHVE];C;88O,QI<"YV>:LP;;."HF)&#RRA"!EB* /Q 7_ ((QV2>'H/ D
M7Q1^&T7A6./3KB\O[?X%>1XSD$.@VWA?5/AO%JEMX]ATN/X(^(+."7Q=J/@)
MM+WR_$.^O]=N-0N$O&A3JO\ ASGX0L(?&%SX8\>> ?"WB?7O&'QM\:>'_%FD
M?!#28M8\'ZO\3?CG\)/C!X,O+&2'Q5#)<7'PNT_X:7O@_1GCDLDN(/%%U/91
M:+:)>Z;J?[*)8ZM\H.MB3:;<R8TR$!RDCF=B1/\ +YRLJMM!V  KEBP##9:L
ML:J-<0-Y31ESI<)^>2=720CS^NQ6BV@;226W!N* /PI\'?\ !%SQ#X?UJ\\1
MZQ\?_!$FJZUXJT[Q%JFH^&_@K<Z!>Z'+'J7P'U;7]8^'\R?$%]/\$^)?$5]\
M"--<?V#IFG>&-&M_$EY:V'A\VNE6JWG?Z+_P2&MH(+RZ\1?$GX;'6;7X:2^
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M7RT\IHYH5(G.4E?#E\[E)(&<[J /PQ7_ ((T>(IK#PO9/\>_!6D/I/@/XH>
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M$^(UEX^^'NF:YKWQ4^&D/Q"\=>'DOO"7B^V\%^(-7T2=#JVCI<:HNC<M;_\
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MXS>&=6\'_$#6+'4_A9\5?".HZ_IDOA/2I=+TBTNS?W2V+/-J^GW,=>D>'_\
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MWAM?V KGTU.[&-NBZ@0[*5/GZ=C+QB1L$7F&*L#&Y&[,C';N0DU(-1U E/\
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MN(Q+$[.SXO2=L#H(IBN6WR+Y.8P[4&^O2@_XD&I%L1'B730PWL5(8F] 8P@
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MX!\)W6I>#/BGKW@[Q!#:?#'XKZ[\9/"VHVFH^%9=#6#6H?'?B34Y]4U$6O\
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M:JTU_P#$;09D\.^*);S0[:"TB /2OC]_P4!^'_P*_:O_ &5OV8]1TB/5[O\
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MP9)OB'%J>@^,GLKFX33OB'=K\.-=G\*Z$CZEI^K6_P!A>6^@76M(:]]!N/\
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M)WA7PQXKU"WL;VXU=#\2M,^%>OZSH%O9:9>0VUQ$UAK%UIBR6$M][?\ $/\
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M^//"WQ L/!?B[Q;XET4>)O#'B;Q/KGB*77=!^)=EHNO>,;3QEXQUWP1%XO\
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MYHQ*",?A]IW_  2O_:%T?2_"5TTWP"\1Z_X(_:"M=3M4\5>"KK4;3XJ_#O\
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M^/OBMXI^(.IQ?%+X>GPMJGB'XM^+/A_HOB#P5XU?5]%\2?&GQI\,_&?B"_\
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MOCC\2?$'@^SU[2WU_P 7ZW\-])F\:0V7PSUW6-3^);:;X%^'*^'/&UMX'L?
MNE>'_B#''<^&]4T[Q?I.E:U;ZS'IMUKT-SH^O:7^UJD!1DCIZ]^I SZ>G7%
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M9^5VGFKUO:0VJHEO%%!$@(6**-(D3<=SA5C55 9\N>Y8DDDU9R/4<=>>E+0
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M&$P4G2V8J9%01%A_: W^4ZL[9(,P;:^W8IIOV+6\DC4K-0P?"MIC.%S%MBW
MW_+1R[I6<$F4,(F"JNX[U% & MEK:E2=3LW(\@L/[**A]F?.P?M_R^:<;#U@
MQM3<IS2I9:V&1GU.Q8J(0Q&E%2Q25GG*_P"G?()DV(F#^[*LW._Y=ZB@##%G
MK8 ']IV).(LXTLC++*[S#_C^X$J,D28'[MD,F"S<(]GK97 U.R4^5,I(THG+
MM*&@)4W^/W48\MD4A7(#$C@5NT4 8'V+6MTFW4K-0S3M&?[+)*ATVP!O]/\
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MJ106M^]S;6UA;_$K1M%OK")+_6)+FWO=0L=/N]*M;NZMM+]GO_@IK^SU\?\
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M2\O3;1Z;IFIWMH ?H(NH7C8)T/54+F,G+Z:6C\U'9P674&_X]V58WV%AF0&
M3(&=%74;U@ VB:HNXQ'+2:<3'YJN7R5U!O\ 48"2!=V6D41&5 [)\/\ @?\
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M$>)],\'7FE67]G:-=_;;[6-;UK27\,VMH);CQ+I%W_;&BQW=C%-+%XK\,_\
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M.^UN>>STBRNVLK6[U:>VAEU:>VTZVE*37DUM;075]-#;K))#;6\US(BQHY4
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MC$ W#><VTEMX.<+G'@7Q/_:2_95^"?Q'^&7PC^+GQ=^$GPW^)WQJOGTGX5^
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M;X2\8^#/$?Q&O[*W\46ESXO\0?$GXE6'B"YTCQA=^,)O$/A*T&B>-K"W\/>
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MC\=:W??&GXRZYXVU:'P%;PV?@J*Q^(.L^/;[QKH$/AFTMXK72K?PYKVE6]O
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M[R+Y2ZQ*)!,,9G+(Q"[-K 'X?^&/^"47Q*L]=?Q9K?Q&\-VUW8^!O#^@^!]
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M.+PG$;#R7XSYA&T,F6 !M45B?VQ<9&=#U=05@8L4LL+YI =3B]SN@!S+@$$
M^67/%(=9GXQHFK'(!)VV6!F<18.+TG(0BXZ?ZG_IIB,@&Y16*=7N "?[$U<_
M*QQLLLY63RPHS>CEU_>KVV'#;7R@4ZM.-W_$EU7Y1.1A;,A_)("!3]LY-P,M
M%G V@^84/% &S1UK$.L3@D?V+JQP2,A+,YQ 9N!]LSRP,'_73D_NSO!_;$_
M_L75<G;D;;/C=")3_P OF3M9A"V!_K2",Q_/0!MT5C+JUPV,Z)JRY,0.Y;/"
M^9&78G%X3B(CRY, _.1LW)\],76+AD5_["U=2P!*,EEO7,OEX8+>L,A?WQP2
M/+Z$O\E &Y16+_:]Q@G^Q-6R!D#99_-^_$6 ?MG79FXYQ^Z!Y#D(6G6;@!C_
M &%J_P HE. MCD^6Z(,?Z;C]XK&1,D?(C;MK;58 W**QGU:90#_8VJL-\ZG"
M6F0L*%E?!N^5G(VQ8R<X,@0<T@U:<G']BZJ!D G;9]X6ESC[9R Z^0>?]801
ME/FH VNM%8HU:X)7&BZK@E 6*V8"[T9R3_IAXC*B.3&<.PVAEW,&?VS<8!_L
M+5\DP@KMLLKYI(;/^FX_<8_>XSR0$WF@#=H_E_4$8K#&L7!S_P 2/5\A20-M
MCDD3"+9_Q^\,4)G^;"^4#SO^2@ZQ<@L/["U@XW\A++!VRK&,9O1G>K&5?^F:
MMG#X4@'Y]?\ !1'XE:QX \$_#[2O"'Q8\=?##XC^//%FJ>%OAC)X:.GZ/X2?
MQD='>;3?%_QC\8:GH.LP:7\*_ALA?Q-K_AA&@G^(ETMAX.M;;5KK4+>U3X#\
M=?M-?&/PUXC^)DWQ:^*O[0'A^[AO?B=H?C;P#\,M$BT'3]-.D^.?A#I'[+EK
M\-_&5UX1U+1?A[I?QSTW6_&FJZ[\1Y-=FM3X6M]>US5]6L(?";R)_0"VL7 $
MF-#U8[!,1\MD-_EN$4K_ *9TF!\Q,X(0$OL;"E#JUPKE1I&K.%=E#%;+:X$9
M=2O^F+D,_P"Z7< V\C.%YH _(7]C3XI?M 7O[2NG^$/BW\1V^-DNJ?"C1;2_
MO?!.H_$#2?!W@@>'/A+\'=2NOB'J_AG6O OAGX?^)])^+'CC5/%#>%?'_A#4
MKV2\O+RYT^Q1[.VUK3/"O[+U@C6+G<H.B:L S( 2MEC#Q"0MG[:3B)R86 !^
M;&P,HW5(FKSMM_XDFK+N\K.Y;+Y/,B:5@V+PC,1 CDQGYV7:63+  V6S@XZX
M./KCWXK\J/V[/CY^T7X#^*GPOL/@-X+^*WB;PE\%M+L?C[^T,? ?AO0M4TSQ
M-X%O?%,/A.V^&VKS:]>Z;=W9N_ ]G\6O'JZ;X'&K>*(->\%^#1-91VNI6\>H
M?IW_ &S<'(_L/5P?*AD(*6/620H\1_TW[\0!:3JI7.QG(P8Y-5N91M&B:KPO
MF@A;(D,DFU=O^FC#,!YB[@,IUVN2H /Y\=/_ ."M/[0VL1^")M*LO@%-H_Q*
MG^(5UX?\0KX"^-=QIFE>(? ^D_&'5=+_ &?YK2"^%YXB^)/BZV^'7A.Y7Q#I
M"Q:;I\7C^"&#0KV>?PI_PDC_  W^W]^V;X+\.W%KK7P^6SU"]\=?$8ZAX\^-
MMKJ5GH?AVTTGQ%X[U3PK\.IHI-6\$^'X=0N].2S\/Z5K.B74]QJ&E^$+FX32
M=?UN]M37[J:;X'\$:+_PB9TKX8:18?\ "OCKLG@9=/\ #?AVU'A)]=2>TUR3
MPOY#1#1&U^SOKR'4&T];<WT$]Q'=[E=D;OSJMP2P&C:H,"8[BEI@^5C: /MF
M<SY(B. ."7*<9 /QL^%W[6/[67Q?^(WQ@:_T_3OAYJ_A?]D7X^^)-)^"VF^
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M7/WUV;OFVM75K@XD.B:P,J#Y96RRC>;Y+(VV^*DA?W^,E?+!.=_RT ?B:_\
MP4J_:BF4>(XO@1IFDZ9J.GV?B;0_AOKO@?XG6_Q%;X1:]X7U7XA67QUU>Z@,
MFEZ?X;\)Z19V/P_\7>%#:MKD7CNZF;[198L]'N=#4?\ @H=^U5J5QX\\8>!O
M@KX<\6_##PSXHUSPMX6TVU\"_%:+Q5X]MKG5?VA[;PSXYTW5I&ALXO#FEZ9\
M(?"&LZE#:Z'?OXBL/%TKZ3>69N]!-U^T+ZQ<#<5T75R5+?*$L<L4D"!5S>J
M902R;FV@*VX!N"\ZQ<*'_P")'J[;/.P=ED-XB95!!^V 9FR6C!V_*K;PAP&
M/R8\ _M9_&WP[^R+\>OC5XB\1V?Q(\4Z;^T_XI\#?#OQ5I'PN\30^!)?!%_K
MOA#0O#>J:/X7U?7O#5]IW@2Q-_?HWB3Q%XS71+"Z^UWU[X@N[*..!Z7[)?\
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MX'EJV[#X2AM6N1NQHNK-CSL!4LB7\IU4;3]L&!,'W1DX^5#OV-PP!^)&O_\
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M  4._;"UGPUX*\5^+OA;X"\"^'?B=)J&C+KNI?#SXL+8_ V+P^WP-?5/B/\
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M<:S=:_-J/AOQ=J7CK0]2T[6)6#Z1<V/BC5;O5(UL8$MRP@LVM_L%NEN:Z_\
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M!;_@GS\*?A!%\0X;C6_&WC:T\:'XMZ%H&C^(/%>LS:%\-?A_\8)=*A\3>%_
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MCK?AOPE<7T>JW4,&MZ]IOA"XTFQ>VL-'O]3U".2[W6-@+::956]LA/QGA/\
MX)=?LN^"K'7;'PS;_$S19_$4T-[J>J6'Q'U:SU ZOIOBOPCXU\/ZU8&RBM['
M1]1\*^)O!>AZOX972;&RL-,G2\A^Q26]T\5,UW_@EM^RIXD\#7/P_P!0TOXC
M-HM[KE_K^J70^)_B5]9UC4]6\#:G\.]9N=1U.ZDNI9KC5_"^LZE;7-\B1:G:
MW=U+J&EW]A=RR2L >HZ+^W+\")?A_I'Q)\<:]-\-=!U_Q'\8- T%O$MK=WJZ
MLGP6\;7O@W6]3@OM$@U"SB75?(MM=T72[B2/5[[2KQI(;226QU%;:M/_ ,%
M/V3[;5+_ $B7XI1J-,UF\\)W6MIX2\;2^$3XST_5(].O?!,'BU- 'A^Z\9V\
M<\>N-X6MM1DUH^%94\6PV;^'W34#I:U^PQ^SMXD^&W@?X3:[X0U+5/!7P]^(
MFM?%+PO9W/BG7$U"W\6^(Y?$UQK<UYJMO=QWM]INHS>,=:^TZ+<22:7(K6@,
M!%C;!/.(_P#@F7^RW!H-MX5LM$\>:?X2T[PSH^CZ5X7L_B;XIBT32/%&@>!=
M%^&VD_%[3[-[F4P_&:#P3H.EZ1/\06EDU.]DM!?WR7.I3SWS@'I/BK]NK]ES
MP7XTU?P#XH^)\>D:]X9U6YT3Q9<S^$_&3^'?"%Y!/<VB?\)=XO@T)_"_ANWO
M]0LYM,TF]U;5;6UU/556PL99[MTC/F4O_!1?X4-X)\6_$6R\%?%.]\+^%/VF
M_AK^S'+&?!'B*R\7ZIK_ ,3M"^'6MZ7XJTOX>WVEVWCB^T:.#XDZ1';Z9;Z)
M)KFM16TM_I%G<6<]K*VZ/^"<O[-MUI?CW2_$VF^.O'@^*6L:+KGQ%U#QK\0-
M<UG4_%]_H/BJ7QA8OJMP'M8TMI=8FD%W9V,%K:R6!6P2&.W50O;^#OV+_A!X
M-\/OX>CNOB+XH27XW>"OVA+C6O&WQ#U[Q+XCN/B/\.=)\):!X/FFUF]E-PV@
MZ)HO@;PQIMMX>14TR2#3F:XBEGN[R6X .4L/^"C'['VJZA>:3H?Q?@\0ZO9>
M"(?B#_9'A[POXPUK5;W1Y=)T77;C2M,TW3M$N+S4/%VC:)XBT+5O$?@VV@D\
M2^&=.OVOO$&G:=;V6IR67C'A_P#X*W_LK>(_&WB_1(=;O[/P#X6T[X;WUA\3
MI[/6;JS\;3?$SP?KWB;3]&\(^$='T+5/%T_B31+W0;CPYKVAZQINDWMMK$GV
M>V6YN8GM#VR_\$NOV6+?2=7\/:9IWC_2/#NMQ:9+>:#I_CW4AI;:[I=UX7N;
M?Q5)#=6]U)?:Y*/".CVVH0ZM)J?A[5+5+V/4-#N)=4OII<KPE_P2=_8W\"RV
M]UX>\&^,Q=VNL^%O$2W5[\2O%=Y<3ZSX.;6I-$NYVN+QUD,<GB#5&N$(2*X\
MZ,21A8(50 ]M\,_MQ_LV>+?%W@GP+H/CC5+KQ-X]U4^%=#L;OP!\0;&WT_QY
M':>*=1D^&OC#5;WPW;Z5X%^)D%AX(\7ZA<^ ?&%WHOB>&RT"ZNI-/CMY+1[C
MFKS_ (*(_LDZ=?7&FWWQ-OK2\B\6:EX,MDN_AW\2;6+5]3\.:AXST_Q7JV@W
M-SX8BM]<\&>"+_X=^-X/''CG29+SPAX4;PSJ;ZUK=G#]E>X\_P!/_P"">NE:
M'^T]X8^-'ACQU=^&_AGHGQ&UWX\ZO\+=.?Q/)=>,?CMXATWXDZ1>^+O%>I7_
M (KO?#&I645G\3=5&GM:^#M-UVPM=(T'11JUQI>FVD=OH^ /^";/P/T&-[WX
MB7?BWXMZ]_PE/QCURQN/%/B;64\.^'_#WQHUKXLWOB?P%X9\)1WT^F:+X1N]
M)^+VNV.JZ=$TK:MJ%GINJ22P_P!GZ;;60!Z)I?[>?[-FMK8IH?B/QGK&H73R
MRZAX>TOX1_%74?%/A;0H[?0M03QAXW\-VOA&;6_!G@:ZTWQ3X>UG3O&WB*RT
M_P -ZEI&JVNIZ=?W%FEQ+#SWA[_@I#^QKXOU72M#\+?&2R\1ZWK_ (K@\'Z+
MH^B^&_%^JZGJDUS&\MKXEL[.PT&YNI? %[;K+<6?C](&\*W-M'/<1ZD;>TN7
M1=&_X)[_  5\-WO]L^'_ !'\;-)\67EBOA_Q-XXLOB_XD3QCXW\%PV/A[2M.
M\#>,=>E\RYU/PGHND>%-&TS0].MTL[K2;:.[-GJ$=QJ>I7-SAM_P3/\ V:F\
M+Z3X'EB^(\O@O0O$NB^(]'\*GQ]>QZ/ID'A>:WN/#7A^R6"UANK;2=!GMH9=
M(NX+F/Q/8MYB1>)O)D:,@'U!\#?C]\*_VCO"E_XX^#_B.[\4^%+36[S0EUN3
M0=?T.PU"ZLHHG>YT277=-TX:UI,T<\<EMK&E_:M-N/F2.X,L,J)[3L&_?ELC
MH,\'KR0.I&X@9SP!7SO\ _V9_AG^S?!X\C^'%KKWVCXC^+#XU\8ZCX@UV36-
M0U778],M](MYVD,%K"'CL+.WAENFA.I:BZ"ZU?4-0NRTU?10& !Z #]* %HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
